
<html lang="en"     class="pb-page"  data-request-id="a17b4601-1375-4c66-8d73-002d16f1b02a"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2011.54.issue-6;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/jm101479y"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Design and Optimization of Potent and Orally Bioavailable Tetrahydronaphthalene Raf Inhibitors" /></meta><meta name="dc.Creator" content="Alexandra E.  Gould" /></meta><meta name="dc.Creator" content="Ruth  Adams" /></meta><meta name="dc.Creator" content="Sharmila  Adhikari" /></meta><meta name="dc.Creator" content="Kathleen  Aertgeerts" /></meta><meta name="dc.Creator" content="Roushan  Afroze" /></meta><meta name="dc.Creator" content="Christopher  Blackburn" /></meta><meta name="dc.Creator" content="Emily F.  Calderwood" /></meta><meta name="dc.Creator" content="Ryan  Chau" /></meta><meta name="dc.Creator" content="Jouhara  Chouitar" /></meta><meta name="dc.Creator" content="Matthew O.  Duffey" /></meta><meta name="dc.Creator" content="Dylan B.  England" /></meta><meta name="dc.Creator" content="Cheryl  Farrer" /></meta><meta name="dc.Creator" content="Nancy  Forsyth" /></meta><meta name="dc.Creator" content="Khristofer  Garcia" /></meta><meta name="dc.Creator" content="Jeffery  Gaulin" /></meta><meta name="dc.Creator" content="Paul D.  Greenspan" /></meta><meta name="dc.Creator" content="Ribo  Guo" /></meta><meta name="dc.Creator" content="Sean J.  Harrison" /></meta><meta name="dc.Creator" content="Shih-Chung  Huang" /></meta><meta name="dc.Creator" content="Natalia  Iartchouk" /></meta><meta name="dc.Creator" content="Dave  Janowick" /></meta><meta name="dc.Creator" content="Mi-Sook  Kim" /></meta><meta name="dc.Creator" content="Bheemashankar  Kulkarni" /></meta><meta name="dc.Creator" content="Steven P.  Langston" /></meta><meta name="dc.Creator" content="Jane X.  Liu" /></meta><meta name="dc.Creator" content="Li-Ting  Ma" /></meta><meta name="dc.Creator" content="Saurabh  Menon" /></meta><meta name="dc.Creator" content="Hirotake  Mizutani" /></meta><meta name="dc.Creator" content="Erin  Paske" /></meta><meta name="dc.Creator" content="Christelle C.  Renou" /></meta><meta name="dc.Creator" content="Mansoureh  Rezaei" /></meta><meta name="dc.Creator" content="R. Scott  Rowland" /></meta><meta name="dc.Creator" content="Michael D.  Sintchak" /></meta><meta name="dc.Creator" content="Michael D.  Smith" /></meta><meta name="dc.Creator" content="Stephen G.  Stroud" /></meta><meta name="dc.Creator" content="Ming  Tregay" /></meta><meta name="dc.Creator" content="Yuan  Tian" /></meta><meta name="dc.Creator" content="Ole P.  Veiby" /></meta><meta name="dc.Creator" content="Tricia J.  Vos" /></meta><meta name="dc.Creator" content="Stepan  Vyskocil" /></meta><meta name="dc.Creator" content="Juliet  Williams" /></meta><meta name="dc.Creator" content="Tianlin  Xu" /></meta><meta name="dc.Creator" content="Johnny J.  Yang" /></meta><meta name="dc.Creator" content="Jason  Yano" /></meta><meta name="dc.Creator" content="Hongbo  Zeng" /></meta><meta name="dc.Creator" content="Dong Mei  Zhang" /></meta><meta name="dc.Creator" content="Qin  Zhang" /></meta><meta name="dc.Creator" content="Katherine M.  Galvin" /></meta><meta name="dc.Description" content="Inhibition of mutant B-Raf signaling, through either direct inhibition of the enzyme or inhibition of MEK, the direct substrate of Raf, has been demonstrated preclinically to inhibit tumor growth. ..." /></meta><meta name="Description" content="Inhibition of mutant B-Raf signaling, through either direct inhibition of the enzyme or inhibition of MEK, the direct substrate of Raf, has been demonstrated preclinically to inhibit tumor growth. ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 22, 2011" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm101479y" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2011 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm101479y" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm101479y" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm101479y" /></link>
        
    
    

<title>Design and Optimization of Potent and Orally Bioavailable Tetrahydronaphthalene Raf Inhibitors | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm101479y" /></meta><meta property="og:title" content="Design and Optimization of Potent and Orally Bioavailable Tetrahydronaphthalene Raf Inhibitors" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-6/jm101479y/production/images/large/jm-2010-01479y_0001.jpeg" /></meta><meta property="og:description" content="Inhibition of mutant B-Raf signaling, through either direct inhibition of the enzyme or inhibition of MEK, the direct substrate of Raf, has been demonstrated preclinically to inhibit tumor growth. Very recently, treatment of B-Raf mutant melanoma patients with a selective B-Raf inhibitor has resulted in promising preliminary evidence of antitumor activity. This article describes the design and optimization of tetrahydronaphthalene-derived compounds as potent inhibitors of the Raf pathway in vitro and in vivo. These compounds possess good pharmacokinetic properties in rodents and inhibit B-Raf mutant tumor growth in mouse xenograft models." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm101479y"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm101479y">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm101479y&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm101479y&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm101479y&amp;href=/doi/10.1021/jm101479y" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2011</span><span class="cit-fg-volume">, 54</span><span class="cit-fg-issue">, 6</span><span class="cit-fg-pageRange">, 1836-1846</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/54/6" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm101477d" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm101493z" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Design and Optimization of Potent and Orally Bioavailable Tetrahydronaphthalene Raf Inhibitors</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Alexandra+E.++Gould">Alexandra E. Gould</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ruth++Adams">Ruth Adams</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sharmila++Adhikari">Sharmila Adhikari</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kathleen++Aertgeerts">Kathleen Aertgeerts</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Roushan++Afroze">Roushan Afroze</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Christopher++Blackburn">Christopher Blackburn</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Emily+F.++Calderwood">Emily F. Calderwood</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ryan++Chau">Ryan Chau</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jouhara++Chouitar">Jouhara Chouitar</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Matthew+O.++Duffey">Matthew O. Duffey</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dylan+B.++England">Dylan B. England</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Cheryl++Farrer">Cheryl Farrer</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Nancy++Forsyth">Nancy Forsyth</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Khristofer++Garcia">Khristofer Garcia</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jeffery++Gaulin">Jeffery Gaulin</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Paul+D.++Greenspan">Paul D. Greenspan</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ribo++Guo">Ribo Guo</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sean+J.++Harrison">Sean J. Harrison</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shih-Chung++Huang">Shih-Chung Huang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Natalia++Iartchouk">Natalia Iartchouk</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dave++Janowick">Dave Janowick</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mi-Sook++Kim">Mi-Sook Kim</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Bheemashankar++Kulkarni">Bheemashankar Kulkarni</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Steven+P.++Langston">Steven P. Langston</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jane+X.++Liu">Jane X. Liu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Li-Ting++Ma">Li-Ting Ma</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Saurabh++Menon">Saurabh Menon</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hirotake++Mizutani">Hirotake Mizutani</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Erin++Paske">Erin Paske</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Christelle+C.++Renou">Christelle C. Renou</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mansoureh++Rezaei">Mansoureh Rezaei</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=R.+Scott++Rowland">R. Scott Rowland</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael+D.++Sintchak">Michael D. Sintchak</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael+D.++Smith">Michael D. Smith</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Stephen+G.++Stroud">Stephen G. Stroud</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ming++Tregay">Ming Tregay</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yuan++Tian">Yuan Tian</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ole+P.++Veiby">Ole P. Veiby</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tricia+J.++Vos">Tricia J. Vos</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Stepan++Vyskocil">Stepan Vyskocil</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Juliet++Williams">Juliet Williams</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tianlin++Xu">Tianlin Xu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Johnny+J.++Yang">Johnny J. Yang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jason++Yano">Jason Yano</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hongbo++Zeng">Hongbo Zeng</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dong+Mei++Zhang">Dong Mei Zhang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Qin++Zhang">Qin Zhang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Katherine+M.++Galvin">Katherine M. Galvin</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Takeda San Diego, 10410 Science Center Drive, San Diego, California 92130, United States</span></div><div class="corresp-info"><strong>*</strong>Tel: 617-761-6959. Fax: 617-551-8907. E-mail: <a href="/cdn-cgi/l/email-protection#394a58575d40175e564c555d79544950175a5654"><span class="__cf_email__" data-cfemail="0b786a656f72256c647e676f4b667b6225686466">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm101479y&amp;href=/doi/10.1021%2Fjm101479y" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2011</span></span><span class="cit-volume">, 54</span><span class="cit-issue">, 6</span><span class="cit-pageRange">, 1836–1846</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">February 22, 2011</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>17 November 2010</li><li><span class="item_label"><b>Published</b> online</span>22 February 2011</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 24 March 2011</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm101479y" title="DOI URL">https://doi.org/10.1021/jm101479y</a></div><div class="article_header-article-copyright"><strong>Copyright © 2011 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D1836%26pageCount%3D11%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DAlexandra%2BE.%2BGould%252C%2BRuth%2BAdams%252C%2BSharmila%2BAdhikari%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D54%26issueNum%3D6%26contentID%3Djm101479y%26title%3DDesign%2Band%2BOptimization%2Bof%2BPotent%2Band%2BOrally%2BBioavailable%2BTetrahydronaphthalene%2BRaf%2BInhibitors%26numPages%3D11%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D1846%26publicationDate%3DMarch%2B2011">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm101479y"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3849</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">27</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm101479y" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Design and Optimization of Potent and Orally Bioavailable Tetrahydronaphthalene Raf Inhibitors&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Alexandra&quot;,&quot;last_name&quot;:&quot;E. Gould&quot;},{&quot;first_name&quot;:&quot;Ruth&quot;,&quot;last_name&quot;:&quot;Adams&quot;},{&quot;first_name&quot;:&quot;Sharmila&quot;,&quot;last_name&quot;:&quot;Adhikari&quot;},{&quot;first_name&quot;:&quot;Kathleen&quot;,&quot;last_name&quot;:&quot;Aertgeerts&quot;},{&quot;first_name&quot;:&quot;Roushan&quot;,&quot;last_name&quot;:&quot;Afroze&quot;},{&quot;first_name&quot;:&quot;Christopher&quot;,&quot;last_name&quot;:&quot;Blackburn&quot;},{&quot;first_name&quot;:&quot;Emily&quot;,&quot;last_name&quot;:&quot;F. Calderwood&quot;},{&quot;first_name&quot;:&quot;Ryan&quot;,&quot;last_name&quot;:&quot;Chau&quot;},{&quot;first_name&quot;:&quot;Jouhara&quot;,&quot;last_name&quot;:&quot;Chouitar&quot;},{&quot;first_name&quot;:&quot;Matthew&quot;,&quot;last_name&quot;:&quot;O. Duffey&quot;},{&quot;first_name&quot;:&quot;Dylan&quot;,&quot;last_name&quot;:&quot;B. England&quot;},{&quot;first_name&quot;:&quot;Cheryl&quot;,&quot;last_name&quot;:&quot;Farrer&quot;},{&quot;first_name&quot;:&quot;Nancy&quot;,&quot;last_name&quot;:&quot;Forsyth&quot;},{&quot;first_name&quot;:&quot;Khristofer&quot;,&quot;last_name&quot;:&quot;Garcia&quot;},{&quot;first_name&quot;:&quot;Jeffery&quot;,&quot;last_name&quot;:&quot;Gaulin&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;D. Greenspan&quot;},{&quot;first_name&quot;:&quot;Ribo&quot;,&quot;last_name&quot;:&quot;Guo&quot;},{&quot;first_name&quot;:&quot;Sean&quot;,&quot;last_name&quot;:&quot;J. Harrison&quot;},{&quot;first_name&quot;:&quot;Shih-Chung&quot;,&quot;last_name&quot;:&quot;Huang&quot;},{&quot;first_name&quot;:&quot;Natalia&quot;,&quot;last_name&quot;:&quot;Iartchouk&quot;},{&quot;first_name&quot;:&quot;Dave&quot;,&quot;last_name&quot;:&quot;Janowick&quot;},{&quot;first_name&quot;:&quot;Mi-Sook&quot;,&quot;last_name&quot;:&quot;Kim&quot;},{&quot;first_name&quot;:&quot;Bheemashankar&quot;,&quot;last_name&quot;:&quot;Kulkarni&quot;},{&quot;first_name&quot;:&quot;Steven&quot;,&quot;last_name&quot;:&quot;P. Langston&quot;},{&quot;first_name&quot;:&quot;Jane&quot;,&quot;last_name&quot;:&quot;X. Liu&quot;},{&quot;first_name&quot;:&quot;Li-Ting&quot;,&quot;last_name&quot;:&quot;Ma&quot;},{&quot;first_name&quot;:&quot;Saurabh&quot;,&quot;last_name&quot;:&quot;Menon&quot;},{&quot;first_name&quot;:&quot;Hirotake&quot;,&quot;last_name&quot;:&quot;Mizutani&quot;},{&quot;first_name&quot;:&quot;Erin&quot;,&quot;last_name&quot;:&quot;Paske&quot;},{&quot;first_name&quot;:&quot;Christelle&quot;,&quot;last_name&quot;:&quot;C. Renou&quot;},{&quot;first_name&quot;:&quot;Mansoureh&quot;,&quot;last_name&quot;:&quot;Rezaei&quot;},{&quot;first_name&quot;:&quot;R.&quot;,&quot;last_name&quot;:&quot;Scott Rowland&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;D. Sintchak&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;D. Smith&quot;},{&quot;first_name&quot;:&quot;Stephen&quot;,&quot;last_name&quot;:&quot;G. Stroud&quot;},{&quot;first_name&quot;:&quot;Ming&quot;,&quot;last_name&quot;:&quot;Tregay&quot;},{&quot;first_name&quot;:&quot;Yuan&quot;,&quot;last_name&quot;:&quot;Tian&quot;},{&quot;first_name&quot;:&quot;Ole&quot;,&quot;last_name&quot;:&quot;P. Veiby&quot;},{&quot;first_name&quot;:&quot;Tricia&quot;,&quot;last_name&quot;:&quot;J. Vos&quot;},{&quot;first_name&quot;:&quot;Stepan&quot;,&quot;last_name&quot;:&quot;Vyskocil&quot;},{&quot;first_name&quot;:&quot;Juliet&quot;,&quot;last_name&quot;:&quot;Williams&quot;},{&quot;first_name&quot;:&quot;Tianlin&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Johnny&quot;,&quot;last_name&quot;:&quot;J. Yang&quot;},{&quot;first_name&quot;:&quot;Jason&quot;,&quot;last_name&quot;:&quot;Yano&quot;},{&quot;first_name&quot;:&quot;Hongbo&quot;,&quot;last_name&quot;:&quot;Zeng&quot;},{&quot;first_name&quot;:&quot;Dong&quot;,&quot;last_name&quot;:&quot;Mei Zhang&quot;},{&quot;first_name&quot;:&quot;Qin&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Katherine&quot;,&quot;last_name&quot;:&quot;M. Galvin&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2011&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;22&quot;,&quot;issue&quot;:&quot;6&quot;,&quot;volume&quot;:&quot;54&quot;,&quot;pages&quot;:&quot;1836-1846&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm101479y&quot;},&quot;abstract&quot;:&quot;Inhibition of mutant B-Raf signaling, through either direct inhibition of the enzyme or inhibition of MEK, the direct substrate of Raf, has been demonstrated preclinically to inhibit tumor growth. Very recently, treatment of B-Raf mutant melanoma patients with a selective B-Raf inhibitor has resulted in promising preliminary evidence of antitumor activity. This article describes the design and optimization of tetrahydronaphthalene-derived compounds as potent inhibitors of the Raf pathway in vitro and in vivo. These compounds possess good pharmacokinetic properties in rodents and inhibit B-Raf mutant tumor growth in mouse xenograft models.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm101479y&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm101479y" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm101479y&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm101479y" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm101479y&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm101479y" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm101479y&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm101479y&amp;href=/doi/10.1021/jm101479y" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm101479y" /></input><a href="/doi/pdf/10.1021/jm101479y" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm101479y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm101479y%26sid%3Dliteratum%253Aachs%26pmid%3D21341678%26genre%3Darticle%26aulast%3DGould%26date%3D2011%26atitle%3DDesign%2Band%2BOptimization%2Bof%2BPotent%2Band%2BOrally%2BBioavailable%2BTetrahydronaphthalene%2BRaf%2BInhibitors%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D54%26issue%3D6%26spage%3D1836%26epage%3D1846%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=290658" title="Amides">Amides</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291181" title="Amines">Amines</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/54/6" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-6/jmcmar.2011.54.issue-6/production/jmcmar.2011.54.issue-6.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-6/jm101479y/production/images/medium/jm-2010-01479y_0001.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-6/jm101479y/production/images/large/jm-2010-01479y_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm101479y&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Inhibition of mutant B-Raf signaling, through either direct inhibition of the enzyme or inhibition of MEK, the direct substrate of Raf, has been demonstrated preclinically to inhibit tumor growth. Very recently, treatment of B-Raf mutant melanoma patients with a selective B-Raf inhibitor has resulted in promising preliminary evidence of antitumor activity. This article describes the design and optimization of tetrahydronaphthalene-derived compounds as potent inhibitors of the Raf pathway in vitro and in vivo. These compounds possess good pharmacokinetic properties in rodents and inhibit B-Raf mutant tumor growth in mouse xenograft models.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31307" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31307" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The mitogen-activated protein kinase (MAPK) signal transduction pathway regulates cellular growth, proliferation, and differentiation in response to many different external stimuli.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> This pathway is also frequently mutated in many types of cancer and thus contains attractive targets for oncology drug discovery.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> One component of this pathway, the Raf isoform B-Raf, has a high rate of activating mutation in melanoma (50−70%) and other cancers including papillary thyroid (49%), colorectal (∼15%), and ovarian (∼30%).<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3, 4)</a> The V600E activating mutation is most common and significantly increases the basal level activity of the enzyme.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Inhibition of mutant B-Raf signaling, through either direct inhibition of the enzyme<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> or inhibition of MEK, the direct substrate of Raf,<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> has been demonstrated preclinically to inhibit tumor growth. Very recently, treatment of B-Raf mutant melanoma patients with a selective B-Raf inhibitor has resulted in antitumor activity.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a></div><div class="NLM_p last">At the time we began our work, sorafenib (<b>1</b>) was the only compound with known Raf activity in the clinic. Sorafenib is reported to have a reasonable enzyme potency against <sup>V600E</sup>ΔB-Raf and C-Raf (IC<sub>50</sub> values of 38 and 6 nM, respectively) and pathway inhibition in cells (IC<sub>50</sub> values of 40−1200 nM depending on the cell line).<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> We took the sorafenib scaffold as a starting point for our efforts and sought to identify compounds that display robust Raf pathway inhibition in an in vitro and in vivo setting. In this paper, we report the optimization of a series of novel tetrahydronaphthalene-derived compounds with respect to cellular activity and pharmacokinetic (PK) properties. In addition, these compounds profoundly inhibit both tumor growth and markers of Raf pathway activity in B-Raf mutant melanoma xenografts.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45324" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45324" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">We devised two modular approaches to the synthesis of the compounds of interest as shown in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>. The appropriately substituted aniline is coupled with a phenylpropionic acid. The resulting propanamide phenol and a substituted pyridine are heated in the presence of a base to provide a biaryl ether (e.g., <b>2</b>, Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>). Alternatively, the biaryl ether bond is formed first when the appropriately substituted pyridine and phenol are heated in the presence of cesium carbonate. These biaryl ethers are then further reacted with either an aniline or a benzoic acid derivative to provide the desired compounds (e.g., <b>4</b> and <b>8</b>, Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>).</div><figure id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-6/jm101479y/production/images/medium/jm-2010-01479y_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-6/jm101479y/production/images/large/jm-2010-01479y_0005.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Amide-Based Raf Inhibitors<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-6/jm101479y/production/images/large/jm-2010-01479y_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm101479y&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 4-Chloro-<i>N</i>-methylpicolinamide, KOtBu, DMPU, DMF, 100 °C. (b) (±)-<b>15</b> or (<i>S</i>)-<b>15</b>, Cs<sub>2</sub>CO<sub>3</sub>, DMF, heat and then amide coupling. (c) Compound <b>17</b>, Cs<sub>2</sub>CO<sub>3</sub>, DMF, heat and then amide coupling.</p></p></figure><div class="NLM_p">The syntheses of several substituted pyridines such as 4-chloro-<i>N</i>-methylpicolinamide,<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a><i>N</i>-(4-nitropyridin-2-yl)acetamide, and cyclopropylacetamide<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> are described in the literature. Pyridine lactam <b>11</b> is prepared in three steps from 2-chloro-4-fluoropyridine (Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>). Palladium-catalyzed amination provides the Boc-protected aminopyridine (<b>9</b>). ortho-Lithiation and iodination set the stage for a one-pot palladium-catalyzed Heck coupling/cyclization to provide lactam <b>11</b> (Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>) in modest yield.</div><figure id="sch2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-6/jm101479y/production/images/medium/jm-2010-01479y_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-6/jm101479y/production/images/large/jm-2010-01479y_0006.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of 4-Fluoropyridine Lactam<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-6/jm101479y/production/images/large/jm-2010-01479y_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm101479y&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <i>t</i>-Butyl carbamate, Pd(OAc)<sub>2</sub>, Xantphos, NaOH, H<sub>2</sub>O, dioxane, 80%. (b) <i>n</i>-BuLi, TMEDA, THF, −78 °C and then I<sub>2</sub>, 86%. (c) Pd catalyst <b>29</b>, 3,3-diethoxy-1-propene, DIPEA, H<sub>2</sub>O, DMF, 140 °C, 47%.</p></p></figure><div class="NLM_p">The synthesis of the (<i>S</i>)-tetrahydronaphthalene carboxylic acid (<i>S</i>)-<b>15</b> (Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>) begins with the Evans' oxazolidinone amide of phenylpropionic acid (<b>12</b>). Asymmetric alkylation of this oxazolidinone with <i>t</i>-butyl bromoacetate proceeds with high diastereoselectivity to provide <b>13</b> in good yield.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Deprotection of the <i>t</i>-butyl ester, Friedel−Crafts cyclization,<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> and removal of the oxazolidinone gives tetralone acid <b>14</b>. Subsequent reduction of the tetralone and deprotection of the methyl ether with BBr<sub>3</sub> affords the desired tetrahydronaphthalene carboxylic acid (<i>S</i>)-<b>15</b> in good yield while maintaining enantiopurity. Careful control of the methyl ether deprotection reaction conditions was crucial as this substrate was prone to racemization, particularly on scale.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a></div><figure id="sch3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-6/jm101479y/production/images/medium/jm-2010-01479y_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-6/jm101479y/production/images/large/jm-2010-01479y_0007.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of <i>S</i>-Tetrahydronaphthalene Carboxylic Acid<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-6/jm101479y/production/images/large/jm-2010-01479y_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm101479y&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) THF, −78 °C, 89%. (b) NaHMDS, THF −78 °C and then <i>t</i>-butyl bromoacetate, 79%. (c) CF<sub>3</sub>SO<sub>3</sub>H, PhH, 80 °C, o/n. (d) H<sub>2</sub>O<sub>2</sub>, NaOH, THF 0 °C, 70% for two steps. (e) Pd/C, H<sub>2</sub>, H<sub>2</sub>SO<sub>4</sub>, AcOH, 80 °C, 20 psi, 65%. (f) BBr<sub>3</sub>, DCM, −78 to 0 °C, 74%.</p></p></figure><div class="NLM_p">To prepare the single enantiomer aminotetralin <b>17</b> (Scheme <a class="ref internalNav" href="#sch4" aria-label="4">4</a>), we modified a procedure described in the patent literature.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Reductive amination of 7-methoxy-2-tetralone and benzyl amine followed by debenzylation provides 7-methoxy-2-aminotetralin (<b>16</b>). Crystallization of the free base of the aminotetralin <b>16</b> with (<i>S</i>)-mandelic acid using slightly modified solvents to those previously reported,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> followed by HBr deprotection of the methyl ether, provides the desired tetralin amine <b>17</b> in high ee and good yield.</div><figure id="sch4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-6/jm101479y/production/images/medium/jm-2010-01479y_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-6/jm101479y/production/images/large/jm-2010-01479y_0008.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Amino Tetrahydronaphthalene<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-6/jm101479y/production/images/large/jm-2010-01479y_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm101479y&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) BnNH<sub>2</sub>, NaBH(OAc)<sub>3</sub>, AcOH, DCM, 100%. (b) Pd(OH)<sub>2</sub>, H<sub>2</sub>, EtOH, AcOH, 92%. (c) NaOH, EtOAc, 92% and then <i>S</i>-(+)-mandelic acid, iPrOH, MeOH, H<sub>2</sub>O, PhMe, 60%. (d) HBr, H<sub>2</sub>O, reflux, 99%.</p></p></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i7">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87461" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87461" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">An examination of the crystal structure of sorafenib bound to <sup>V600E</sup>ΔB-Raf<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> reveals several important features that contribute to the potency of the molecule as it occupies the ATP binding site of the enzyme in its DFG-out conformation. The pyridine ring makes key contacts in the hinge region of the enzyme. The trifluoromethyl group on the phenyl ring occupies a hydrophobic pocket formed by regions of the DFG motif and the catalytic loop of the enzyme, while the urea forms two hydrogen bonds with the enzyme. We decided to explore the importance of these two hydrogen bonds by replacing the urea with a variety of alternative moieties and quickly identified <b>2</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>) in which the urea of sorafenib has been replaced with a propionamide. The enzyme tolerates the increase in chain length as well as the loss of one of the hydrogen bond donor groups of the urea. Both meta- and para-substituted molecules are acceptable (<b>2</b> and <b>3</b>, Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>) and have similar potency against both <sup>V600E</sup>ΔB-Raf and C-Raf.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Sorafenib and Initial Amide-Based Raf Inhibitors</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-6/jm101479y/production/images/medium/jm-2010-01479y_0009.gif" alt="" id="fx2" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"><sup>V600E</sup>ΔB-Raf IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">C-Raf IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">pERK IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left">61 ± 11</td><td class="colsep0 rowsep0" align="left">10 ± 2</td><td class="colsep0 rowsep0" align="left">>25000<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="left">47 ± 12</td><td class="colsep0 rowsep0" align="left">9 ± 2</td><td class="colsep0 rowsep0" align="left">>25000<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="left">32<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">28<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">2900<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">IC<sub>50</sub> values are shown as mean values of three or more determinations.</p></div><div class="footnote" id="t1fn2"><sup>b</sup><p class="last">IC<sub>50</sub> values are shown as mean of two determinations.</p></div><div class="footnote" id="t1fn3"><sup>c</sup><p class="last">IC<sub>50</sub> values are shown as single determinations.</p></div></div></div><div class="NLM_p">Although these compounds were quite potent in our enzyme assays, they did not show any activity in a cellular assay measuring inhibition of extracellular signal-regulated kinase (ERK) kinase phosphorylation (pERK) in A375 cells (a melanoma cell line that contains <sup>V600E</sup>ΔB-Raf). Constraint of the flexible central core of compound <b>3</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>) through cyclization did not improve the enzyme activity but did improve cellular activity, as tetralin <b>4</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>), prepared as a racemic mixture, now has cellular activity in the low micromolar range.</div><div class="NLM_p">Having identified a series of novel compounds with modest cellular activity, we next focused on improving the cellular potency of the series while keeping a close eye on the physicochemical and PK behavior of the molecules. Introduction of a basic amine to the aryl amide portion of the molecule was evaluated as a means of improving the aqueous solubility of the series. Replacement of the 4-chloro substituent with a primary benzyl amine at either the 4- or the 5-position of the phenyl ring (<b>18</b> and <b>19</b>, respectively, Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>) was tolerated, although this modification did not improve inhibitory activity in the enzyme or cellular assays.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Enzyme and Cellular Potencies of Raf Inhibitors</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-6/jm101479y/production/images/medium/jm-2010-01479y_0010.gif" alt="" id="fx3" /></img><div class="scrollable-table-wrap"><table class="table single-image" border="0"><colgroup><col /></col></colgroup><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-6/jm101479y/production/images/medium/jm-2010-01479y_0011.gif" alt="" id="fx4" /></img></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">IC<sub>50</sub> values are shown as mean values of three or more determinations.</p></div><div class="footnote" id="t2fn2"><sup>b</sup><p class="last">IC<sub>50</sub> values are shown as mean of two determinations.</p></div></div></div><div class="NLM_p">Major improvements in enzyme and cellular activity were observed with alteration of the substituent on the pyridine ring, the hinge-binding element of the series. A simple reversal of the pyridine amide moiety (which is expected to maintain this interaction) provided a 10-fold improvement in cellular potency (cf. <b>19</b> and <b>5</b>, Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). A cyclopropyl amide (compound <b>6</b>) was also well tolerated, but more sterically demanding amides (e.g., isobutyryl or pivaloyl) led to decreases in cellular and enzyme activity (compounds and data not shown).</div><div class="NLM_p">The enantiomers of <b>6</b> were separated by chiral HPLC, and the absolute stereochemistry was subsequently confirmed by synthesis of the individual enantiomers. While the enzyme activity of these two antipodes is quite similar, (<i>S</i>)-enantiomer <b>20</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>) appears to be somewhat more potent in a cellular setting.</div><div class="NLM_p">Amine <b>6</b> is a potent inhibitor of Raf in cells, but it has some significant PK liabilities. While the compound has low in vivo clearance (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>), it exhibits poor oral exposure and bioavailability in rats. In an effort to improve the PK properties, we focused on two areas of the molecule, the benzylic amine and the pyridine amide moiety. Exploration of the amine moiety revealed that various secondary and tertiary benzyl amines are all potent inhibitors of Raf. Dimethylation of the primary benzyl amine of <b>6</b> provided tertiary amine <b>22</b>, which maintained good potency and demonstrated improved oral exposures (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>); the isopropyl benzyl amine <b>23</b> also showed good cellular potency (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>) and significantly improved oral exposures in a rat PK experiment (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>, discrete rat IV data were not obtained for this molecule). Efforts to replace the amide substituent on the pyridine with a variety of heterocycles did not lead to compounds with an acceptable combination of cellular activity and in vivo clearance. As mentioned above, more sterically demanding amides were not well tolerated, but cyclization of the amide to a lactam provided potent compounds with improved oral exposures. A combination of the lactam and isopropyl benzyl amine in one molecule yielded <b>7</b> as one of our better compounds with respect to potency, in vivo clearance, and oral exposure (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Structures, Raf Potency, and Rrat PK Parameters for Key Raf Inhibitors</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-6/jm101479y/production/images/medium/jm-2010-01479y_0012.gif" alt="" id="fx5" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"><sup>V600E</sup>ΔB-Raf IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">pERK IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">Clp (L/h/kg)<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">Vss (L/kg)<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">po AUC<sub>1−24h</sub> (μM h)<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">po % <i>F</i><a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">8 ± 1</td><td class="colsep0 rowsep0" align="left">150<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">0.4<a class="ref internalNav" href="#t3fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">6.4</td><td class="colsep0 rowsep0" align="left">0.58<a class="ref internalNav" href="#t3fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">1.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="left">4 ± 1</td><td class="colsep0 rowsep0" align="left">130 ± 26</td><td class="colsep0 rowsep0" align="left">1.41<a class="ref internalNav" href="#t3fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">6.07</td><td class="colsep0 rowsep0" align="left">2.87<a class="ref internalNav" href="#t3fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">27</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="left">5.0 ± 0.5</td><td class="colsep0 rowsep0" align="left">190 ± 42</td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t3fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">15.6<a class="ref internalNav" href="#t3fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="left">3.3 ± 0.3</td><td class="colsep0 rowsep0" align="left">110 ± 40</td><td class="colsep0 rowsep0" align="left">0.32</td><td class="colsep0 rowsep0" align="left">3.87</td><td class="colsep0 rowsep0" align="left">20.7</td><td class="colsep0 rowsep0" align="left">20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24</b></td><td class="colsep0 rowsep0" align="left">2.9<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">79 ± 37</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="left">2.9 ± 0.5</td><td class="colsep0 rowsep0" align="left">70 ± 26</td><td class="colsep0 rowsep0" align="left">2.14</td><td class="colsep0 rowsep0" align="left">2.19</td><td class="colsep0 rowsep0" align="left">0.51</td><td class="colsep0 rowsep0" align="left">22</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25</b></td><td class="colsep0 rowsep0" align="left">3.2 ± 0.2</td><td class="colsep0 rowsep0" align="left">1100<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>26</b></td><td class="colsep0 rowsep0" align="left">2.7 ± 0.5</td><td class="colsep0 rowsep0" align="left">50 ± 26</td><td class="colsep0 rowsep0" align="left">0.23</td><td class="colsep0 rowsep0" align="left">0.75</td><td class="colsep0 rowsep0" align="left">98.6</td><td class="colsep0 rowsep0" align="left">100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27</b></td><td class="colsep0 rowsep0" align="left">2.1 ± 0.5</td><td class="colsep0 rowsep0" align="left">60 ± 30</td><td class="colsep0 rowsep0" align="left">0.44</td><td class="colsep0 rowsep0" align="left">3.93</td><td class="colsep0 rowsep0" align="left">35.9</td><td class="colsep0 rowsep0" align="left">85</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>28</b></td><td class="colsep0 rowsep0" align="left">2.2 ± 0.5</td><td class="colsep0 rowsep0" align="left">45 ± 11</td><td class="colsep0 rowsep0" align="left">0.73</td><td class="colsep0 rowsep0" align="left">4.01</td><td class="colsep0 rowsep0" align="left">12.4</td><td class="colsep0 rowsep0" align="left">50</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">Unless otherwise noted, IC<sub>50</sub> values are shown as mean values of three or more determinations.</p></div><div class="footnote" id="t3fn2"><sup>b</sup><p class="last">IC<sub>50</sub> values are shown as means of two determinations.</p></div><div class="footnote" id="t3fn3"><sup>c</sup><p class="last">Average of three rats dosed at 1 mg/kg iv or 10 mg/kg po. Vehicle, 10% HPbCD.</p></div><div class="footnote" id="t3fn4"><sup>d</sup><p class="last">Vehicle: po, 20% HPbCD; iv, PEG400/H<sub>2</sub>O/EtOH/DMA (4:4:1:1).</p></div><div class="footnote" id="t3fn5"><sup>e</sup><p class="last">ND, not determined.</p></div><div class="footnote" id="t3fn6"><sup>f</sup><p class="last">Data from a single rat dosed at 10 mg/kg po. Vehicle, 20% HPbCD.</p></div></div></div><div class="NLM_p">Continued optimization and exploration of the series led us to examine the effect of reversing the internal amide in this series. As exemplified by compound <b>8</b>, this modification appeared to have little impact on either the potency or the PK properties of the molecule (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). Interestingly, the more potent enantiomer (<b>8</b>, <i>R</i>) with this amide bond orientation has the opposite stereochemistry when compared to the more potent enantiomer in the opposite amide bond orientation (<b>22</b>, <i>S</i>).</div><div class="NLM_p">Because of the straightforward nature of the synthesis of the aminotetralin template required for this subseries, as well as the lack of a risk of racemization (which was occasionally observed in the synthesis of molecules related to compound <b>7</b>), the focus of our efforts now shifted to optimizing compound <b>8</b>. We were able to apply what we had learned from the optimization of the initial tetralin scaffold to improve the PK properties of this subseries and quickly identified <b>26</b> (ML721)<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> as a molecule with excellent cellular potency and PK properties (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>).</div><div class="NLM_p">Significant demethylation of <b>26</b> to the monomethyl benzyl amine <b>28</b> was observed in vivo, and this metabolite was generally found to be present at ∼30% of the circulating levels of <b>26</b> after oral dosing, as measured by area under the curve (AUC). We investigated <b>28</b> as a potential substitute for <b>26</b> and found that it did not perform as well as desired in vivo either in rat PK studies (see Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>) or in mouse PK/pharmacodynamic (PD) studies (data not shown). A variety of substituted benzyl amines (as well as other amine-containing moieties) were explored, and we identified <b>27</b> (ML786)<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> as a molecule that maintained good cellular potency and acceptable PK properties but did not form any known active metabolites in vivo.</div><div class="NLM_p">Both of these compounds, <b>26</b> and <b>27</b>, were found to have activity in vivo. As can be seen from Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>, both compounds strongly inhibit the Raf pathway in vivo following a 75 or 100 mg/kg oral dose. As a class, these compounds have been found to inhibit a significant number of kinases (Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>)<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> and are inhibitors of wild-type B-Raf and C-Raf. Although <b>26</b> and <b>27</b> display significant receptor tyrosine kinase activity, we were confident that this additional activity would not contribute significantly to pERK inhibition in melanoma tumors with constituitively activated B-Raf. This hypothesis was confirmed with the observation that neither sunitinib [a multi-RTK (receptor tyrosine kinase)] nor erlotinib (an EGFR inhibitor) demonstrated significant pERK inhibition in A375 cells in a cellular setting or in A375 M tumors upon in vivo dosing (data not shown).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Inhibition of pERK Formation In Vivo Following an Oral Dose of Select Raf Inhibitors<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">hours postdose</th><th class="colsep0 rowsep0" align="center">pERK (% inhibition)<a class="ref internalNav" href="#t4fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center">plasma concentration (μM)<a class="ref internalNav" href="#t4fn5" aria-label="e">e</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="left"><b>26</b></td><td class="colsep0 rowsep0" align="left">4<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">93 ± 2</td><td class="colsep0 rowsep0" align="left">28 ± 7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">8<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">92 ± 1</td><td class="colsep0 rowsep0" align="left">29 ± 5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">24<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">72 ± 6</td><td class="colsep0 rowsep0" align="left">0.4 ± 0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="left"><b>27</b></td><td class="colsep0 rowsep0" align="left">4<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">87 ± 4</td><td class="colsep0 rowsep0" align="left">23 ± 4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">8<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">90 ± 2</td><td class="colsep0 rowsep0" align="left">27 ± 3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">24<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">83 ± 7</td><td class="colsep0 rowsep0" align="left">3.0 ± 0.6</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">PK/PD studies were performed in nude mice bearing A375 M xenografts. Compounds were dosed as solutions in 10% HPbCD.</p></div><div class="footnote" id="t4fn2"><sup>b</sup><p class="last">Xenografts were harvested for analysis at the time listed after a single 100 mg/kg dose.</p></div><div class="footnote" id="t4fn3"><sup>c</sup><p class="last">Xenografts were harvested for analysis at the time listed after a single 75 mg/kg dose.</p></div><div class="footnote" id="t4fn4"><sup>d</sup><p class="last">Average of pERK levels determined by Li-Cor quantitative Western blots (3 or 4 animals per group) as compared to vehicle control set at 100%.</p></div><div class="footnote" id="t4fn5"><sup>e</sup><p class="last">Average of compound levels in the plasma of mice determined by LC/MS/MS quantitation (3 or 4 animals per group).</p></div></div></div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Selected Kinase Selectivity Data for <b>26</b> and <b>27</b><a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center"><b>26</b></th><th class="colsep0 rowsep0" align="center"><b>27</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><sup>V600E</sup>ΔB-Raf</td><td class="colsep0 rowsep0" align="left">2.7</td><td class="colsep0 rowsep0" align="left">2.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">wt B-Raf</td><td class="colsep0 rowsep0" align="left">4.7</td><td class="colsep0 rowsep0" align="left">4.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">C-Raf</td><td class="colsep0 rowsep0" align="left">2.2</td><td class="colsep0 rowsep0" align="left">2.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Abl-1</td><td class="colsep0 rowsep0" align="left">1.2</td><td class="colsep0 rowsep0" align="left"><0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">DDR2</td><td class="colsep0 rowsep0" align="left">2.6</td><td class="colsep0 rowsep0" align="left">7.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EGFR</td><td class="colsep0 rowsep0" align="left">4900</td><td class="colsep0 rowsep0" align="left">190</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EPHA2</td><td class="colsep0 rowsep0" align="left">18</td><td class="colsep0 rowsep0" align="left">11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">KDR</td><td class="colsep0 rowsep0" align="left">59</td><td class="colsep0 rowsep0" align="left">6.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">LCK</td><td class="colsep0 rowsep0" align="left">610</td><td class="colsep0 rowsep0" align="left">170</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MEK</td><td class="colsep0 rowsep0" align="left">>10000</td><td class="colsep0 rowsep0" align="left">1400</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">p38α</td><td class="colsep0 rowsep0" align="left">91</td><td class="colsep0 rowsep0" align="left">42</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PDGFR</td><td class="colsep0 rowsep0" align="left">1100</td><td class="colsep0 rowsep0" align="left">47</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">RET</td><td class="colsep0 rowsep0" align="left">1.6</td><td class="colsep0 rowsep0" align="left">0.8</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">IC<sub>50</sub> values are shown as means of two determinations. ATP concentration for each kinase = <i>K</i><sub>mapp</sub>. Single-concentration binding data for 220 kinases can be found in the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>, Table 1.</p></div></div></div><div class="NLM_p">Furthermore, once daily dosing for 21 days at 100 mg/kg for <b>26</b> or 75 mg/kg for <b>27</b> induces partial regressions of the tumor xenografts. These doses are well tolerated by the mice and show no indication of toxicity or weight loss as compared to vehicle-treated animals (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>).</div><figure id="fig1" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-6/jm101479y/production/images/medium/jm-2010-01479y_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-6/jm101479y/production/images/large/jm-2010-01479y_0003.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Inhibition of subcutaneous A375 M xenografts in immunocompromised mice by <b>26</b> and <b>27</b>. The doses shown are the maximum daily dose tolerated without body weight loss. Each compound was administered po/qd for 21 days.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-6/jm101479y/production/images/large/jm-2010-01479y_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm101479y&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A crystal structure of a representative of this series, compound <b>24</b>, bound to the active site of wt B-Raf revealed the expected mode of binding to the DFG-out conformation (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>). Key hinge contacts are achieved by the bicyclic pyridine lactam moiety nitrogens, the CF<sub>3</sub> substituent occupies a key hydrophobic pocket, and the central amide supplies a single hydrogen bond.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></div><figure id="fig2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-6/jm101479y/production/images/medium/jm-2010-01479y_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-6/jm101479y/production/images/large/jm-2010-01479y_0004.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Crystal structure of <b>24</b> solved in complex with B-Raf (3.1 Å resolution).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-6/jm101479y/production/images/large/jm-2010-01479y_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm101479y&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">We began our work searching for novel compounds that robustly inhibit the Raf pathway and demonstrate a strong antitumor effect in models of B-Raf mutant melanoma at well-tolerated doses. In identifying <b>26</b> and <b>27</b>, we have fulfilled that search. These molecules show potent inhibition of B-Raf in cells, possess excellent physicochemical and PK properties, potently inhibit the B-Raf pathway in mouse PK/PD studies, and show good efficacy in B-Raf mutant xenograft studies.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_84060" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_84060" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">NMR spectra were recorded in the solvent reported on a Bruker 300 MHz Avance1 or 400 MHz Avance2 (5 mm QnProbe) using residual solvent peaks as the reference. Compound purity was determined by analysis of the diode array UV trace of an LC-MS spectrum using the following procedure. Compounds were dissolved in DMSO, methanol, or acetonitrile, and the solutions were analyzed using an Agilent 1100 LC interfaced to a micromass Waters Micromass Zspray Mass Detector (ZMD). One of two gradients was used to elute the compounds either a formic acid (FA) gradient (acetonitrile containing 0−100% 0.1% formic acid in water) or an ammonium acetate (AA) gradient (acetonitrile containing 0−100% 10 mM ammonium acetate in water). All compounds were determined to be >95% pure unless otherwise noted. High-resolution mass spectra were recorded using a Thermo LTQ-FT Ultra mass spectrometer equipped with an Eksigent nanoLC Ultra system. About 500 pg of each compound was injected into an in-house packed reverse phase nanobore column (75 μm ID) with Magic C18 resin (Michrom BioResources, Auburn, CA) to a length of 12 cm. The pump flow rate was 300 nL/min. Buffer A is the aqueous solvent and consisted of 0.1% formic acid (Sigma, St. Louis, MO) in HPLC grade water (VWR Scientific, West Chester, PA). Buffer B, the organic phase, consisted of 0.1% formic acid in 90% acetonitrile (VWR Scientific) and 10% HPLC grade water. The gradient was set as follows: 0 min, 2% buffer B; 32 min, 42% buffer B; 35 min, 90% buffer B; and 36 min, 2% buffer B. The compounds were ionized using a New Objective PicoView Nanospray Source with 2.2 kV voltage. The mass spectrometer was set to acquire masses from 350 to 2000 D in positive mode. MS/MS spectra of each compound were also acquired under data-dependent acquisition mode to confirm the chemical structure of the compounds (data not shown).</div><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> 4-[4-(3-{[4-Chloro-3-(trifluoromethyl)phenyl]amino}-3-oxopropyl)phenoxy]-<i>N</i>-methylpyridine-2-carboxamide (<b>2</b>)</h3><div class="NLM_p">A mixture of 3-(4-hydroxyphenyl)propanoic acid (4 × 250 mg, 24.1 mmol total), 4-chloro-3-(trifluoromethyl)aniline (4 × 190 mg, 15.5 mmol total), and HATU (4 × 0.58 g, 24.1 mmol total) were added to four microwave-safe vials. To each vial, NMP (5 mL) and DIPEA (0.425 mL, 9.7 mmol) were added. The vials were then sealed and subjected to microwave irradiation at 220 °C for 15 min. The reaction vessels were unsealed, and the mixtures were combined and diluted with EtOAc. The organic solution was extracted with 1 N HCl and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give a brown oil. Purification by column chromatography (SiO<sub>2</sub>, elution with EtOAc in hexane) provided <i>N</i>-[4-chloro-3-(trifluoromethyl)phenyl]-3-(4-hydroxyphenyl)propanamide as a yellow oil that solidified upon exposure to DCM (960 mg, 47% yield, ∼95% pure). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 7.74 (br d, <i>J</i> = 2.4 Hz, 1H), 7.65 (br dd, <i>J</i> = 8.5 Hz, 2.3 Hz, 1H), 7.42 (d, <i>J</i> = 8.7 Hz, 1H), 7.16 (br s, 1H), 7.10 (d, <i>J =</i> 8.5 Hz, 2H), 6.79 (d, <i>J</i> = 8.5 Hz, 2H), 2.99 (t, <i>J</i> = 7.4 Hz, 2H), 2.65 (t, <i>J</i> = 7.4 Hz, 2H).</div><div class="NLM_p last">To a mixture of DMPU (0.7 mL) and DMF (2.8 mL) was added <i>N</i>-[4-chloro-3-(trifluoromethyl)phenyl]-3-(4-hydroxyphenyl)propanamide (600 mg, 1.75 mmol) and 4-chloro-N-methylpicolinamide<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> (328 mg, 1.92 mmol). To this solution was added KO<sup><i>t</i></sup>Bu (590 mg, 5.25 mmol). The reaction mixture was stirred at 100 °C for 18 h and then cooled to room temperature, diluted with water, and extracted with EtOAc and DCM. The combined organic solutions were washed with water and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give a brown oil. Purification by column chromatography provided 4-[4-(3-{[4-chloro-3-(trifluoromethyl)phenyl]amino}-3-oxopropyl)phenoxy]-<i>N</i>-methylpyridine-2-carboxamide as a colorless solid (100 mg, 12% yield). <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD): δ 10.11 (br s, 0.3H), 8.41 (d, <i>J</i> = 5.6 Hz, 1H), 8.07 (br d, <i>J</i> = 2.2 Hz, 1H), 7.74 (br dd, <i>J =</i> 8.7, 2.1 Hz, 1H), 7.48−7.51 (m, 2H), 7.36 (d, <i>J</i> = 8.5 Hz, 1H), 7.05 (d, <i>J =</i> 8.5 Hz, 2H), 6.98 (dd, <i>J =</i> 5.6, 2.5 Hz, 1H), 3.34 (s, 0.8H), 3.04 (t, <i>J</i> = 7.5 Hz, 2H), 2.92 (s, 3H), 2.71 (t, <i>J</i> = 7.5 Hz, 2H).</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> 4-[3-(3-{[4-Chloro-3-(trifluoromethyl)phenyl]amino}-3-oxopropyl)phenoxy]-<i>N</i>-methylpyridine-2-carboxamide (<b>3</b>)</h3><div class="NLM_p last">A mixture of <i>N</i>-[4-chloro-3-(trifluoromethyl)phenyl]-3-(3-hydroxyphenyl)propanamide [585 mg, 1.70 mmol, prepared as described above using 3-(3-hydroxyphenyl)propanoic acid and 4-chloro-3-(trifluoromethyl)aniline], 4-chloro-<i>N</i>-methylpicolinamide<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> (318 mg, 1.87 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (7.76 g, 8.5 mmol) in DMF (3.4 mL) was heated at 100 °C overnight. The reaction mixture was concentrated and diluted with EtOAc. The organic solution was washed with brine, dried over MgSO<sub>4</sub>, filtered, and concentrated. The residue was purified by column chromatography (SiO<sub>2</sub>, 0−30% EtOAc in hexanes) to give <b>3</b> as a white solid (10 mg, 1% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 8.39 (d, <i>J</i> = 5.58 Hz, 1H), 8.03 (d, <i>J</i> = 2.43 Hz, 1H), 7.74−7.66 (m, 1H), 7.50 (dd, <i>J</i> = 8.12, 5.65 Hz, 2H), 7.40 (d, <i>J</i> = 7.86 Hz, 1H), 7.22 (d, <i>J</i> = 7.68 Hz, 1H), 7.06 (s, 1H), 7.03−6.96 (m, 2H), 3.05 (t, <i>J</i> = 7.48, 7.48 Hz, 2H), 2.93 (s, 3H), and 2.71 (t, <i>J</i> = 7.46, 7.46 Hz, 2H). LCMS: <i>m</i>/<i>z</i> 478.3 [M + H]<sup>+</sup> (AA).</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> General Procedure A1, Biaryl Ether Bond Formation</h3><div class="NLM_p last">A mixture of 7-hydroxy-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid (8.00 g, 41.6 mmol), 4-chloro-<i>N</i>-methylpicolinamide<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> (8.58 g, 50.3 mmol), and cesium carbonate (40.7 g, 125 mmol) in DMF (150 mL) was heated at 100 °C overnight. The reaction was cooled to room temperature and concentrated under vacuum. The resulting slurry was diluted with water and acidified with 1 N HCl solution to pH 3. The mixture was allowed to stand at room temperature, and a precipitate formed. This precipitate was isolated by filtration, washed well with water, and thoroughly dried to give 7-({2-[(methylamino)carbonyl]pyridin-4-yl}oxy)-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid as a white solid (12.10 g, 89%). <sup>1</sup>H NMR (400 MHz, <i>d</i><sub>6</sub>-DMSO): δ 8.48 (d, <i>J =</i> 5.6 Hz, 1H), 8.76 (d, <i>J =</i> 4.8 Hz, 1H), 12.30 (s, 1H), 7.35 (d, <i>J =</i> 2.6 Hz, 1H), 7.20 (d, <i>J =</i> 8.3 Hz, 1H), 7.13 (dd, <i>J =</i> 5.6, 2.6 Hz, 1H), 6.99 (d, <i>J =</i> 2.4 Hz, 1H), 6.94 (dd, <i>J =</i> 8.3, 2.6 Hz, 1H), 2.93 (d, <i>J =</i> 5.4 Hz, 1H), 2.83 (ddd, <i>J =</i> 9.4, 7.8, 3.6 Hz, 1H), 2.72 (s, 1H), 2.16−2.06 (m, 1H), and 1.81−1.68 (m, 1H).</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> 4-{[7-({[4-Chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)-5,6,7,8-tetrahydronaphthalen-2-yl]oxy}-<i>N</i>-methylpyridine-2-carboxamide (<b>4</b>)</h3><div class="NLM_p last">4-Chloro-3-(trifluoromethyl)aniline (160 mg, 0.817 mmol), 7-({2-[(methylamino)carbonyl]pyridine-4-yl}oxy)-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid (254 mg, 0.778 mmol), EDCI (149 mg, 0.778 mmol), and DMAP (114 mg, 0.943 mmol) were suspended in DCM (2.74 mL) in a microwave vial. The vial was sealed, and the reaction mixture was subjected to microwave irradiation at 60 °C for 5 min. Water and DCM were added to the reaction mixture, and the phases were separated. The organic phase was dried over MgSO<sub>4</sub>, filtered, and concentrated. Purification by column chromatography (SiO<sub>2</sub>, elution with 10−50% EtOAc in hexanes) provided 210 mg of desired product. This material was taken up in DCM and treated with 1 N HCl in Et<sub>2</sub>O. The solution was concentrated to give the HCl salt of <b>4</b> as an off-white solid (175 mg, 42%). <sup>1</sup>H NMR (400 MHz, <i>d</i><sub>6</sub>-DMSO): δ 10.43 (s, 1H), 8.49 (d, <i>J</i> = 5.71 Hz, 1H), 8.21 (d, <i>J</i> = 2.48 Hz, 1H), 7.85 (dd, <i>J</i> = 8.81, 2.45 Hz, 1H), 7.61 (d, <i>J</i> = 8.83 Hz, 1H), 7.46 (d, <i>J</i> = 2.27 Hz, 1H), 7.23 (d, <i>J</i> = 8.30 Hz, 1H), 7.16 (dd, <i>J</i> = 5.73, 2.57 Hz, 1H), 6.99 (d, <i>J</i> = 2.39 Hz, 1H), 6.95 (dd, <i>J</i> = 8.23, 2.51 Hz, 1H), 3.01−2.92 (m, 2H), 2.91−2.72 (m, 6H), 2.19−2.06 (m, 1H), and 1.92−1.72 (m, 1H). LC-MS: <i>m</i>/<i>z</i> 504.3/506.3 [M + H]<sup>+</sup>, 502.4/504.3 [M − H]<sup>−</sup> (AA). HRMS: <i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>22</sub>N<sub>3</sub>O<sub>3</sub>ClF<sub>3</sub> ([M + H])<sup>+</sup>, 504.12963; found, 504.130179.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> General Procedure B1, Amide Bond Formation</h3><div class="NLM_p last">7-({2-[(Methylamino)carbonyl]pyridine-4-yl}oxy)-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid (400 mg, 1.22 mmol), 5-amino-2-cyanobenzotrifluoride (251 mg, 1.35 mmol), EDCI (258 mg, 1.35 mmol), and DMAP (180 mg, 1.47 mmol) were combined in DCM (10 mL), and the resulting mixture was stirred overnight at room temperature. The reaction mixture was concentrated in vacuo, diluted with EtOAc, and extracted with aqueous 1 N HCl solution. The organic phase was washed with brine, dried over MgSO<sub>4</sub>, filtered, and concentrated. Purification by column chromatography (SiO<sub>2</sub>, elution with 0−50% EtOAc in hexanes) provided 4-{[7-({[4-cyano-3-(trifluoromethyl)phenyl]amino}carbonyl)-5,6,7,8-tetrahydronaphthalen-2-yl]oxy}-<i>N</i>-methylpyridine-2-carboxamide as a white powder (480 mg, 79%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.30 (s, 1H), 8.33 (d, <i>J =</i> 5.6 Hz, 1H), 8.25−8.18 (m, 1H), 8.22 (d, <i>J =</i> 4.9 Hz, 1H), 8.11 (d, <i>J =</i> 1.8 Hz, 1H), 8.03 (dd, <i>J =</i> 8.5, 1.9 Hz, 1H), 7.73 (d, <i>J =</i> 8.5 Hz, 1H), 7.52 (d, <i>J =</i> 2.5 Hz, 1H), 7.06 (d, <i>J =</i> 8.3 Hz, 1H), 7.00 (dd, <i>J =</i> 5.6, 2.5 Hz, 1H), 6.81 (dd, <i>J =</i> 8.2, 2.3 Hz, 1H), 6.67 (d, <i>J =</i> 2.0 Hz, 1H), 3.05−2.97 (m, 4H), 2.88 (dd, <i>J =</i> 16.9, 3.4 Hz, 2H), 2.77−2.60 (m, 2H), 2.22−2.13 (m, 1H), and 2.01−1.89 (m, 1H).</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> 4-{[7-({[4-(Aminomethyl)-3-(trifluoromethyl)phenyl]amino}carbonyl)-5,6,7,8-tetrahydronaphthalen-2-yl]oxy}-<i>N</i>-methylpyridine-2-carboxamide (<b>18</b>)</h3><div class="NLM_p last">4-{[7-({[4-Cyano-3-(trifluoromethyl)phenyl]amino}carbonyl)-5,6,7,8-tetrahydronaphthalen-2-yl]oxy}-<i>N</i>-methylpyridine-2-carboxamide (200 mg, 0.4 mmol) was dissolved in 7.0 M NH<sub>3</sub> in MeOH solution. To this solution was added Raney 2800 nickel (50% v/v slurry in water, approx 2 mL), and the mixture was stirred under an atmosphere of hydrogen gas for 5 h. The reaction mixture was filtered through a pad of Celite, and the filtrate was concentrated. Purification by column chromatography [SiO<sub>2</sub>, elution with 0−5% MeOH (with 1% NH<sub>4</sub>OH) in DCM] provided <b>18</b> as a white solid. This material was taken up in DCM and treated with 1 N HCl in Et<sub>2</sub>O. The solution was concentrated to give the HCl salt of <b>18</b> as a white solid (110 mg, 52%). <sup>1</sup>H NMR (300 MHz, <i>d</i><sub>6</sub>-DMSO): δ 10.73 (s, 1H), 8.86 (dd, <i>J</i> = 9.32, 4.51 Hz, 1H), 8.60 (bs, 2H), 8.51 (d, <i>J</i> = 5.69 Hz, 1H), 8.21 (d, <i>J</i> = 1.72 Hz, 1H), 7.94 (d, <i>J</i> = 8.54 Hz, 1H), 7.73 (d, <i>J</i> = 8.50 Hz, 1H), 7.44 (d, <i>J</i> = 2.40 Hz, 1H), 7.24 (d, <i>J</i> = 8.28 Hz, 1H), 7.18 (dd, <i>J</i> = 5.67, 2.52 Hz, 1H), 7.02 (d, <i>J</i> = 2.16 Hz, 1H), 6.97 (dd, <i>J</i> = 8.20, 2.37 Hz, 1H), 4.14−4.03 (m, 2H), 2.99−2.92 (m, 2H), 2.91−2.81 (m, 3H), 2.78 (d, <i>J</i> = 4.76 Hz, 3H), 2.18−2.06 (m, 1H), and 1.90−1.72 (m, 1H). LC-MS: <i>m</i>/<i>z</i> 499.4 [M + H]<sup>+</sup>, 497.4 [M − H]<sup>−</sup> (FA).</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> General Procedure B2, Amide Bond Formation</h3><div class="NLM_p last">7-(2-Acetamidopyridin-4-yloxy)-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid (1.00 mg, 3.06 mmol), DIPEA (1.60 mL, 9.19 mmol), and HATU (1.75 g, 4.60 mmol) were combined in DMF (30 mL), and the solution was stirred for 30 min. <i>tert</i>-Butyl [4-amino-2-(trifluoromethyl)benzyl]carbamate (889 mg, 3.06 mmol) was added, and the resulting mixture was stirred overnight at room temperature. Water was added to the reaction mixture, and the resulting precipitate was isolated by filtration, washed well with water and hexane, and dried under vacuum. Purification by column chromatography (SiO<sub>2</sub>, elution with 20−80% EtOAc in hexane) provided <i>tert</i>-butyl [3-{[((2<i>S</i>)-7-{[2-(acetylamino)pyridin-4-yl]oxy}-1,2,3,4-tetrahydronaphthalen-2-yl)carbonyl]amino}-5-(trifluoromethyl)benzyl]carbamate as an off white solid (1.21 g, 66%) <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.20 (s, 1H), 8.05 (d, <i>J =</i> 6.1 Hz, 1H), 7.83 (s, 1H), 7.75−7.70 (m, 1H), 7.12 (d, <i>J =</i> 8.3 Hz, 1H), 6.90−6.79 (m, 2H), 6.71 (dd, <i>J =</i> 6.1, 2.3 Hz, 1H), 5.01 (s, 1H), 4.32 (d, <i>J =</i> 6.0 Hz, 1H), 3.14−2.85 (m, 4H), 2.84−2.60 (m, 2H), 2.21 (s, 3H), 2.17−2.12 (m, 1H), 2.02−1.92 (m, 1H), and 1.45 (s, 9H).</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> General Procedure C, <i>tert</i>-Butyl Carbamate Deprotection</h3><div class="NLM_p last"><i>tert</i>-Butyl [3-{[((2<i>S</i>)-7-{[2-(acetylamino)pyridin-4-yl]oxy}-1,2,3,4-tetrahydronaphthalen-2-yl)carbonyl]amino}-5-(trifluoromethyl)benzyl]carbamate (1.21 g, 2.02 mmol) was dissolved in a 4.0 M HCl in dioxane solution (10 mL), and the solution was stirred for 2 h. The mixture was concentrated in vacuo. Purification of the resulting residue by column chromatography (SiO<sub>2</sub>, elution with 4−10% MeOH (with 2% NH<sub>4</sub>OH) in DCM) provided a white solid. This solid was dissolved in DCM (10 mL), and 2.0 M HCl in Et<sub>2</sub>O was added (2 mL). This mixture was stirred for 5 min and then concentrated in vacuo to give (2<i>S</i>)-7-{[2-(acetylamino)pyridin-4-yl]oxy}-<i>N</i>-[3-(aminomethyl)-5-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydronaphthalene-2-carboxamide·2HCl (<b>5</b>) as a white solid (807 mg, 70%). <sup>1</sup>H NMR (300 MHz, <i>d</i><sub>6</sub>-DMSO, HCl salt): δ 11.23 (br s, 1H), 10.74 (s, 1H), 8.43 (s, 2H), 8.23 (d, 1H), 8.13−7.99 (m, 2H), 7.58 (s, 1H), 7.35 (s, 1H), 7.28−7.22 (m, 1H), 7.05−6.94 (m, 2H), 6.87−6.80 (m, 1H), 4.13−4.02 (m, 2H), 2.98−2.79 (m, 5H), 2.10 (s, 4H), and 1.79 (br s, 1H). LC-MS: <i>m</i>/<i>z</i> 499.7 [M + H]<sup>+</sup>; 497.4 [M − H]<sup>−</sup> (FA). HRMS: <i>m</i>/<i>z</i> calcd for C<sub>26</sub>H<sub>25</sub>F<sub>3</sub>N<sub>4</sub>O<sub>3</sub> ([M + H])<sup>+</sup>, 499.19515; found, 499.195700.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> 5-Fluoro-3,4-dihydro-1,8-naphthyridin-2(1<i>H</i>)-one (<b>11</b>)</h3><div class="NLM_p">Palladium acetate (341 mg, 1.52 mmol) and 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (1.76 g, 3.04 mmol) were added to a three-necked, round-bottomed flask, and the flask was purged three times with argon. Degassed 1,4-dioxane (240 mL) was added, and the mixture was stirred and degassed again with argon. To this solution was added a solution of 2-chloro-4-fluoropyridine (20 g, 152 mmol) in degassed 1,4-dioxane (120 mL), <i>tert</i>-butyl carbamate (19.6 g, 167 mmol), NaOH (8.88 g, 222 mmol), and degassed water (4.0 mL, 222 mmol). The resulting mixture was stirred at 100 °C. After 1.5 h, the reaction mixture was cooled to room temperature and filtered through a pad of Celite. The pad was washed well with dioxane, and the filtrate was concentrated under reduced pressure to dryness. The resulting solid was recrystallized from 2-propanol (∼250 mL) to give <i>tert</i>-butyl (4-fluoropyridin-2-yl)carbamate (<b>9</b>) as a pale yellow crystalline solid (25.65 g, 79.5% yield). <sup>1</sup>H NMR (400 MHz, <i>d</i><sub>6</sub>-DMSO): δ 10.10 (s, 1H), 8.26 (dd, <i>J =</i> 9.5, 5.6 Hz, 1H), 7.60 (dd, <i>J =</i> 12.3, 2.3 Hz, 1H), 6.95 (ddd, <i>J =</i> 8.3, 5.6, 2.3 Hz, 1H), and 1.47 (s, 9H). LC-MS: <i>m</i>/<i>z</i> 213 [M + H]<sup>+</sup> (FA).</div><div class="NLM_p">An oven-dried, three-neck, round-bottomed flask equipped with an overhead stirrer, temperature probe, and addition funnel was charged with <i>tert</i>-butyl (4-fluoropyridin-2-yl)carbamate (31.8 g, 150 mmol), TMEDA (56.6 mL, 375 mmol), and THF (200 mL). The solution was cooled to −78 °C, and a solution of <i>n</i>-BuLi (2.50 M in hexane, 150 mL, 375 mmol) was added dropwise so that the reaction mixture temperature remained below −70 °C. The reaction mixture was stirred at −78 °C for 1 h, and a solution of I<sub>2</sub> (95.2 g, 375 mmol) in THF (160 mL) was added via addition funnel. The addition was controlled to keep the reaction mixture temperature below −70 °C, and the resulting mixture was stirred at −78 °C for 1 h. A solution of NaHSO<sub>4</sub> (61 g, 580 mmol) in water (200 mL) was added to the reaction mixture as it warmed to room temperature. Ethyl acetate was added, and the two-phase mixture was stirred at room temperature for 1 h. Water (500 mL) was added, and the phases were separated. The aqueous phase was extracted with EtOAc (3 × 400 mL), and the organic phases were combined, dried over MgSO<sub>4</sub>, filtered, and concentrated to give an off white solid. This solid was suspended in DCM (50 mL), and the solid was isolated by filtration and washed with a minimum of DCM. The filtrate was concentrated and filtered to give a second crop of product. The solids were combined and dried under vacuum to give <i>tert</i>-butyl (4-fluoro-3-iodopyridin-2-yl)carbamate (<b>10</b>) as a white solid (45.63 g, 86% yield). <sup>1</sup>H NMR (400 MHz, <i>d</i><sub>6</sub>-DMSO): δ 9.47 (s, 1H), 8.32 (dd, <i>J =</i> 8.9, 5.5 Hz, 1H), 7.18 (dd, <i>J =</i> 7.2, 5.5 Hz, 1H), and 1.44 (s, 9H). LC-MS: <i>m</i>/<i>z</i> 339 [M + H]<sup>+</sup> (FA).</div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-6/jm101479y/production/images/medium/jm-2010-01479y_0014.gif" alt="" id="_i23" /></img><div class="NLM_p last">A round-bottomed flask was charged with <i>tert</i>-butyl (4-fluoro-3-iodopyridin-2-yl)carbamate (20.0 g, 59.2 mmol), 3,3-diethoxy-1-propene (13.5 mL, 88.7 mmol), DMF (150 mL), water (50 mL), DIPEA (15.4 mL, 88.7 mmol), and Pd catalyst <b>29</b><a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> (480 mg, 0.827 mmol), and the reaction mixture was warmed to 140 °C. After 5 h, the reaction mixture was cooled in a refrigerator for 2 days. The precipitate was isolated by filtration, washed with diethyl ether, and dried to give 3.25 g of pink needles. The filtrate was concentrated to give a reddish semisolid. This material was redissolved in DCM, and the solution was passed through 200 g of SiO<sub>2</sub>. Concentration of the resulting solution provided a red/orange residue, which was recrystallized from 2-propanol (150 mL) to give 9.4 g of a pink solid. Purification of this pink solid by column chromatography (SiO<sub>2</sub>, elution with 0−75% EtOAc/DCM) provided 1.41 g of a white powder. Overall, 4.66 g of 5-fluoro-3,4-dihydro-1,8-naphthyridin-2(1<i>H</i>)-one (<b>11</b>) was isolated (47% yield). <sup>1</sup>H NMR (400 MHz, <i>d</i><sub>6</sub>-DMSO): δ 10.7 (s, 1H), 8.11 (dd, <i>J =</i> 8.5, 5.7 Hz, 1H), 6.91 (dd, <i>J =</i> 8.8, 5.7 Hz, 1H), 2.91−2.85 (m, 2H), and 2.55−2.50 (m, 2H). LC-MS: <i>m</i>/<i>z</i> 167 [M + H]<sup>+</sup> (FA).</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> (2<i>S</i>)-<i>N</i>-[3-[(Isopropylamino)methyl]-5-(trifluoromethyl)phenyl]-7-[(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-4-yl)oxy]-1,2,3,4-tetrahydronaphthalene-2-carboxamide (<b>7</b>)</h3><div class="NLM_p">A mixture of 5-fluoro-3,4-dihydro-1,8-naphthyridin-2(1<i>H</i>)-one (<b>11</b>, 50.0 mg, 0.301 mmol), (2<i>S</i>)-7-hydroxy-1,2,3,4-tetrahydro-naphthalene-2-carboxylic acid [(<i>S</i>)-<b>15</b>, 63.6 mg, 0.331 mmol], cesium carbonate (294 mg, 0.903 mmol), and <i>N</i>,<i>N</i>-dimethylacetamide (1.40 mL) was combined. The mixture was sealed in a microwave vial and heated in the microwave at 150 °C for 1 h. Water (5 mL) was added, and the mixture was allowed to stir for a few minutes. The clear solution was then neutralized by the addition of 1 N HCl solution, and the resulting suspension was filtered through a Celite pad. The solid residue was washed with MeOH, and the filtrate was concentrated in vacuo. The residue was purified by column chromatography (SiO<sub>2</sub>, eluting with 2−10% MeOH in DCM) to give (2<i>S</i>)-7-[(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-4-yl)oxy]-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid (42 mg, 41% yield), ee 93.2% (ee determined by chiral HPLC, Column: IA 4.6 mm × 250 mm, eluting with 100/0.1 EtOH/TFA, at 0.5 mL/min for 50 min). <sup>1</sup>H NMR (400 MHz, <i>d</i><sub>6</sub>-DMSO): δ 11.94 (s, 1H), 10.10 (s, 1H), 7.57 (d, <i>J =</i> 5.8 Hz, 1H), 6.76 (d, <i>J =</i> 8.3 Hz, 1H), 6.54−6.44 (m, 2H), 5.89 (d, <i>J =</i> 5.8 Hz, 1H), 2.64−2.34 (m, 6H), 2.33−2.23 (m, 1H), 2.16−2.12 (m, 2H), 1.79−1.65 (m, 1H), and 1.42−1.28 (m, 1H).</div><div class="NLM_p last">(2<i>S</i>)-7-[(7-Oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-4-yl)oxy]-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid and <i>tert</i>-butyl [3-amino-5-(trifluoromethyl)benzyl]isopropylcarbamate were combined as described in General Procedure B2, Amide Bond Formation, and the Boc group was removed as described in General Procedure C, <i>tert</i>-Butyl Carbamate Deprotection, to give <b>7</b> as the HCl salt (67% yield over both steps). <sup>1</sup>H NMR (400 MHz, <i>d</i><sub>6</sub>-DMSO): δ 10.71 (s, 1H), 10.61 (s, 1H), 9.07 (s, 2H), 8.11 (s, 1H), 8.05 (s, 1H), 7.99 (d, <i>J =</i> 5.9 Hz, 1H), 7.68 (s, 1H), 7.19 (d, <i>J =</i> 8.3 Hz, 1H), 6.95−6.88 (m, 2H), 6.32 (d, <i>J =</i> 5.9 Hz, 1H), 4.22−4.17 (m, 2H), 3.38−3.28 (m, 1H), 3.01−2.75 (m, 7H), 2.54 (t, <i>J =</i> 7.7, 7.7 Hz, 2H), 2.16−2.07 (m, 1H), 1.88−1.72 (m, 1H), 1.30 (s, 3H), and 1.28 (s, 3H). HRMS: <i>m</i>/<i>z</i> calcd for C<sub>30</sub>H<sub>31</sub>F<sub>3</sub>N<sub>4</sub>O<sub>3</sub> ([M + H])<sup>+</sup>, 553.24210; found, 553.24265.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> General Procedure B3, Amide Bond Formation</h3><div class="NLM_p last">A solution of <i>N</i>-(4-{[(7<i>R</i>)-7-amino-5,6,7,8-tetrahydronaphthalen-2-yl]oxy}pyridin-2-yl)cyclopropanecarboxamide (10.2 g, 31.5 mmol) and HCl (2.0 M solution in Et<sub>2</sub>O, 32 mL, 63 mmol) in pyridine (170 mL) was treated with 3-[(dimethylamino)methyl]-5-(trifluoromethyl)benzoic acid·Li salt (9.18 g, 36.3 mmol) and EDCI (9.67 g, 50.5 mmol). This solution was stirred overnight and then partitioned between EtOAc (500 mL) and half-saturated NaHCO<sub>3</sub> solution (500 mL). The aqueous phase was extracted with DCM (2 × 100 mL), and the combined organic phases were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. Purification by column chromatography (SiO<sub>2</sub>, elution with 100% DCM to 15% EtOH, 15% MeCN, and 75% DCM) provided <i>N</i>-[(2<i>R</i>)-7-({2-[(cyclopropylcarbonyl)amino]pyridin-4-yl}oxy)-1,2,3,4-tetrahydronaphthalen-2-yl]-3-[(dimethylamino)methyl]-5-(trifluoromethyl)benzamide (<b>8</b>) as a beige powder (14.3 g, 82%).</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> General Procedure D, HCl Salt Formation</h3><div class="NLM_p last">Compound <b>8</b> (14.3 g, 25.9 mmol) was dissolved in Et<sub>2</sub>O (200 mL), and the solution was cooled to 0 °C. HCl (2.0 M in Et<sub>2</sub>O, 39 mL, 78 mmol) was added dropwise over 10 min, and a precipitate appeared immediately. The mixture was warmed to room temperature and stirred for 15 min. The hygroscopic precipitate was isolated by filtration, redissolved in EtOH and MeOH, concentrated in vacuo, and dried in a vacuum oven at 37 °C overnight. Compound <b>8</b>·2HCl was provided as an off white solid (14.2 g, 88%). <sup>1</sup>H NMR (400 MHz, <i>d</i><sub>6</sub>-DMSO, HCl salt): δ 11.62−11.77 (m, 1H), 10.77 (s, 1H), 8.43 (br s, 2H), 8.22 (d, 1H), 8.06 (s, 1H), 8.03 (s, 1H), 7.59 (s, 1H), 7.33 (s, 1H), 7.24 (d, 1H), 7.04−6.95 (m, 2H), 6.88−6.82 (m, 1H), 4.05−4.11 (m, 2H), 2.99−2.75 (m, 5H), 2.17−1.72 (m, 3H), and 0.91−0.80 (m, 4H). LC-MS: <i>m</i>/<i>z</i> 525.6 [M + H]<sup>+</sup>, 523.3 [M − H]<sup>−</sup> (FA). HRMS: <i>m</i>/<i>z</i> calcd for C<sub>30</sub>H<sub>31</sub>F<sub>3</sub>N<sub>4</sub>O<sub>3</sub> ([M + H])<sup>+</sup>, 553.24210; found, 553.242651.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> General Procedure A2, Biaryl Ether Bond Formation</h3><div class="NLM_p last">A mixture of (7<i>R</i>)-7-amino-5,6,7,8-tetrahydronaphthalen-2-ol hydrobromide (<b>17</b>, 16.7 g, 68.2 mmol), 5-fluoro-3,4-dihydro-1,8-naphthyridin-2(1<i>H</i>)-one (<b>11</b>, 11.36 g, 64.95 mmol), and cesium carbonate (63.49 g, 194.9 mmol) in DMF (216 mL) was stirred at 140 °C for 2 h. The reaction was not complete, so additional (7<i>R</i>)-7-amino-5,6,7,8-tetrahydronaphthalen-2-ol hydrobromide (<b>17</b>, 1.70 g, 6.82 mmol) was added. After an additional 1 h at 140 °C, the reaction mixture was cooled to room temperature and carefully treated with an aqueous 1 M HCl solution. The reaction mixture was then diluted with DCM and filtered through Celite. The phases were separated, and the aqueous phase was brought to pH 7 by the addition of a solution of NaOH (1.0 M). The brown precipitate was then removed by filtration through Celite, and the filtrate was washed with DCM. The aqueous phase was then brought to pH 14 by addition of a solution of NaOH (1.0 M), and an off-white precipitate formed. This suspension was treated with solid NaCl and stirred for 1 h. The solid was isolated by filtration and dried under vacuum to give 5-{[(7<i>R</i>)-7-amino-5,6,7,8-tetrahydronaphthalen-2-yl]oxy}-3,4-dihydro-1,8-naphthyridin-2(1<i>H</i>)-one as an off-white solid (17.7 g, 88% yield). <sup>1</sup>H NMR (400 MHz, <i>d</i><sub>6</sub>-DMSO): δ 10.6−10.4 (br s, 1H), 7.94 (d, <i>J =</i> 5.8 Hz, 1H), 7.13 (d, <i>J =</i> 7.9 Hz, 1H), 6.87−6.81 (m, 2H), 6.27 (d, <i>J =</i> 5.8 Hz, 1H), 3.05−2.96 (m, 1H), 2.93−2.79 (m, 4H), 2.77−2.66 (m, 1H), 2.55−2.50 (m, 2H), 2.46−2.38 (m, 1H), 1.92−1.84 (m, 1H), 1.82−1.60 (br s, 2H), and 1.51−1.40 (m, 1H). LC-MS: <i>m</i>/<i>z</i> 310 [M + H]<sup>+</sup> (AA).</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> 3-[(Dimethylamino)methyl]-<i>N</i>-{(2<i>R</i>)-7-[(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-4-yl)oxy]-1,2,3,4-tetrahydronaphthalen-2-yl}-5-(trifluoromethyl)benzamide (<b>26</b>)</h3><div class="NLM_p last">3-[(Dimethylamino)methyl]-5-(trifluoromethyl)benzoic acid·Li salt and 5-{[(7<i>R</i>)-7-amino-5,6,7,8-tetrahydronaphthalen-2-yl]oxy}-3,4-dihydro-1,8-naphthyridin-2(1<i>H</i>)-one were combined as described in General Procedures B3, Amide Bond Formation, and D, HCl Salt Formation, to provide <b>26</b> (20.9 g, 67%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 8.36 (s, 1 H), 8.30 (s, 1H), 8.10−8.06 (m, 2H), 7.33−7.26 (m, 1H), 7.04−6.96 (m, 2H), 6.68 (d, <i>J</i> = 7.0 Hz, 1H), 4.51 (s, 2H), 4.40−4.31 (m, 1H), 3.24−3.16 (m, 3H), 3.06−2.94 (m, 3H), 2.90 (s, 6H), 2.81−2.77 (m, 2H), 2.26−2.19 (m, 1H), 2.01−1.89 (m, 1H). HRMS: <i>m</i>/<i>z</i> calcd for C<sub>29</sub>H<sub>29</sub>F<sub>3</sub>N<sub>4</sub>O<sub>3</sub> ([M + H])<sup>+</sup>, 539.22645; found, 539.22700.</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> 3-(1-Amino-1-methylethyl)-<i>N</i>-{(2<i>R</i>)-7-[(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-4-yl)oxy]-1,2,3,4-tetrahydronaphthalen-2-yl}-5-(trifluoromethyl)benzamide (<b>27</b>)</h3><div class="NLM_p last">3-{1-[(<i>tert</i>-Butoxycarbonyl)amino]-1-methylethyl}-5-(trifluoromethyl)benzoic acid and 5-{[(7<i>R</i>)-7-amino-5,6,7,8-tetrahydronaphthalen-2-yl]oxy}-3,4-dihydro-1,8-naphthyridin-2(1<i>H</i>)-one were combined as described in General Procedure B3, Amide Bond Formation, without the addition of HCl and General Procedure C to provide <b>27</b> (44.1 g, 61%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 8.06 (s, 1H), 7.87 (s, 1H), 7.75 (d, <i>J</i> = 6.88 Hz, 1H), 7.67 (s, 1H), 6.95 (d, <i>J</i> = 8.40 Hz, 1H), 6.68−6.63 (m, 2H), 6.35 (d, <i>J</i> = 6.93 Hz, 1H), 4.05−3.95 (m, 1H), 2.88−2.81 (m, 3H), 2.70−2.58 (m, 3H), 2.45 (t, <i>J</i> = 7.46, 7.46 Hz, 2H), 1.91−1.83 (m, 1H), 1.67−1.55 (m, 1H), and 1.47 (s, 6H). HRMS: <i>m</i>/<i>z</i> calcd for C<sub>29</sub>H<sub>29</sub>F<sub>3</sub>N<sub>4</sub>O<sub>3</sub> ([M + H])<sup>+</sup>, 539.22645; found, 539.22700.</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> V600E and C-Raf Enzyme Assays</h3><div class="NLM_p last">Raf enzyme activity was determined using a Flash Plate Assay format by adding 15 μL of a solution containing 50 mM HEPES, pH 7.5, 0.025% Brij 35, 10 mM DTT, and 10 nM Raf (<sup>V600E</sup>ΔB-Raf or C-Raf) to the wells of an assay plate containing compound and was incubated for 20 min. A substrate solution (15 μL) containing 50 mM HEPES, pH 7.5, 0.025% Brij 35, 5 mM β-glycerol phosphate, 10 mM MnCl<sub>2</sub>, 2 μM peptide (Biotin-DRGFPRARYRARTTNYNSSRSRFYSGFNSRPRGRVYRGRARATSWYSPY-NH<sub>2</sub>, New England Peptide), 1 μM ATP, 0.1 mg/mL BSA, and <sup>33</sup>P ATP 0.5 μCi/reaction was then added. The reaction mixture was incubated for 3 h and then stopped by the addition of 50 μL of 100 mM EDTA. The stopped reaction mixture (65 μL) was transferred to a Flash Plate (Perkin-Elmer) and incubated for 1 (C-Raf) or 2 (<sup>V600E</sup>ΔB-Raf) h. The wells were washed three times with 0.02% Tween-20. Plates were read on a TopCount analyzer.</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> pERK Cell-Based Assay</h3><div class="NLM_p last">Inhibition of Raf kinase activity in whole cells was assessed by determining the decrease in phosphorylation of the pERK, a kinase downstream of Raf, phosphorylated by MEK. A375 cells were seeded in a 96-well cell culture plate (12 × 103 cells/75 μL/well) and incubated overnight at 37 °C. Compounds were added, and cells were incubated with Raf kinase inhibitors for 3 h at 37 °C. Medium was removed, and cells were fixed with 4% paraformaldehyde for 15 min at room temperature. Four percent paraformaldehyde was replaced with methanol for a 15 min treatment and then blocked with 10% sheep serum and 1% BSA in PBS for 1 h. Cells were then incubated with anti-pERK antibody (1:100, Cell Signaling Technologies, #9101 L) (20 μL/well) overnight at 4 °C. After they were washed with PBS three times, the cells were stained with antirabbit horseradish peroxidase-linked antibody from donkey (1:100, Amersham Bioscience #NA9340) for 1 h at room temperature. Cells were washed three times with 0.5% Tween-20 in PBS and then three more times with PBS. 3,3′,5,5′-Tetramethylbenzidine liquid substrate system (50 μL/well) was added, and cells were incubated for 20−30 min at room temperature. The optical density was read at 650 nm. The cells were then washed 3−5 times with PBS to remove color solution. Results were normalized for the protein content in each well using a BCA protein assay kit (Pierce).</div></div><div id="sec4_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> Xenograft Studies</h3><div class="NLM_p">The A375 M cell line (a derivative of A375<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a>) was licensed from MD Anderson Cancer Center. Nude NCR (ν/ν) mice were purchased from Taconic. All animals were housed and handled in accordance with the Guide for the Care and Use of Laboratory Animals and Millennium Institutional Animal Care and Use Committee guidelines. Six to eight week old mice were inoculated subcutaneously with A375 M cells (5 × 10<sup>6</sup>) in the right flank. Mice were dosed orally with 0.2 mL of <b>26</b> or <b>27</b> or vehicle only as a control. The vehicle was 10% (2-hydroxypropyl)-β-cyclodextrin (HPbCD) in water, and the pH was adjusted to between 4 and 6 by the addition of 0.1 N NaOH.</div><div class="NLM_p">For efficacy studies, mice were randomized to generate groups of 10 per treatment with equivalent average initial tumor volume (150−200 mm<sup>3</sup>) and dosed daily for 21 days. Tumor volumes were measured twice a week using vernier calipers, and volumes were calculated using the formula <i>L</i> × <i>W</i><sup>2</sup> × 0.5.</div><div class="NLM_p last">For PK/PD studies, mice were euthanized, and blood was collected by cardiac puncture and processed to plasma. Compound levels were measured in plasma by LC/MS/MS. Xenograft tumors were excised and trimmed of necrotic areas and flash-frozen for PD analysis. pERK levels were measured in tumor lysates by Li-Cor quantitative Western blot using a rabbit monoclonal antibody (pERK1/2-Thr202/Tyr204, Cell Signaling Catalog #4377).</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i34"><a href="/doi/suppl/10.1021/jm101479y">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77330" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77330" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Synthetic details and characterization data for 7-(2-acetamidopyridin-4-yloxy)-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid, <i>N</i>-(4-{[(7<i>R</i>)-7-amino-5,6,7,8-tetrahydronaphthalen-2-yl]oxy}pyridin-2-yl)cyclopropanecarboxamide, <i>N</i>-(4-nitropyridin-2-yl)-acetamide, <i>N</i>-(4-nitropyridin-2-yl)-cyclopropane-carboxamide, <i>tert</i>-butyl [3-amino-5-(trifluoromethyl)benzyl]isopropylcarbamate, 3-[(dimethylamino)methyl]-5-(trifluoromethyl)benzoic acid·Li salt, 3-{1-[(<i>tert</i>-butoxycarbonyl)amino]-1-methylethyl}-5-(trifluoromethyl)benzoic acid, and compounds <b>6</b>, (±)-<b>15</b>, (<i>S</i>)-<b>15</b>, <b>17</b>, and <b>19</b>−<b>25</b>; and kinase binding data for <b>26</b> and <b>27</b>. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm101479y/suppl_file/jm101479y_si_001.pdf">jm101479y_si_001.pdf (240.42 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm101479y" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21845" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21845" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alexandra E. Gould</span> - <span class="hlFld-Affiliation affiliation">Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#9be8faf5ffe2b5fcf4eef7ffdbf6ebf2b5f8f4f6"><span class="__cf_email__" data-cfemail="6f1c0e010b164108001a030b2f021f06410c0002">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ruth Adams</span> - <span class="hlFld-Affiliation affiliation">Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sharmila Adhikari</span> - <span class="hlFld-Affiliation affiliation">Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kathleen Aertgeerts</span> - <span class="hlFld-Affiliation affiliation">Takeda San Diego, 10410 Science Center Drive, San Diego, California 92130, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Roushan Afroze</span> - <span class="hlFld-Affiliation affiliation">Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christopher Blackburn</span> - <span class="hlFld-Affiliation affiliation">Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Emily F. Calderwood</span> - <span class="hlFld-Affiliation affiliation">Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ryan Chau</span> - <span class="hlFld-Affiliation affiliation">Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jouhara Chouitar</span> - <span class="hlFld-Affiliation affiliation">Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthew O. Duffey</span> - <span class="hlFld-Affiliation affiliation">Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dylan B. England</span> - <span class="hlFld-Affiliation affiliation">Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Cheryl Farrer</span> - <span class="hlFld-Affiliation affiliation">Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nancy Forsyth</span> - <span class="hlFld-Affiliation affiliation">Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Khristofer Garcia</span> - <span class="hlFld-Affiliation affiliation">Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeffery Gaulin</span> - <span class="hlFld-Affiliation affiliation">Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul D. Greenspan</span> - <span class="hlFld-Affiliation affiliation">Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ribo Guo</span> - <span class="hlFld-Affiliation affiliation">Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sean J. Harrison</span> - <span class="hlFld-Affiliation affiliation">Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shih-Chung Huang</span> - <span class="hlFld-Affiliation affiliation">Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Natalia Iartchouk</span> - <span class="hlFld-Affiliation affiliation">Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dave Janowick</span> - <span class="hlFld-Affiliation affiliation">Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mi-Sook Kim</span> - <span class="hlFld-Affiliation affiliation">Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bheemashankar Kulkarni</span> - <span class="hlFld-Affiliation affiliation">Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Steven P. Langston</span> - <span class="hlFld-Affiliation affiliation">Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jane X. Liu</span> - <span class="hlFld-Affiliation affiliation">Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Li-Ting Ma</span> - <span class="hlFld-Affiliation affiliation">Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Saurabh Menon</span> - <span class="hlFld-Affiliation affiliation">Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hirotake Mizutani</span> - <span class="hlFld-Affiliation affiliation">Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Erin Paske</span> - <span class="hlFld-Affiliation affiliation">Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christelle C. Renou</span> - <span class="hlFld-Affiliation affiliation">Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mansoureh Rezaei</span> - <span class="hlFld-Affiliation affiliation">Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">R. Scott Rowland</span> - <span class="hlFld-Affiliation affiliation">Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael D. Sintchak</span> - <span class="hlFld-Affiliation affiliation">Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael D. Smith</span> - <span class="hlFld-Affiliation affiliation">Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stephen G. Stroud</span> - <span class="hlFld-Affiliation affiliation">Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ming Tregay</span> - <span class="hlFld-Affiliation affiliation">Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yuan Tian</span> - <span class="hlFld-Affiliation affiliation">Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ole P. Veiby</span> - <span class="hlFld-Affiliation affiliation">Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tricia J. Vos</span> - <span class="hlFld-Affiliation affiliation">Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stepan Vyskocil</span> - <span class="hlFld-Affiliation affiliation">Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Juliet Williams</span> - <span class="hlFld-Affiliation affiliation">Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tianlin Xu</span> - <span class="hlFld-Affiliation affiliation">Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Johnny J. Yang</span> - <span class="hlFld-Affiliation affiliation">Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jason Yano</span> - <span class="hlFld-Affiliation affiliation">Takeda San Diego, 10410 Science Center Drive, San Diego, California 92130, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hongbo Zeng</span> - <span class="hlFld-Affiliation affiliation">Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dong Mei Zhang</span> - <span class="hlFld-Affiliation affiliation">Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qin Zhang</span> - <span class="hlFld-Affiliation affiliation">Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Katherine M. Galvin</span> - <span class="hlFld-Affiliation affiliation">Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li></ul></li><li></li><li></li><li></li></ul></div><div class="ack"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i33">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58383" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58383" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Ashok Patil and Nanda Gulavita for assistance in purification; Xiaofeng Yang for determining the exact masses; David Lok and Nina Molchanova for determining the HPLC purity of our compounds; Bi-Ching Sang, Garret Textor, Matt Kroeger, and Gyorgy Snell from Takeda San Diego for their assistance in determining the crystal structure of compound <b>24</b>; and Matt Jones, Ling Xu, David Lok, Susan Chen, and Shaoxia Yu for determining plasma levels of the compounds described in this paper. We also thank ALS, which is supported by the Director, Office of Science, Office of Basic Energy Sciences, Materials Sciences Division of the U.S. Department of Energy, under contract DE-AC03-76SF00098 at Lawrence Berkeley National Laboratory.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i35" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i35"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i36" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i36"> Abbreviations Used</h2><tr><td class="NLM_term">MAPK</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase</p></td></tr><tr><td class="NLM_term">ERK</td><td class="NLM_def"><p class="first last">extracellular signal-regulated kinase</p></td></tr><tr><td class="NLM_term">MEK</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">Clp</td><td class="NLM_def"><p class="first last">plasma clearance</p></td></tr><tr><td class="NLM_term">Vss</td><td class="NLM_def"><p class="first last">steady state volume of distribution</p></td></tr><tr><td class="NLM_term">AUC</td><td class="NLM_def"><p class="first last">area under the curve</p></td></tr><tr><td class="NLM_term">HPbCD</td><td class="NLM_def"><p class="first last">(2-hydroxypropyl)-β-cyclodextrin</p></td></tr><tr><td class="NLM_term">PK/PD</td><td class="NLM_def"><p class="first last">pharmacokinetic/pharmacodynamic</p></td></tr><tr><td class="NLM_term">RTK</td><td class="NLM_def"><p class="first last">receptor tyrosine kinase</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i37">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13052" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13052" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 22 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Robinson, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cobb, M. H.</span><span> </span><span class="NLM_article-title">Mitogen-activated Protein Kinase Pathways</span> <span class="citation_source-journal">Curr. Opin. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">180</span><span class="NLM_x">–</span> <span class="NLM_lpage">186</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm101479y&amp;key=10.1016%2FS0955-0674%2897%2980061-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm101479y&amp;key=9069255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm101479y&amp;key=1%3ACAS%3A528%3ADyaK2sXisVWntLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1997&pages=180-186&author=M.+J.+Robinsonauthor=M.+H.+Cobb&title=Mitogen-activated+Protein+Kinase+Pathways"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Mitogen-activated protein kinase pathways</span></div><div class="casAuthors">Robinson, Megan J.; Cobb, Melanie H.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Cell Biology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">180-186</span>CODEN:
                <span class="NLM_cas:coden">COCBE3</span>;
        ISSN:<span class="NLM_cas:issn">0955-0674</span>.
    
            (<span class="NLM_cas:orgname">Current Biology</span>)
        </div><div class="casAbstract">A review with 87 refs.  Nearly all cell surface receptors utilize one or more of the mitogen-activated protein kinase cascades in their repertoire of signal transduction mechanisms.  Recent advances in the study of such cascades include the cloning of genes encoding novel members of the cascades, further definition of the roles of the cascades in responses to extracellular signals, and examn. of cross-talk between different cascades.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHUil3pmYpQbVg90H21EOLACvtfcHk0lgJppwDZiGAIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXisVWntLk%253D&md5=c51543227d52f723ba92072d72c3006a</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS0955-0674%2897%2980061-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0955-0674%252897%252980061-0%26sid%3Dliteratum%253Aachs%26aulast%3DRobinson%26aufirst%3DM.%2BJ.%26aulast%3DCobb%26aufirst%3DM.%2BH.%26atitle%3DMitogen-activated%2520Protein%2520Kinase%2520Pathways%26jtitle%3DCurr.%2520Opin.%2520Cell%2520Biol.%26date%3D1997%26volume%3D9%26spage%3D180%26epage%3D186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Roberts, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Der, C. J.</span><span> </span><span class="NLM_article-title">Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">3291</span><span class="NLM_x">–</span> <span class="NLM_lpage">3310</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm101479y&amp;key=10.1038%2Fsj.onc.1210422" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm101479y&amp;key=17496923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm101479y&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlt1Wktb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=3291-3310&author=P.+J.+Robertsauthor=C.+J.+Der&title=Targeting+the+Raf-MEK-ERK+mitogen-activated+protein+kinase+cascade+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer</span></div><div class="casAuthors">Roberts, P. J.; Der, C. J.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">3291-3310</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Mitogen-activated protein kinase (MAPK) cascades are key signaling pathways involved in the regulation of normal cell proliferation, survival and differentiation.  Aberrant regulation of MAPK cascades contribute to cancer and other human diseases.  In particular, the extracellular signal-regulated kinase (ERK) MAPK pathway has been the subject of intense research scrutiny leading to the development of pharmacol. inhibitors for the treatment of cancer.  ERK is a downstream component of an evolutionarily conserved signaling module that is activated by the Raf serine/threonine kinases.  Raf activates the MAPK/ERK kinase (MEK)1/2 dual-specificity protein kinases, which then activate ERK1/2.  The mutational activation of Raf in human cancers supports the important role of this pathway in human oncogenesis.  Addnl., the Raf-MEK-ERK pathway is a key downstream effector of the Ras small GTPase, the most frequently mutated oncogene in human cancers.  Finally, Ras is a key downstream effector of the epidermal growth factor receptor (EGFR), which is mutationally activated and/or overexpressed in a wide variety of human cancers.  ERK activation also promotes upregulated expression of EGFR ligands, promoting an autocrine growth loop crit. for tumor growth.  Thus, the EGFR-Ras-Raf-MEK-ERK signaling network has been the subject of intense research and pharmaceutical scrutiny to identify novel target-based approaches for cancer treatment.  In this review, we summarize the current status of the different approaches and targets that are under evaluation and development for the therapeutic intervention of this key signaling pathway in human disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7hdVDVyRBHrVg90H21EOLACvtfcHk0lhgmu8kzhv3ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlt1Wktb4%253D&md5=bf56109e3b4defc12004471da30178c0</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1210422&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1210422%26sid%3Dliteratum%253Aachs%26aulast%3DRoberts%26aufirst%3DP.%2BJ.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26atitle%3DTargeting%2520the%2520Raf-MEK-ERK%2520mitogen-activated%2520protein%2520kinase%2520cascade%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D3291%26epage%3D3310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Davies, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bignell, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephens, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edkins, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clegg, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teague, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woffendin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garnett, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bottomley, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dicks, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ewing, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawes, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosmidou, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menzies, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mould, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hooper, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayatilake, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Busterson, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shipley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hargrave, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard-Jones, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maitland, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chenevix-Trench, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riggins, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bigner, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmieri, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cossu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flanagan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, J. W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuen, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seigler, H. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darrow, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paterson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marais, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wooster, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stratton, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Futreal, P. A.</span><span> </span><span class="NLM_article-title">Mutations of the BRAF Gene in Human Cancer</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">417</span><span class="NLM_x">, </span> <span class="NLM_fpage">949</span><span class="NLM_x">–</span> <span class="NLM_lpage">954</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm101479y&amp;key=10.1038%2Fnature00766" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm101479y&amp;key=12068308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm101479y&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvVagsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=417&publication_year=2002&pages=949-954&author=H.+Daviesauthor=G.+R.+Bignellauthor=C.+Coxauthor=P.+Stephensauthor=S.+Edkinsauthor=S.+Cleggauthor=J.+Teagueauthor=H.+Woffendinauthor=M.+J.+Garnettauthor=W.+Bottomleyauthor=N.+Davisauthor=E.+Dicksauthor=R.+Ewingauthor=Y.+Floydauthor=K.+Grayauthor=S.+Hallauthor=R.+Hawesauthor=J.+Hughesauthor=V.+Kosmidouauthor=A.+Menziesauthor=C.+Mouldauthor=A.+Parkerauthor=C.+Stevensauthor=S.+Wattauthor=S.+Hooperauthor=R.+Wilsonauthor=H.+Jayatilakeauthor=B.+A.+Bustersonauthor=C.+Cooperauthor=J.+Shipleyauthor=D.+Hargraveauthor=K.+Pritchard-Jonesauthor=N.+Maitlandauthor=G.+Chenevix-Trenchauthor=G.+J.+Rigginsauthor=D.+D.+Bignerauthor=G.+Palmieriauthor=A.+Cossuauthor=A.+Flanaganauthor=A.+Nicholsonauthor=J.+W.+C.+Hoauthor=S.+Y.+Leungauthor=S.+T.+Yuenauthor=B.+L.+Weberauthor=H.+F.+Seiglerauthor=T.+L.+Darrowauthor=H.+Patersonauthor=R.+Maraisauthor=C.+J.+Marshallauthor=R.+Woosterauthor=M.+R.+Strattonauthor=P.+A.+Futreal&title=Mutations+of+the+BRAF+Gene+in+Human+Cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations of the BRAF gene in human cancer</span></div><div class="casAuthors">Davies, Helen; Bignell, Graham R.; Cox, Charles; Stephens, Philip; Edkins, Sarah; Clegg, Sheila; Teague, Jon; Woffendin, Hayley; Garnett, Mathew J.; Bottomley, William; Davis, Neil; Dicks, Ed; Ewing, Rebecca; Floyd, Yvonne; Gray, Kristian; Hall, Sarah; Hawes, Rachel; Hughes, Jaime; Kosmidou, Vivian; Menzies, Andrew; Mould, Catherine; Parker, Adrian; Stevens, Claire; Watt, Stephen; Hooper, Steven; Wilson, Rebecca; Jayatilake, Hiran; Gusterson, Barry A.; Cooper, Colin; Shipley, Janet; Hargrave, Darren; Pritchard-Jones, Katherine; Maitland, Norman; Chenevix-Trench, Georgia; Riggins, Gregory J.; Bigner, Darell D.; Palmieri, Giuseppe; Cossu, Antonio; Flanagan, Adrienne; Nicholson, Andrew; Ho, Judy W. C.; Leung, Suet Y.; Yuen, Siu T.; Weber, Barbara L.; Seigler, Hilliard F.; Darrow, Timothy L.; Paterson, Hugh; Marais, Richard; Marshall, Christopher J.; Wooster, Richard; Stratton, Michael R.; Futreal, P. Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">417</span>
        (<span class="NLM_cas:issue">6892</span>),
    <span class="NLM_cas:pages">949-954</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cancers arise owing to the accumulation of mutations in crit. genes that alter normal programs of cell proliferation, differentiation and death.  As the first stage of a systematic genome-wide screen for these genes, we have prioritized for anal. signalling pathways in which at least one gene is mutated in human cancer.  The RAS-RAF-MEK-ERK-MAP kinase pathway mediates cellular responses to growth signals.  RAS is mutated to an oncogenic form in about 15% of human cancer.  The three RAF genes code for cytoplasmic serine/threonine kinases that are regulated by binding RAS.  Here we report BRAF somatic missense mutations in 66% of malignant melanomas and at lower frequency in a wide range of human cancers.  All mutations are within the kinase domain, with a single substitution (V599E) accounting for 80%.  Mutated BRAF proteins have elevated kinase activity and are transforming in NIH3T3 cells.  Furthermore, RAS function is not required for the growth of cancer cell lines with the V599E mutation.  As BRAF is a serine/threonine kinase that is commonly activated by somatic point mutation in human cancer, it may provide new therapeutic opportunities in malignant melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPBmhJC0GAjrVg90H21EOLACvtfcHk0lhgmu8kzhv3ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvVagsLo%253D&md5=4625be53ad9a382d51b6ee753d0c17e8</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnature00766&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature00766%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DH.%26aulast%3DBignell%26aufirst%3DG.%2BR.%26aulast%3DCox%26aufirst%3DC.%26aulast%3DStephens%26aufirst%3DP.%26aulast%3DEdkins%26aufirst%3DS.%26aulast%3DClegg%26aufirst%3DS.%26aulast%3DTeague%26aufirst%3DJ.%26aulast%3DWoffendin%26aufirst%3DH.%26aulast%3DGarnett%26aufirst%3DM.%2BJ.%26aulast%3DBottomley%26aufirst%3DW.%26aulast%3DDavis%26aufirst%3DN.%26aulast%3DDicks%26aufirst%3DE.%26aulast%3DEwing%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DY.%26aulast%3DGray%26aufirst%3DK.%26aulast%3DHall%26aufirst%3DS.%26aulast%3DHawes%26aufirst%3DR.%26aulast%3DHughes%26aufirst%3DJ.%26aulast%3DKosmidou%26aufirst%3DV.%26aulast%3DMenzies%26aufirst%3DA.%26aulast%3DMould%26aufirst%3DC.%26aulast%3DParker%26aufirst%3DA.%26aulast%3DStevens%26aufirst%3DC.%26aulast%3DWatt%26aufirst%3DS.%26aulast%3DHooper%26aufirst%3DS.%26aulast%3DWilson%26aufirst%3DR.%26aulast%3DJayatilake%26aufirst%3DH.%26aulast%3DBusterson%26aufirst%3DB.%2BA.%26aulast%3DCooper%26aufirst%3DC.%26aulast%3DShipley%26aufirst%3DJ.%26aulast%3DHargrave%26aufirst%3DD.%26aulast%3DPritchard-Jones%26aufirst%3DK.%26aulast%3DMaitland%26aufirst%3DN.%26aulast%3DChenevix-Trench%26aufirst%3DG.%26aulast%3DRiggins%26aufirst%3DG.%2BJ.%26aulast%3DBigner%26aufirst%3DD.%2BD.%26aulast%3DPalmieri%26aufirst%3DG.%26aulast%3DCossu%26aufirst%3DA.%26aulast%3DFlanagan%26aufirst%3DA.%26aulast%3DNicholson%26aufirst%3DA.%26aulast%3DHo%26aufirst%3DJ.%2BW.%2BC.%26aulast%3DLeung%26aufirst%3DS.%2BY.%26aulast%3DYuen%26aufirst%3DS.%2BT.%26aulast%3DWeber%26aufirst%3DB.%2BL.%26aulast%3DSeigler%26aufirst%3DH.%2BF.%26aulast%3DDarrow%26aufirst%3DT.%2BL.%26aulast%3DPaterson%26aufirst%3DH.%26aulast%3DMarais%26aufirst%3DR.%26aulast%3DMarshall%26aufirst%3DC.%2BJ.%26aulast%3DWooster%26aufirst%3DR.%26aulast%3DStratton%26aufirst%3DM.%2BR.%26aulast%3DFutreal%26aufirst%3DP.%2BA.%26atitle%3DMutations%2520of%2520the%2520BRAF%2520Gene%2520in%2520Human%2520Cancer%26jtitle%3DNature%26date%3D2002%26volume%3D417%26spage%3D949%26epage%3D954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Lee, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, E.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y.-S.</span><span> </span><span class="NLM_article-title">Clinicopathologic Significance of BRAF V600E Mutations in Papillary Carcinomas of the Thyroid</span> <span class="citation_source-journal">Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">38</span><span class="NLM_x">–</span> <span class="NLM_lpage">46</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2007&pages=38-46&author=J.+H.+Leeauthor=E.-S.+Leeauthor=Y.-S.+Kim&title=Clinicopathologic+Significance+of+BRAF+V600E+Mutations+in+Papillary+Carcinomas+of+the+Thyroid"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DLee%26aufirst%3DE.-S.%26aulast%3DKim%26aufirst%3DY.-S.%26atitle%3DClinicopathologic%2520Significance%2520of%2520BRAF%2520V600E%2520Mutations%2520in%2520Papillary%2520Carcinomas%2520of%2520the%2520Thyroid%26jtitle%3DCancer%26date%3D2007%26volume%3D110%26spage%3D38%26epage%3D46" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Gray-Schopfer, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wellbrock, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marais, R.</span><span> </span><span class="NLM_article-title">Melanoma biology and new targeted therapy</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">445</span><span class="NLM_x">, </span> <span class="NLM_fpage">851</span><span class="NLM_x">–</span> <span class="NLM_lpage">857</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm101479y&amp;key=10.1038%2Fnature05661" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm101479y&amp;key=17314971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm101479y&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvFGiu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=445&publication_year=2007&pages=851-857&author=V.+Gray-Schopferauthor=C.+Wellbrockauthor=R.+Marais&title=Melanoma+biology+and+new+targeted+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Melanoma biology and new targeted therapy</span></div><div class="casAuthors">Gray-Schopfer, Vanessa; Wellbrock, Claudia; Marais, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">445</span>
        (<span class="NLM_cas:issue">7130</span>),
    <span class="NLM_cas:pages">851-857</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Melanoma is a cancer that arises from melanocytes, specialized pigmented cells that are found predominantly in the skin.  The incidence of melanoma is rising steadily in western populations - the no. of cases worldwide has doubled in the past 20 years.  In its early stages malignant melanoma can be cured by surgical resection, but once it has progressed to the metastatic stage it is extremely difficult to treat and does not respond to current therapies.  Recent discoveries in cell signalling have provided greater understanding of the biol. that underlies melanoma, and these advances are being exploited to provide targeted drugs and new therapeutic approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXWnhlx-AzCbVg90H21EOLACvtfcHk0lj0WRkzNME_ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvFGiu7g%253D&md5=a898105964c68ba64eca76489a703e8d</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnature05661&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature05661%26sid%3Dliteratum%253Aachs%26aulast%3DGray-Schopfer%26aufirst%3DV.%26aulast%3DWellbrock%26aufirst%3DC.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DMelanoma%2520biology%2520and%2520new%2520targeted%2520therapy%26jtitle%3DNature%26date%3D2007%26volume%3D445%26spage%3D851%26epage%3D857" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6a"><span><span class="NLM_contrib-group">King, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patrick, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batorsky, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Do, H. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusnak, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takle, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hugger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wnag, L</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karreth, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lougheed, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chau, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stout, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">May, E. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rominger, Ch. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaber, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lou., L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lakdawala, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Contractor, R. G</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smalley, K. S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herlyn, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrissey, M M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuveson, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, P. S.</span><span> </span><span class="NLM_article-title">Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">11100</span><span class="NLM_x">–</span> <span class="NLM_lpage">11105</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=11100-11105&author=A.+J.+Kingauthor=D.+R.+Patrickauthor=R.+S.+Batorskyauthor=M.+L.+Hoauthor=H.+T.+Doauthor=S.+Y.+Zhangauthor=R.+Kumarauthor=D.+W.+Rusnakauthor=A.+K.+Takleauthor=D.+M.+Wilsonauthor=E.+Huggerauthor=L+Wnagauthor=F.+Karrethauthor=J.+C.+Lougheedauthor=J.+Leeauthor=D.+Chauauthor=T.+J.+Stoutauthor=E.+W.+Mayauthor=Ch.+M.+Romingerauthor=M.+D.+Schaberauthor=L.+Lou.author=A.+S.+Lakdawalaauthor=J.+L.+Adamsauthor=R.+G+Contractorauthor=K.+S.+M.+Smalleyauthor=M.+Herlynauthor=M+M.+Morrisseyauthor=D.+A.+Tuvesonauthor=P.+S.+Huang&title=Demonstration+of+a+genetic+therapeutic+index+for+tumors+expressing+oncogenic+BRAF+by+the+kinase+inhibitor+SB-590885"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKing%26aufirst%3DA.%2BJ.%26aulast%3DPatrick%26aufirst%3DD.%2BR.%26aulast%3DBatorsky%26aufirst%3DR.%2BS.%26aulast%3DHo%26aufirst%3DM.%2BL.%26aulast%3DDo%26aufirst%3DH.%2BT.%26aulast%3DZhang%26aufirst%3DS.%2BY.%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DTakle%26aufirst%3DA.%2BK.%26aulast%3DWilson%26aufirst%3DD.%2BM.%26aulast%3DHugger%26aufirst%3DE.%26aulast%3DWnag%26aufirst%3DL%26aulast%3DKarreth%26aufirst%3DF.%26aulast%3DLougheed%26aufirst%3DJ.%2BC.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DChau%26aufirst%3DD.%26aulast%3DStout%26aufirst%3DT.%2BJ.%26aulast%3DMay%26aufirst%3DE.%2BW.%26aulast%3DRominger%26aufirst%3DCh.%2BM.%26aulast%3DSchaber%26aufirst%3DM.%2BD.%26aulast%3DLou.%26aufirst%3DL.%26aulast%3DLakdawala%26aufirst%3DA.%2BS.%26aulast%3DAdams%26aufirst%3DJ.%2BL.%26aulast%3DContractor%26aufirst%3DR.%2BG%26aulast%3DSmalley%26aufirst%3DK.%2BS.%2BM.%26aulast%3DHerlyn%26aufirst%3DM.%26aulast%3DMorrissey%26aufirst%3DM%2BM.%26aulast%3DTuveson%26aufirst%3DD.%2BA.%26aulast%3DHuang%26aufirst%3DP.%2BS.%26atitle%3DDemonstration%2520of%2520a%2520genetic%2520therapeutic%2520index%2520for%2520tumors%2520expressing%2520oncogenic%2520BRAF%2520by%2520the%2520kinase%2520inhibitor%2520SB-590885%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D11100%26epage%3D11105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6b"><span><span class="NLM_contrib-group">Tsai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mamo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bremer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillette, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haass, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sproesser, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smalley, K. S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fong, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Y.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marimuthu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settachatgul, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shellooe, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantwell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlessinger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, K. Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habets, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ibrahim, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirth, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Artis, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herlyn, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bollag, G.</span><span> </span><span class="NLM_article-title">Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">3041</span><span class="NLM_x">–</span> <span class="NLM_lpage">3046</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Fjm101479y&amp;key=10.1073%2Fpnas.0711741105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=8&amp;doi=10.1021%2Fjm101479y&amp;key=18287029" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=32&amp;doi=10.1021%2Fjm101479y&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjtVSitrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=3041-3046&author=J.+Tsaiauthor=J.+T.+Leeauthor=W.+Wangauthor=J.+Zhangauthor=H.+Choauthor=S.+Mamoauthor=R.+Bremerauthor=S.+Gilletteauthor=J.+Kongauthor=N.+K.+Haassauthor=K.+Sproesserauthor=L.+Liauthor=K.+S.+M.+Smalleyauthor=D.+Fongauthor=Y.-L.+Zhuauthor=A.+Marimuthuauthor=H.+Nguyenauthor=B.+Lamauthor=J.+Liuauthor=I.+Cheungauthor=J.+Riceauthor=Y.+Suzukiauthor=C.+Luuauthor=C.+Settachatgulauthor=R.+Shellooeauthor=J.+Cantwellauthor=S.-H.+Kimauthor=J.+Schlessingerauthor=K.+Y.+J.+Zhangauthor=B.+L.+Westauthor=B.+Powellauthor=G.+Habetsauthor=C.+Zhangauthor=P.+N.+Ibrahimauthor=P.+Hirthauthor=D.+R.+Artisauthor=M.+Herlynauthor=G.+Bollag&title=Discovery+of+a+selective+inhibitor+of+oncogenic+B-Raf+kinase+with+potent+antimelanoma+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6bR"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity</span></div><div class="casAuthors">Tsai, James; Lee, John T.; Wang, Weiru; Zhang, Jiazhong; Cho, Hanna; Mamo, Shumeye; Bremer, Ryan; Gillette, Sam; Kong, Jun; Haass, Nikolas K.; Sproesser, Katrin; Li, Ling; Smalley, Keiran S. M.; Fong, Daniel; Zhu, Yong-Liang; Marimuthu, Adhirai; Nguyen, Hoa; Lam, Billy; Liu, Jennifer; Cheung, Ivana; Rice, Julie; Suzuki, Yoshihisa; Luu, Catherine; Settachatgul, Calvin; Shellooe, Rafe; Cantwell, John; Kim, Sung-Hou; Schlessinger, Joseph; Zhang, Kam Y. J.; West, Brian L.; Powell, Ben; Habets, Gaston; Zhang, Chao; Ibrahim, Prabha N.; Hirth, Peter; Artis, Dean R.; Herlyn, Meenhard; Bollag, Gideon</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3041-3046</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">BRAFV600E is the most frequent oncogenic protein kinase mutation known.  Furthermore, inhibitors targeting "active" protein kinases have demonstrated significant utility in the therapeutic repertoire against cancer.  Therefore, the authors pursued the development of specific kinase inhibitors targeting B-Raf, and the V600E allele in particular.  By using a structure-guided discovery approach, a potent and selective inhibitor of active B-Raf has been discovered.  PLX4720, a 7-azaindole deriv. that inhibits B-RafV600E with an IC50 of 13 nM, defines a class of kinase inhibitor with marked selectivity in both biochem. and cellular assays.  PLX4720 preferentially inhibits the active B-RafV600E kinase compared with a broad spectrum of other kinases, and potent cytotoxic effects are also exclusive to cells bearing the V600E allele.  Consistent with the high degree of selectivity, ERK phosphorylation is potently inhibited by PLX4720 in B-RafV600E-bearing tumor cell lines but not in cells lacking oncogenic B-Raf.  In melanoma models, PLX4720 induces cell cycle arrest and apoptosis exclusively in B-RafV600E-pos. cells.  In B-RafV600E-dependent tumor xenograft models, orally dosed PLX4720 causes significant tumor growth delays, including tumor regressions, without evidence of toxicity.  The work described here represents the entire discovery process, from initial identification through structural and biol. studies in animal models to a promising therapeutic for testing in cancer patients bearing B-RafV600E-driven tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPX53IQCbDJ7Vg90H21EOLACvtfcHk0lj0WRkzNME_ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjtVSitrk%253D&md5=273b94202f99984e6eb24723d0c6141f</span></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0711741105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0711741105%26sid%3Dliteratum%253Aachs%26aulast%3DTsai%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DJ.%2BT.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DCho%26aufirst%3DH.%26aulast%3DMamo%26aufirst%3DS.%26aulast%3DBremer%26aufirst%3DR.%26aulast%3DGillette%26aufirst%3DS.%26aulast%3DKong%26aufirst%3DJ.%26aulast%3DHaass%26aufirst%3DN.%2BK.%26aulast%3DSproesser%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DSmalley%26aufirst%3DK.%2BS.%2BM.%26aulast%3DFong%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DY.-L.%26aulast%3DMarimuthu%26aufirst%3DA.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DLam%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DCheung%26aufirst%3DI.%26aulast%3DRice%26aufirst%3DJ.%26aulast%3DSuzuki%26aufirst%3DY.%26aulast%3DLuu%26aufirst%3DC.%26aulast%3DSettachatgul%26aufirst%3DC.%26aulast%3DShellooe%26aufirst%3DR.%26aulast%3DCantwell%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DS.-H.%26aulast%3DSchlessinger%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DK.%2BY.%2BJ.%26aulast%3DWest%26aufirst%3DB.%2BL.%26aulast%3DPowell%26aufirst%3DB.%26aulast%3DHabets%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DIbrahim%26aufirst%3DP.%2BN.%26aulast%3DHirth%26aufirst%3DP.%26aulast%3DArtis%26aufirst%3DD.%2BR.%26aulast%3DHerlyn%26aufirst%3DM.%26aulast%3DBollag%26aufirst%3DG.%26atitle%3DDiscovery%2520of%2520a%2520selective%2520inhibitor%2520of%2520oncogenic%2520B-Raf%2520kinase%2520with%2520potent%2520antimelanoma%2520activity%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2008%26volume%3D105%26spage%3D3041%26epage%3D3046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6c"><span><span class="NLM_contrib-group">Yang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higgins, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolinsky, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Packman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Go, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iyer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grippo, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schostack, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simcox, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heimbrook, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bollag, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, F.</span><span> </span><span class="NLM_article-title">RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">5518</span><span class="NLM_x">–</span> <span class="NLM_lpage">5527</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=5518-5527&author=H.+Yangauthor=B.+Higginsauthor=K.+Kolinskyauthor=K.+Packmanauthor=Z.+Goauthor=R.+Iyerauthor=S.+Kolisauthor=S.+Zhaoauthor=R.+Leeauthor=J.+F.+Grippoauthor=K.+Schostackauthor=M.+E.+Simcoxauthor=D.+Heimbrookauthor=G.+Bollagauthor=F.+Su&title=RG7204+%28PLX4032%29%2C+a+Selective+BRAFV600E+Inhibitor%2C+Displays+Potent+Antitumor+Activity+in+Preclinical+Melanoma+Models"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DH.%26aulast%3DHiggins%26aufirst%3DB.%26aulast%3DKolinsky%26aufirst%3DK.%26aulast%3DPackman%26aufirst%3DK.%26aulast%3DGo%26aufirst%3DZ.%26aulast%3DIyer%26aufirst%3DR.%26aulast%3DKolis%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DR.%26aulast%3DGrippo%26aufirst%3DJ.%2BF.%26aulast%3DSchostack%26aufirst%3DK.%26aulast%3DSimcox%26aufirst%3DM.%2BE.%26aulast%3DHeimbrook%26aufirst%3DD.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DSu%26aufirst%3DF.%26atitle%3DRG7204%2520%2528PLX4032%2529%252C%2520a%2520Selective%2520BRAFV600E%2520Inhibitor%252C%2520Displays%2520Potent%2520Antitumor%2520Activity%2520in%2520Preclinical%2520Melanoma%2520Models%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D5518%26epage%3D5527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6d"><span><span class="NLM_contrib-group">Joseph, E. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pratilas, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poulikakos, P. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tadi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halilovic, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Persaud, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xing, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viale, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bollag, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solit, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, N.</span><span> </span><span class="NLM_article-title">The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner</span> <span class="citation_source-journal">Proc. Natl Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">14903</span><span class="NLM_x">–</span> <span class="NLM_lpage">14908</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6d&amp;dbid=16&amp;doi=10.1021%2Fjm101479y&amp;key=10.1073%2Fpnas.1008990107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6d&amp;dbid=8&amp;doi=10.1021%2Fjm101479y&amp;key=20668238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6d&amp;dbid=32&amp;doi=10.1021%2Fjm101479y&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVOjsLrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=14903-14908&author=E.+W.+Josephauthor=C.+A.+Pratilasauthor=P.+I.+Poulikakosauthor=M.+Tadiauthor=W.+Wangauthor=B.+S.+Taylorauthor=E.+Halilovicauthor=Y.+Persaudauthor=F.+Xingauthor=A.+Vialeauthor=J.+Tsaiauthor=P.+B.+Chapmanauthor=G.+Bollagauthor=D.+B.+Solitauthor=N.+Rosen&title=The+RAF+inhibitor+PLX4032+inhibits+ERK+signaling+and+tumor+cell+proliferation+in+a+V600E+BRAF-selective+manner"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6dR"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner</span></div><div class="casAuthors">Joseph, Eric W.; Pratilas, Christine A.; Poulikakos, Poulikos I.; Tadi, Madhavi; Wang, Weiqing; Taylor, Barry S.; Halilovic, Ensar; Persaud, Yogindra; Xing, Feng; Viale, Agnes; Tsai, James; Chapman, Paul B.; Bollag, Gideon; Solit, David B.; Rosen, Neal</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">14903-14908, S14903/1-S14903/8</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Tumors with mutant BRAF and some with mutant RAS are dependent upon ERK signaling for proliferation, and their growth is suppressed by MAPK/ERK kinase (MEK) inhibitors.  In contrast, tumor cells with human EGF receptor (HER) kinase activation proliferate in a MEK-independent manner.  These findings have led to the development of RAF and MEK inhibitors as anticancer agents.  Like MEK inhibitors, the RAF inhibitor PLX4032 inhibits the proliferation of BRAFV600E tumor cells but not that of HER kinase-dependent tumors.  However, tumors with RAS mutation that are sensitive to MEK inhibition are insensitive to PLX4032.  MEK inhibitors inhibit ERK phosphorylation in all normal and tumor cells, whereas PLX4032 inhibits ERK signaling only in tumor cells expressing BRAFV600E.  In contrast, the drug activates MEK and ERK phosphorylation in cells with wild-type BRAF.  In BRAFV600E tumor cells, MEK and RAF inhibitors affect the expression of a common set of genes.  PLX4032 inhibits ERK signaling output in mutant BRAF cells, whereas it transiently activates the expression of these genes in tumor cells with wild-type RAF.  Thus, PLX4032 inhibits ERK signaling output in a mutant BRAF-selective manner.  These data explain why the drug selectively inhibits the growth of mutant BRAF tumors and suggest that it will not cause toxicity resulting from the inhibition of ERK signaling in normal cells.  This selectivity may lead to a broader therapeutic index and help explain the greater antitumor activity obsd. with this drug than with MEK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_6Gff4DQiprVg90H21EOLACvtfcHk0liQtZRdOAe-0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVOjsLrP&md5=c5c99b7faca898bd8e4b1d4ae82a5f84</span></div><a href="/servlet/linkout?suffix=cit6d&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1008990107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1008990107%26sid%3Dliteratum%253Aachs%26aulast%3DJoseph%26aufirst%3DE.%2BW.%26aulast%3DPratilas%26aufirst%3DC.%2BA.%26aulast%3DPoulikakos%26aufirst%3DP.%2BI.%26aulast%3DTadi%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DTaylor%26aufirst%3DB.%2BS.%26aulast%3DHalilovic%26aufirst%3DE.%26aulast%3DPersaud%26aufirst%3DY.%26aulast%3DXing%26aufirst%3DF.%26aulast%3DViale%26aufirst%3DA.%26aulast%3DTsai%26aufirst%3DJ.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DSolit%26aufirst%3DD.%2BB.%26aulast%3DRosen%26aufirst%3DN.%26atitle%3DThe%2520RAF%2520inhibitor%2520PLX4032%2520inhibits%2520ERK%2520signaling%2520and%2520tumor%2520cell%2520proliferation%2520in%2520a%2520V600E%2520BRAF-selective%2520manner%26jtitle%3DProc.%2520Natl%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2010%26volume%3D107%26spage%3D14903%26epage%3D14908" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7a"><span><span class="NLM_contrib-group">Solit, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garraway, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pratilas, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Getz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basso, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lobo, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">She, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osman, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golub, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sebolt-Leopold, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellers, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, N.</span><span> </span><span class="NLM_article-title">BRAF mutation predicts sensitivity to MEK inhibition</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">439</span><span class="NLM_x">, </span> <span class="NLM_fpage">358</span><span class="NLM_x">–</span> <span class="NLM_lpage">362</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Fjm101479y&amp;key=10.1038%2Fnature04304" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=8&amp;doi=10.1021%2Fjm101479y&amp;key=16273091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=32&amp;doi=10.1021%2Fjm101479y&amp;key=1%3ACAS%3A528%3ADC%252BD28XkvF2mtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=439&publication_year=2006&pages=358-362&author=D.+B.+Solitauthor=L.+A.+Garrawayauthor=C.+A.+Pratilasauthor=A.+Sawaiauthor=G.+Getzauthor=A.+Bassoauthor=Q.+Yeauthor=J.+M.+Loboauthor=Y.+Sheauthor=I.+Osmanauthor=T.+R.+Golubauthor=J.+Sebolt-Leopoldauthor=W.+R.+Sellersauthor=N.+Rosen&title=BRAF+mutation+predicts+sensitivity+to+MEK+inhibition"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7aR"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">BRAF mutation predicts sensitivity to MEK inhibition</span></div><div class="casAuthors">Solit, David B.; Garraway, Levi A.; Pratilas, Christine A.; Sawai, Ayana; Getz, Gad; Basso, Andrea; Ye, Qing; Lobo, Jose M.; She, Yuhong; Osman, Iman; Golub, Todd R.; Sebolt-Leopold, Judith; Sellers, William R.; Rosen, Neal</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">439</span>
        (<span class="NLM_cas:issue">7074</span>),
    <span class="NLM_cas:pages">358-362</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The kinase pathway comprising RAS, RAF, mitogen-activated protein kinase kinase (MEK) and extracellular signal regulated kinase (ERK) is activated in most human tumors, often through gain-of-function mutations of RAS and RAF family members.  Using small-mol. inhibitors of MEK and an integrated genetic and pharmacol. anal., we find that mutation of BRAF is assocd. with enhanced and selective sensitivity to MEK inhibition when compared to either 'wild-type' cells or cells harboring a RAS mutation.  This MEK dependency was obsd. in BRAF mutant cells regardless of tissue lineage, and correlated with both downregulation of cyclin D1 protein expression and the induction of G1 arrest.  Pharmacol. MEK inhibition completely abrogated tumor growth in BRAF mutant xenografts, whereas RAS mutant tumors were only partially inhibited.  These data suggest an exquisite dependency on MEK activity in BRAF mutant tumors, and offer a rational therapeutic strategy for this genetically defined tumor subtype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpBpONOvd0vbVg90H21EOLACvtfcHk0liQtZRdOAe-0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XkvF2mtw%253D%253D&md5=37c8976aa5bb371ef5580aab2a91f89e</span></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1038%2Fnature04304&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature04304%26sid%3Dliteratum%253Aachs%26aulast%3DSolit%26aufirst%3DD.%2BB.%26aulast%3DGarraway%26aufirst%3DL.%2BA.%26aulast%3DPratilas%26aufirst%3DC.%2BA.%26aulast%3DSawai%26aufirst%3DA.%26aulast%3DGetz%26aufirst%3DG.%26aulast%3DBasso%26aufirst%3DA.%26aulast%3DYe%26aufirst%3DQ.%26aulast%3DLobo%26aufirst%3DJ.%2BM.%26aulast%3DShe%26aufirst%3DY.%26aulast%3DOsman%26aufirst%3DI.%26aulast%3DGolub%26aufirst%3DT.%2BR.%26aulast%3DSebolt-Leopold%26aufirst%3DJ.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DRosen%26aufirst%3DN.%26atitle%3DBRAF%2520mutation%2520predicts%2520sensitivity%2520to%2520MEK%2520inhibition%26jtitle%3DNature%26date%3D2006%26volume%3D439%26spage%3D358%26epage%3D362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7b"><span><span class="NLM_contrib-group">Davies, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Logie, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKay, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stelle, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cockerill, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cartlidge, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P. D.</span><span> </span><span class="NLM_article-title">AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">2209</span><span class="NLM_x">–</span> <span class="NLM_lpage">2219</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Fjm101479y&amp;key=10.1158%2F1535-7163.MCT-07-0231" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Fjm101479y&amp;key=17699718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Fjm101479y&amp;key=1%3ACAS%3A528%3ADC%252BD2sXptVGltb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=2209-2219&issue=8&author=B.+R.+Daviesauthor=A.+Logieauthor=J.+S.+McKayauthor=P.+Martinauthor=S.+Stelleauthor=R.+Jenkinsauthor=M.+Cockerillauthor=S.+Cartlidgeauthor=P.+D.+Smith&title=AZD6244+%28ARRY-142886%29%2C+a+potent+inhibitor+of+mitogen-activated+protein+kinase%2Fextracellular+signal-regulated+kinase+kinase+1%2F2+kinases%3A+mechanism+of+action+in+vivo%2C+pharmacokinetic%2Fpharmacodynamic+relationship%2C+and+potential+for+combination+in+preclinical+models"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models</span></div><div class="casAuthors">Davies, Barry R.; Logie, Armelle; McKay, Jennifer S.; Martin, Paul; Steele, Samantha; Jenkins, Richard; Cockerill, Mark; Cartlidge, Sue; Smith, Paul D.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2209-2219</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Constitutive activation of the extracellular signal-regulated kinase 1/2 (ERK1/2) mitogen-activated protein kinase (MAPK) signaling pathway in human cancers is often assocd. with mutational activation of BRAF or RAS.  MAPK/ERK kinase 1/2 kinases lie downstream of RAS and BRAF and are the only acknowledged activators of ERK1/2, making them attractive targets for therapeutic intervention.  AZD6244 (ARRY-142886) is a potent, selective, and ATP-uncompetitive inhibitor of MAPK/ERK kinase 1/2.  In vitro cell viability inhibition screening of a tumor cell line panel found that lines harboring BRAF or RAS mutations were more likely to be sensitive to AZD6244.  The in vivo mechanisms by which AZD6244 inhibits tumor growth were investigated.  Chronic dosing with 25 mg/kg AZD6244 bd resulted in suppression of growth of Colo-205, Calu-6, and SW-620 xenografts, whereas an acute dose resulted in significant inhibition of ERK1/2 phosphorylation.  Increased cleaved caspase-3, a marker of apoptosis, was detected in Colo-205 and Calu-6 but not in SW-620 tumors where a significant decrease in cell proliferation was detected.  Chronic dosing of AZD6244 induced a morphol. change in SW-620 tumors to a more differentiated phenotype.  The potential of AZD6244 in combination with cytotoxic drugs was evaluated in mice bearing SW-620 xenografts.  Treatment with tolerated doses of AZD6244 and either irinotecan or docetaxel resulted in significantly enhanced antitumor efficacy relative to that of either agent alone.  These results indicate that AZD6244 has potential to inhibit proliferation and induce apoptosis and differentiation, but the response varies between different xenografts.  Moreover, enhanced antitumor efficacy can be obtained by combining AZD6244 with the cytotoxic drugs irinotecan or docetaxel.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2EFINn6kko7Vg90H21EOLACvtfcHk0lgRkBURhZ4hAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXptVGltb8%253D&md5=0720c73c534ebc08a40dbb309e98ffa4</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-0231&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-0231%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DB.%2BR.%26aulast%3DLogie%26aufirst%3DA.%26aulast%3DMcKay%26aufirst%3DJ.%2BS.%26aulast%3DMartin%26aufirst%3DP.%26aulast%3DStelle%26aufirst%3DS.%26aulast%3DJenkins%26aufirst%3DR.%26aulast%3DCockerill%26aufirst%3DM.%26aulast%3DCartlidge%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DP.%2BD.%26atitle%3DAZD6244%2520%2528ARRY-142886%2529%252C%2520a%2520potent%2520inhibitor%2520of%2520mitogen-activated%2520protein%2520kinase%252Fextracellular%2520signal-regulated%2520kinase%2520kinase%25201%252F2%2520kinases%253A%2520mechanism%2520of%2520action%2520in%2520vivo%252C%2520pharmacokinetic%252Fpharmacodynamic%2520relationship%252C%2520and%2520potential%2520for%2520combination%2520in%2520preclinical%2520models%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26issue%3D8%26spage%3D2209%26epage%3D2219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8a"><span><span class="NLM_contrib-group">Bollag, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirth, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ibrahim, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spevak, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habets, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burton, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shellooe, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marimuthu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, K. Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Artis, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlessinger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higgins, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iyer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D'Andrea, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koehler, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stumm, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grippo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puzanov, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nathanson, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolop, K.</span><span> </span><span class="NLM_article-title">Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">467</span><span class="NLM_x">, </span> <span class="NLM_fpage">596</span><span class="NLM_x">–</span> <span class="NLM_lpage">599</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=16&amp;doi=10.1021%2Fjm101479y&amp;key=10.1038%2Fnature09454" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=8&amp;doi=10.1021%2Fjm101479y&amp;key=20823850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=32&amp;doi=10.1021%2Fjm101479y&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1ajtbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=467&publication_year=2010&pages=596-599&author=G.+Bollagauthor=P.+Hirthauthor=J.+Tsaiauthor=J.+Zhangauthor=P.+N.+Ibrahimauthor=H.+Choauthor=W.+Spevakauthor=C.+Zhangauthor=Y.+Zhangauthor=G.+Habetsauthor=E.+A.+Burtonauthor=B.+Wongauthor=G.+Tsangauthor=B.+L.+Westauthor=B.+Powellauthor=R.+Shellooeauthor=A.+Marimuthuauthor=H.+Nguyenauthor=K.+Y.+J.+Zhangauthor=D.+R.+Artisauthor=J.+Schlessingerauthor=F.+Suauthor=B.+Higginsauthor=R.+Iyerauthor=K.+D%27Andreaauthor=A.+Koehlerauthor=M.+Stummauthor=P.+S.+Linauthor=R.+J.+Leeauthor=J.+Grippoauthor=I.+Puzanovauthor=K.+B.+Kimauthor=A.+Ribasauthor=G.+A.+McArthurauthor=J.+A.+Sosmanauthor=P.+B.+Chapmanauthor=K.+T.+Flahertyauthor=X.+Xuauthor=K.+L.+Nathansonauthor=K.+Nolop&title=Clinical+efficacy+of+a+RAF+inhibitor+needs+broad+target+blockade+in+BRAF-mutant+melanoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8aR"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma</span></div><div class="casAuthors">Bollag, Gideon; Hirth, Peter; Tsai, James; Zhang, Jiazhong; Ibrahim, Prabha N.; Cho, Hanna; Spevak, Wayne; Zhang, Chao; Zhang, Ying; Habets, Gaston; Burton, Elizabeth A.; Wong, Bernice; Tsang, Garson; West, Brian L.; Powell, Ben; Shellooe, Rafe; Marimuthu, Adhirai; Nguyen, Hoa; Zhang, Kam Y. J.; Artis, Dean R.; Schlessinger, Joseph; Su, Fei; Higgins, Brian; Iyer, Raman; D'Andrea, Kurt; Koehler, Astrid; Stumm, Michael; Lin, Paul S.; Lee, Richard J.; Grippo, Joseph; Puzanov, Igor; Kim, Kevin B.; Ribas, Antoni; McArthur, Grant A.; Sosman, Jeffrey A.; Chapman, Paul B.; Flaherty, Keith T.; Xu, Xiaowei; Nathanson, Katherine L.; Nolop, Keith</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">467</span>
        (<span class="NLM_cas:issue">7315</span>),
    <span class="NLM_cas:pages">596-599</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">B-RAF is the most frequently mutated protein kinase in human cancers.  The finding that oncogenic mutations in BRAF are common in melanoma, followed by the demonstration that these tumors are dependent on the RAF/MEK/ERK pathway, offered hope that inhibition of B-RAF kinase activity could benefit melanoma patients.  Herein, we describe the structure-guided discovery of PLX4032 (RG7204), a potent inhibitor of oncogenic B-RAF kinase activity.  Preclin. expts. demonstrated that PLX4032 selectively blocked the RAF/MEK/ERK pathway in BRAF mutant cells and caused regression of BRAF mutant xenografts.  Toxicol. studies confirmed a wide safety margin consistent with the high degree of selectivity, enabling Phase 1 clin. trials using a cryst. formulation of PLX4032 (ref. 5).  In a subset of melanoma patients, pathway inhibition was monitored in paired biopsy specimens collected before treatment initiation and following 2 wk of treatment.  This anal. revealed substantial inhibition of ERK phosphorylation, yet clin. evaluation did not show tumor regressions.  At higher drug exposures afforded by a new amorphous drug formulation, greater than 80% inhibition of ERK phosphorylation in the tumors of patients correlated with clin. response.  Indeed, the Phase 1 clin. data revealed a remarkably high 81% response rate in metastatic melanoma patients treated at an oral dose of 960 mg twice daily.  These data demonstrate that BRAF-mutant melanomas are highly dependent on B-RAF kinase activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpYwlns1EfcLVg90H21EOLACvtfcHk0lgRkBURhZ4hAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1ajtbfK&md5=8a26d0ab41970f39a109ddafff2f17b4</span></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=10.1038%2Fnature09454&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09454%26sid%3Dliteratum%253Aachs%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DHirth%26aufirst%3DP.%26aulast%3DTsai%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DIbrahim%26aufirst%3DP.%2BN.%26aulast%3DCho%26aufirst%3DH.%26aulast%3DSpevak%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHabets%26aufirst%3DG.%26aulast%3DBurton%26aufirst%3DE.%2BA.%26aulast%3DWong%26aufirst%3DB.%26aulast%3DTsang%26aufirst%3DG.%26aulast%3DWest%26aufirst%3DB.%2BL.%26aulast%3DPowell%26aufirst%3DB.%26aulast%3DShellooe%26aufirst%3DR.%26aulast%3DMarimuthu%26aufirst%3DA.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DK.%2BY.%2BJ.%26aulast%3DArtis%26aufirst%3DD.%2BR.%26aulast%3DSchlessinger%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DF.%26aulast%3DHiggins%26aufirst%3DB.%26aulast%3DIyer%26aufirst%3DR.%26aulast%3DD%2527Andrea%26aufirst%3DK.%26aulast%3DKoehler%26aufirst%3DA.%26aulast%3DStumm%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DP.%2BS.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DGrippo%26aufirst%3DJ.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DNathanson%26aufirst%3DK.%2BL.%26aulast%3DNolop%26aufirst%3DK.%26atitle%3DClinical%2520efficacy%2520of%2520a%2520RAF%2520inhibitor%2520needs%2520broad%2520target%2520blockade%2520in%2520BRAF-mutant%2520melanoma%26jtitle%3DNature%26date%3D2010%26volume%3D467%26spage%3D596%26epage%3D599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit8b"><span><span class="NLM_contrib-group">Flaherty, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puzanov, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grippo, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolop, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, P.</span><span> </span><span class="NLM_article-title">Phase I study of PLX4032: Proof of concept for V600EBRAF mutation as a therapeutic target in human cancer</span> <span class="citation_source-journal">J. Clin. Oncol. (Meeting Abstr.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">9000</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=9000&author=K.+Flahertyauthor=I.+Puzanovauthor=J.+Sosmanauthor=K.+Kimauthor=A.+Ribasauthor=G.+McArthurauthor=R.+J.+Leeauthor=J.+F.+Grippoauthor=K.+Nolopauthor=P.+Chapman&title=Phase+I+study+of+PLX4032%3A+Proof+of+concept+for+V600EBRAF+mutation+as+a+therapeutic+target+in+human+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFlaherty%26aufirst%3DK.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DSosman%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DK.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DMcArthur%26aufirst%3DG.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DGrippo%26aufirst%3DJ.%2BF.%26aulast%3DNolop%26aufirst%3DK.%26aulast%3DChapman%26aufirst%3DP.%26atitle%3DPhase%2520I%2520study%2520of%2520PLX4032%253A%2520Proof%2520of%2520concept%2520for%2520V600EBRAF%2520mutation%2520as%2520a%2520therapeutic%2520target%2520in%2520human%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%2520%2528Meeting%2520Abstr.%2529%26date%3D2009%26volume%3D27%26spage%3D9000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit8c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Wellbrock, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurlstone, A.</span><span> </span><span class="NLM_article-title">BRAF as therapeutic target in melanoma</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">80</span><span class="NLM_x">, </span> <span class="NLM_fpage">561</span><span class="NLM_x">–</span> <span class="NLM_lpage">567</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2010&pages=561-567&author=C.+Wellbrockauthor=A.+Hurlstone&title=BRAF+as+therapeutic+target+in+melanoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWellbrock%26aufirst%3DC.%26aulast%3DHurlstone%26aufirst%3DA.%26atitle%3DBRAF%2520as%2520therapeutic%2520target%2520in%2520melanoma%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2010%26volume%3D80%26spage%3D561%26epage%3D567" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="note"><p class="first last">Sorafenib (<b>1</b>) is a multikinase inhibitor with modest inhibitory activity against Raf. This compound has shown efficacy in the clinic and is now marketed as Nexavar. </p></div><div class="NLM_citation" id="cit9a"><span><span class="NLM_contrib-group">Wilhelm, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNabola, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHugh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shujath, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gawlak, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eveleigh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowley, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adnane, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Auclair, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gedrich, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voznesensky, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riedl, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Post, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bollag, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trail, P. A.</span><span> </span><span class="NLM_article-title">BAY43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">7099</span><span class="NLM_x">–</span> <span class="NLM_lpage">7109</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=7099-7109&author=S.+M.+Wilhelmauthor=C.+Carterauthor=L.+Tangauthor=D.+Wilkieauthor=A.+McNabolaauthor=H.+Rongauthor=C.+Chenauthor=X.+Zhangauthor=P.+Vincentauthor=M.+McHughauthor=Y.+Caoauthor=J.+Shujathauthor=S.+Gawlakauthor=D.+Eveleighauthor=B.+Rowleyauthor=L.+Liuauthor=L.+Adnaneauthor=M.+Lynchauthor=D.+Auclairauthor=I.+Taylorauthor=R.+Gedrichauthor=A.+Voznesenskyauthor=B.+Riedlauthor=L.+E.+Postauthor=G.+Bollagauthor=P.+A.+Trail&title=BAY43-9006+exhibits+broad+spectrum+oral+antitumor+activity+and+targets+the+RAF%2FMEK%2FERK+pathway+and+receptor+tyrosine+kinases+involved+in+tumor+progression+and+angiogenesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWilhelm%26aufirst%3DS.%2BM.%26aulast%3DCarter%26aufirst%3DC.%26aulast%3DTang%26aufirst%3DL.%26aulast%3DWilkie%26aufirst%3DD.%26aulast%3DMcNabola%26aufirst%3DA.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DVincent%26aufirst%3DP.%26aulast%3DMcHugh%26aufirst%3DM.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DShujath%26aufirst%3DJ.%26aulast%3DGawlak%26aufirst%3DS.%26aulast%3DEveleigh%26aufirst%3DD.%26aulast%3DRowley%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DAdnane%26aufirst%3DL.%26aulast%3DLynch%26aufirst%3DM.%26aulast%3DAuclair%26aufirst%3DD.%26aulast%3DTaylor%26aufirst%3DI.%26aulast%3DGedrich%26aufirst%3DR.%26aulast%3DVoznesensky%26aufirst%3DA.%26aulast%3DRiedl%26aufirst%3DB.%26aulast%3DPost%26aufirst%3DL.%2BE.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DTrail%26aufirst%3DP.%2BA.%26atitle%3DBAY43-9006%2520exhibits%2520broad%2520spectrum%2520oral%2520antitumor%2520activity%2520and%2520targets%2520the%2520RAF%252FMEK%252FERK%2520pathway%2520and%2520receptor%2520tyrosine%2520kinases%2520involved%2520in%2520tumor%2520progression%2520and%2520angiogenesis%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D7099%26epage%3D7109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9b"><span><span class="NLM_contrib-group">Adnane, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trail, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilhelm, S. M.</span><span> </span><span class="NLM_article-title">Sorafenib (BAY43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinasese VEGFR/PDGFR in tumor vasculature</span> <span class="citation_source-journal">Methods Enzymol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">407</span><span class="NLM_x">, </span> <span class="NLM_fpage">597</span><span class="NLM_x">–</span> <span class="NLM_lpage">612</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=407&publication_year=2006&pages=597-612&author=L.+Adnaneauthor=P.+A.+Trailauthor=I.+Taylorauthor=S.+M.+Wilhelm&title=Sorafenib+%28BAY43-9006%2C+Nexavar%29%2C+a+dual-action+inhibitor+that+targets+RAF%2FMEK%2FERK+pathway+in+tumor+cells+and+tyrosine+kinasese+VEGFR%2FPDGFR+in+tumor+vasculature"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAdnane%26aufirst%3DL.%26aulast%3DTrail%26aufirst%3DP.%2BA.%26aulast%3DTaylor%26aufirst%3DI.%26aulast%3DWilhelm%26aufirst%3DS.%2BM.%26atitle%3DSorafenib%2520%2528BAY43-9006%252C%2520Nexavar%2529%252C%2520a%2520dual-action%2520inhibitor%2520that%2520targets%2520RAF%252FMEK%252FERK%2520pathway%2520in%2520tumor%2520cells%2520and%2520tyrosine%2520kinasese%2520VEGFR%252FPDGFR%2520in%2520tumor%2520vasculature%26jtitle%3DMethods%2520Enzymol.%26date%3D2006%26volume%3D407%26spage%3D597%26epage%3D612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10a"><span><span class="NLM_contrib-group">Bankston, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dumas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Natero, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riedl, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monahan, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sibley, R.</span><span> </span><span class="NLM_article-title">A Scaleable Synthesis of BAY43-9006: A Potent Raf Kinase Inhibitor for the Treatment of Cancer</span> <span class="citation_source-journal">Org. Process Res. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">777</span><span class="NLM_x">–</span> <span class="NLM_lpage">781</span></span><div class="citationLinks">[<a href="/doi/10.1021/op020205n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2002&pages=777-781&author=D.+Bankstonauthor=J.+Dumasauthor=R.+Nateroauthor=B.+Riedlauthor=M.+K.+Monahanauthor=R.+Sibley&title=A+Scaleable+Synthesis+of+BAY43-9006%3A+A+Potent+Raf+Kinase+Inhibitor+for+the+Treatment+of+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1021%2Fop020205n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop020205n%26sid%3Dliteratum%253Aachs%26aulast%3DBankston%26aufirst%3DD.%26aulast%3DDumas%26aufirst%3DJ.%26aulast%3DNatero%26aufirst%3DR.%26aulast%3DRiedl%26aufirst%3DB.%26aulast%3DMonahan%26aufirst%3DM.%2BK.%26aulast%3DSibley%26aufirst%3DR.%26atitle%3DA%2520Scaleable%2520Synthesis%2520of%2520BAY43-9006%253A%2520A%2520Potent%2520Raf%2520Kinase%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Cancer%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2002%26volume%3D6%26spage%3D777%26epage%3D781" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10b"><span><span class="NLM_contrib-group">Riedl, B.; Dumas, J.; Khire, U.; Lowinger, T. B.; Scott, W. J.; Smith, R. A.; Wood, J. E.; Monahan, M.-K.; Natero, R.; Renick, J.; Sibley, R. N.</span> U.S. Patent 7 235 576 B1,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Riedl%2C+B.%3B+Dumas%2C+J.%3B+Khire%2C+U.%3B+Lowinger%2C+T.+B.%3B+Scott%2C+W.+J.%3B+Smith%2C+R.+A.%3B+Wood%2C+J.+E.%3B+Monahan%2C+M.-K.%3B+Natero%2C+R.%3B+Renick%2C+J.%3B+Sibley%2C+R.+N.+U.S.+Patent+7+235+576+B1%2C+2007."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRiedl%26aufirst%3DB.%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Calderwood, E. F.; Duffey, M.; Gould, A. E.; Greenspan, P. D.; Kulkarni, B.; Lamarche, M. J.; Rowland, R. S.; Tregay, M.; Vos, T. J.</span> PCT Int. Appl. WO 2007067444 A1 20070614,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Calderwood%2C+E.+F.%3B+Duffey%2C+M.%3B+Gould%2C+A.+E.%3B+Greenspan%2C+P.+D.%3B+Kulkarni%2C+B.%3B+Lamarche%2C+M.+J.%3B+Rowland%2C+R.+S.%3B+Tregay%2C+M.%3B+Vos%2C+T.+J.+PCT+Int.+Appl.+WO+2007067444+A1+20070614%2C+2007."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCalderwood%26aufirst%3DE.%2BF.%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Xi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hale, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norman, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stec, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumgartner, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fotsch, C.</span><span> </span><span class="NLM_article-title">Synthesis of novel melanocortin 4 recpetor agonists and antagonists containing a succinamide core</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">377</span><span class="NLM_x">–</span> <span class="NLM_lpage">381</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=377-381&author=N.+Xiauthor=C.+Haleauthor=M.+G.+Kellyauthor=M.+H.+Normanauthor=M.+Stecauthor=S.+Xuauthor=J.+W.+Baumgartnerauthor=C.+Fotsch&title=Synthesis+of+novel+melanocortin+4+recpetor+agonists+and+antagonists+containing+a+succinamide+core"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DXi%26aufirst%3DN.%26aulast%3DHale%26aufirst%3DC.%26aulast%3DKelly%26aufirst%3DM.%2BG.%26aulast%3DNorman%26aufirst%3DM.%2BH.%26aulast%3DStec%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DBaumgartner%26aufirst%3DJ.%2BW.%26aulast%3DFotsch%26aufirst%3DC.%26atitle%3DSynthesis%2520of%2520novel%2520melanocortin%25204%2520recpetor%2520agonists%2520and%2520antagonists%2520containing%2520a%2520succinamide%2520core%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D377%26epage%3D381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Van Heerden, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bezuidenhoudt, B. C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferreira, D.</span><span> </span><span class="NLM_article-title">Efficient Asymmetric Synthesis of the Four Diastereomers of Diphenacoum and Brodifacoum</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x"> (</span><span class="NLM_issue">17</span><span class="NLM_x">) </span> <span class="NLM_fpage">6045</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1997&pages=6045&issue=17&author=P.+S.+Van+Heerdenauthor=B.+C.+B.+Bezuidenhoudtauthor=D.+Ferreira&title=Efficient+Asymmetric+Synthesis+of+the+Four+Diastereomers+of+Diphenacoum+and+Brodifacoum"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BHeerden%26aufirst%3DP.%2BS.%26aulast%3DBezuidenhoudt%26aufirst%3DB.%2BC.%2BB.%26aulast%3DFerreira%26aufirst%3DD.%26atitle%3DEfficient%2520Asymmetric%2520Synthesis%2520of%2520the%2520Four%2520Diastereomers%2520of%2520Diphenacoum%2520and%2520Brodifacoum%26jtitle%3DTetrahedron%26date%3D1997%26volume%3D53%26issue%3D17%26spage%3D6045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="note"><p class="first last">The opposite enantiomer can be prepared by employing the opposite enantiomer of the Evans' auxiliary.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Boigegrain, R.; Cecchi, R.; Boveri, S.</span> U.S. Patent 5 159 103,<span class="NLM_x"> </span><span class="NLM_year">1992</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Boigegrain%2C+R.%3B+Cecchi%2C+R.%3B+Boveri%2C+S.+U.S.+Patent+5+159+103%2C+1992."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBoigegrain%26aufirst%3DR.%26date%3D1992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Hirayama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikuaka, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsumoto, J.</span><span> </span><span class="NLM_article-title">An Expeditious Scalable Synthesis of (S)-2-Amino-5-methoxytetralin via Resolution</span> <span class="citation_source-journal">Org. Process Res. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">30</span><span class="NLM_x">–</span> <span class="NLM_lpage">38</span></span><div class="citationLinks">[<a href="/doi/10.1021/op0498363" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2005&pages=30-38&author=Y.+Hirayamaauthor=M.+Ikuakaauthor=J.+Matsumoto&title=An+Expeditious+Scalable+Synthesis+of+%28S%29-2-Amino-5-methoxytetralin+via+Resolution"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fop0498363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop0498363%26sid%3Dliteratum%253Aachs%26aulast%3DHirayama%26aufirst%3DY.%26aulast%3DIkuaka%26aufirst%3DM.%26aulast%3DMatsumoto%26aufirst%3DJ.%26atitle%3DAn%2520Expeditious%2520Scalable%2520Synthesis%2520of%2520%2528S%2529-2-Amino-5-methoxytetralin%2520via%2520Resolution%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2005%26volume%3D9%26spage%3D30%26epage%3D38" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Wan, P. T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garnett, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roe, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niculescu-Duvaz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Good, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springer, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barford, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marais, R.</span><span> </span><span class="NLM_article-title">Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">855</span><span class="NLM_x">–</span> <span class="NLM_lpage">867</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm101479y&amp;key=10.1016%2FS0092-8674%2804%2900215-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm101479y&amp;key=15035987" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm101479y&amp;key=1%3ACAS%3A528%3ADC%252BD2cXivVyksLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2004&pages=855-867&author=P.+T.+C.+Wanauthor=M.+J.+Garnettauthor=M.+S.+Roeauthor=S.+Leeauthor=D.+Niculescu-Duvazauthor=V.+M.+Goodauthor=M.+J.+Jonesauthor=C.+J.+Marshallauthor=C.+J.+Springerauthor=D.+Barfordauthor=R.+Marais&title=Mechanism+of+Activation+of+the+RAF-ERK+Signaling+Pathway+by+Oncogenic+Mutations+of+B-RAF"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF</span></div><div class="casAuthors">Wan, Paul T. C.; Garnett, Mathew J.; Roe, S. Mark; Lee, Sharlene; Niculescu-Duvaz, Dan; Good, Valerie M.; Project, Cancer Genome; Jones, C. Michael; Marshall, Christopher J.; Springer, Caroline J.; Barford, David; Marais, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">855-867</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Over 30 mutations of the B-RAF gene assocd. with human cancers have been identified, the majority of which are located within the kinase domain.  Here the authors show that of 22 B-RAF mutants analyzed, 18 have elevated kinase activity and signal to ERK in vivo.  Surprisingly, three mutants have reduced kinase activity towards MEK in vitro but, by activating C-RAF in vivo, signal to ERK in cells.  The structures of wild type and oncogenic V599EB-RAF kinase domains in complex with the RAF inhibitor BAY43-9006 show that the activation segment is held in an inactive conformation by assocn. with the P loop.  The clustering of most mutations to these two regions suggests that disruption of this interaction converts B-RAF into its active conformation.  The high activity mutants signal to ERK by directly phosphorylating MEK, whereas the impaired activity mutants stimulate MEK by activating endogenous C-RAF, possibly via an allosteric or transphosphorylation mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYiQicwc1xVLVg90H21EOLACvtfcHk0liu1WC-mhoOzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXivVyksLw%253D&md5=4cc020056c64e514286c000666da1972</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2804%2900215-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252804%252900215-6%26sid%3Dliteratum%253Aachs%26aulast%3DWan%26aufirst%3DP.%2BT.%2BC.%26aulast%3DGarnett%26aufirst%3DM.%2BJ.%26aulast%3DRoe%26aufirst%3DM.%2BS.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DNiculescu-Duvaz%26aufirst%3DD.%26aulast%3DGood%26aufirst%3DV.%2BM.%26aulast%3DJones%26aufirst%3DM.%2BJ.%26aulast%3DMarshall%26aufirst%3DC.%2BJ.%26aulast%3DSpringer%26aufirst%3DC.%2BJ.%26aulast%3DBarford%26aufirst%3DD.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DMechanism%2520of%2520Activation%2520of%2520the%2520RAF-ERK%2520Signaling%2520Pathway%2520by%2520Oncogenic%2520Mutations%2520of%2520B-RAF%26jtitle%3DCell%26date%3D2004%26volume%3D116%26spage%3D855%26epage%3D867" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Gould, A. E.; Harrison, S. J.; Mizutani, H.; Shen, M.; Smyser, T. E.; Stroud, S. G.</span> U.S. Patent Appl. US 20100197924 A1 20100805,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Gould%2C+A.+E.%3B+Harrison%2C+S.+J.%3B+Mizutani%2C+H.%3B+Shen%2C+M.%3B+Smyser%2C+T.+E.%3B+Stroud%2C+S.+G.+U.S.+Patent+Appl.+US+20100197924+A1+20100805%2C+2010."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGould%26aufirst%3DA.%2BE.%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="note"><p class="first last">Additional kinase binding data for <b>26</b> and <b>27</b> can be found in the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>, Table 1.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="note"><p class="first last">Crystallization work was done with wt B-Raf protein (residues 445−726). The crystallization conditions were as follows: 14.025% PEG 8000, 0.8 M NP Lithium Cl, 0.06 M Tris base, and 0.04 M Tris Cl. A 50 mM stock concentration of compound was made in 100% DMSO. The compound (50 mM) was mixed with B-raf (2.64 mg/mL) to a final concentration of 1 mM compound at room temperature. The precipitate was removed by centrifugation. The crystals appeared after 7 days. Crystals were frozen by flash freezing in liquid nitrogen using 25% ethylene glycol in mother liquor. The crystals diffracted to 3.1 Å, and clear omit electron density for the compound was observed. The data collection summary and refinement statistics have been deposited in the RCSB Protein Data Bank (RCSB ID code rcsb063351 and PDB ID code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3Q96">3Q96</a>).</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Corma, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leyva, A.</span><span> </span><span class="NLM_article-title">Comparison between polyethylenglycol and imidazolium ionic liquids as solvents for developing a homogeneous and reusable palladium catalytic system for the Suzuki and Sonogashira coupling</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">9848</span><span class="NLM_x">–</span> <span class="NLM_lpage">9854</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2005&pages=9848-9854&author=A.+Cormaauthor=H.+Garciaauthor=A.+Leyva&title=Comparison+between+polyethylenglycol+and+imidazolium+ionic+liquids+as+solvents+for+developing+a+homogeneous+and+reusable+palladium+catalytic+system+for+the+Suzuki+and+Sonogashira+coupling"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCorma%26aufirst%3DA.%26aulast%3DGarcia%26aufirst%3DH.%26aulast%3DLeyva%26aufirst%3DA.%26atitle%3DComparison%2520between%2520polyethylenglycol%2520and%2520imidazolium%2520ionic%2520liquids%2520as%2520solvents%2520for%2520developing%2520a%2520homogeneous%2520and%2520reusable%2520palladium%2520catalytic%2520system%2520for%2520the%2520Suzuki%2520and%2520Sonogashira%2520coupling%26jtitle%3DTetrahedron%26date%3D2005%26volume%3D61%26spage%3D9848%26epage%3D9854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Li, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bucana, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidler, I. J.</span><span> </span><span class="NLM_article-title">Correlation of growth capacity of human tumor cells in hard agarose with their in vivo proliferative capacity at specific metastatic sites</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">81</span><span class="NLM_x">, </span> <span class="NLM_fpage">1406</span><span class="NLM_x">–</span> <span class="NLM_lpage">1412</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm101479y&amp;key=10.1093%2Fjnci%2F81.18.1406" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm101479y&amp;key=2778827" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm101479y&amp;key=1%3ACAS%3A280%3ADyaL1Mzot1Kktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=1989&pages=1406-1412&author=L.+Liauthor=J.+E.+Priceauthor=D.+Fanauthor=R.+D.+Zhangauthor=C.+D.+Bucanaauthor=I.+J.+Fidler&title=Correlation+of+growth+capacity+of+human+tumor+cells+in+hard+agarose+with+their+in+vivo+proliferative+capacity+at+specific+metastatic+sites"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Correlation of growth capacity of human tumor cells in hard agarose with their in vivo proliferative capacity at specific metastatic sites</span></div><div class="casAuthors">Li L; Price J E; Fan D; Zhang R D; Bucana C D; Fidler I J</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1406-12</span>
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    </div><div class="casAbstract">The purpose of this study was to determine whether the degree of anchorage-independent growth of human tumor cells in increasing concentrations of agarose correlated with the capacity of the cells to produce experimental metastases in nude mice.  Human melanoma, breast carcinoma, and colon carcinoma cells from parental lines and variants selected in vivo for metastasis and in vitro cloned lines were plated into medium containing 0.3%, 0.6%, 0.9%, or 1.2% of agarose.  These cells were also injected into nude mice: intravenously for melanoma, into the mammary fat pad for breast carcinoma, and into the spleen for colon carcinoma.  Production of tumor cell colonies in dense agarose (greater than 0.6%) correlated with production of experimental metastases in the lung (melanoma, breast carcinoma) or liver (colon carcinoma).  We conclude that the degree of anchorage-independent growth of tumor cells can predict their biological behavior and metastatic potential in vivo.  Thus, this technique may be useful for the isolation of metastatic cells from heterogeneous human neoplasms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSbQIPR-IkehmGmni0r9GoKfW6udTcc2eYSxqXeK8OZOrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL1Mzot1Kktg%253D%253D&md5=9846886e6d86091aa7aae686b2c95823</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2F81.18.1406&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252F81.18.1406%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DL.%26aulast%3DPrice%26aufirst%3DJ.%2BE.%26aulast%3DFan%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DR.%2BD.%26aulast%3DBucana%26aufirst%3DC.%2BD.%26aulast%3DFidler%26aufirst%3DI.%2BJ.%26atitle%3DCorrelation%2520of%2520growth%2520capacity%2520of%2520human%2520tumor%2520cells%2520in%2520hard%2520agarose%2520with%2520their%2520in%2520vivo%2520proliferative%2520capacity%2520at%2520specific%2520metastatic%2520sites%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D1989%26volume%3D81%26spage%3D1406%26epage%3D1412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6a','cit6b','cit6c','cit6d'],'ref7':['cit7a','cit7b'],'ref8':['cit8a','cit8b','cit8c'],'ref9':['cit9a','cit9b'],'ref10':['cit10a','cit10b'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':[],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':[],'ref20':[],'ref21':['cit21'],'ref22':['cit22']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 27 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Galina Karabanovich, Jan Dušek, Karin Savková, Oto Pavliš, Ivona Pávková, Jan Korábečný, Tomáš Kučera, Hana Kočová Vlčková, Stanislav Huszár, Zuzana Konyariková, Klára Konečná, Ondřej Jand’ourek, Jiřina Stolaříková, Jana Korduláková, Kateřina Vávrová, Petr Pávek, Věra Klimešová, Alexandr Hrabálek, Katarína Mikušová, <span class="NLM_string-name hlFld-ContribAuthor">Jaroslav Roh</span>. </span><span class="cited-content_cbyCitation_article-title">Development of 3,5-Dinitrophenyl-Containing 1,2,4-Triazoles and Their Trifluoromethyl Analogues as Highly Efficient Antitubercular Agents Inhibiting Decaprenylphosphoryl-β-d-ribofuranose 2′-Oxidase. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (17)
                                     , 8115-8139. <a href="https://doi.org/10.1021/acs.jmedchem.9b00912" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00912</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00912%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDevelopment%252Bof%252B3%25252C5-Dinitrophenyl-Containing%252B1%25252C2%25252C4-Triazoles%252Band%252BTheir%252BTrifluoromethyl%252BAnalogues%252Bas%252BHighly%252BEfficient%252BAntitubercular%252BAgents%252BInhibiting%252BDecaprenylphosphoryl-%2525CE%2525B2-d-ribofuranose%252B2%2525E2%252580%2525B2-Oxidase%26aulast%3DKarabanovich%26aufirst%3DGalina%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D07062019%26date%3D22082019%26date%3D08082019%26volume%3D62%26issue%3D17%26spage%3D8115%26epage%3D8139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Bogos Agianian, <span class="NLM_string-name hlFld-ContribAuthor">Evripidis Gavathiotis</span>. </span><span class="cited-content_cbyCitation_article-title">Current Insights of BRAF Inhibitors in Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (14)
                                     , 5775-5793. <a href="https://doi.org/10.1021/acs.jmedchem.7b01306" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01306</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01306%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DCurrent%252BInsights%252Bof%252BBRAF%252BInhibitors%252Bin%252BCancer%26aulast%3DAgianian%26aufirst%3DBogos%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D01092017%26date%3D06032018%26date%3D20022018%26volume%3D61%26issue%3D14%26spage%3D5775%26epage%3D5793" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yanmin  Zhang</span>, <span class="hlFld-ContribAuthor ">Lu  Wang</span>, <span class="hlFld-ContribAuthor ">Qing  Zhang</span>, <span class="hlFld-ContribAuthor ">Gaoyuan  Zhu</span>, <span class="hlFld-ContribAuthor ">Zhimin  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiang  Zhou</span>, <span class="hlFld-ContribAuthor ">Yadong  Chen</span>, <span class="hlFld-ContribAuthor ">Tao  Lu</span>, and <span class="hlFld-ContribAuthor ">Weifang  Tang</span>  . </span><span class="cited-content_cbyCitation_article-title">Potent Pan-Raf and Receptor Tyrosine Kinase Inhibitors Based on a Cyclopropyl Formamide Fragment Overcome Resistance. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2017,</strong> <em>57 </em>
                                    (6)
                                     , 1439-1452. <a href="https://doi.org/10.1021/acs.jcim.6b00795" title="DOI URL">https://doi.org/10.1021/acs.jcim.6b00795</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.6b00795&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.6b00795%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DPotent%252BPan-Raf%252Band%252BReceptor%252BTyrosine%252BKinase%252BInhibitors%252BBased%252Bon%252Ba%252BCyclopropyl%252BFormamide%252BFragment%252BOvercome%252BResistance%26aulast%3DZhang%26aufirst%3DYanmin%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D31122016%26date%3D19052017%26date%3D26062017%26date%3D09052017%26volume%3D57%26issue%3D6%26spage%3D1439%26epage%3D1452" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yikai  Wang</span>, <span class="hlFld-ContribAuthor ">Jean-Yves  Wach</span>, <span class="hlFld-ContribAuthor ">Patrick  Sheehan</span>, <span class="hlFld-ContribAuthor ">Cheng  Zhong</span>, <span class="hlFld-ContribAuthor ">Chenyang  Zhan</span>, <span class="hlFld-ContribAuthor ">Richard  Harris</span>, <span class="hlFld-ContribAuthor ">Steven C.  Almo</span>, <span class="hlFld-ContribAuthor ">Joshua  Bishop</span>, <span class="hlFld-ContribAuthor ">Stephen J.  Haggarty</span>, <span class="hlFld-ContribAuthor ">Alexander  Ramek</span>, <span class="hlFld-ContribAuthor ">Kayla N.  Berry</span>, <span class="hlFld-ContribAuthor ">Conor  O’Herin</span>, <span class="hlFld-ContribAuthor ">Angela N.  Koehler</span>, <span class="hlFld-ContribAuthor ">Alvin W.  Hung</span>, and <span class="hlFld-ContribAuthor ">Damian W.  Young</span>  . </span><span class="cited-content_cbyCitation_article-title">Diversity-Oriented Synthesis as a Strategy for Fragment Evolution against GSK3β. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>7 </em>
                                    (9)
                                     , 852-856. <a href="https://doi.org/10.1021/acsmedchemlett.6b00230" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.6b00230</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.6b00230&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.6b00230%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiversity-Oriented%252BSynthesis%252Bas%252Ba%252BStrategy%252Bfor%252BFragment%252BEvolution%252Bagainst%252BGSK3%2525CE%2525B2%26aulast%3DWang%26aufirst%3DYikai%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D04062016%26date%3D14072016%26date%3D02082016%26date%3D08092016%26date%3D14072016%26volume%3D7%26issue%3D9%26spage%3D852%26epage%3D856" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Li  Tan</span>, <span class="hlFld-ContribAuthor ">Tyzoon  Nomanbhoy</span>, <span class="hlFld-ContribAuthor ">Deepak  Gurbani</span>, <span class="hlFld-ContribAuthor ">Matthew  Patricelli</span>, <span class="hlFld-ContribAuthor ">John  Hunter</span>, <span class="hlFld-ContribAuthor ">Jiefei  Geng</span>, <span class="hlFld-ContribAuthor ">Lina  Herhaus</span>, <span class="hlFld-ContribAuthor ">Jianming  Zhang</span>, <span class="hlFld-ContribAuthor ">Eduardo  Pauls</span>, <span class="hlFld-ContribAuthor ">Youngjin  Ham</span>, <span class="hlFld-ContribAuthor ">Hwan Geun  Choi</span>, <span class="hlFld-ContribAuthor ">Ting  Xie</span>, <span class="hlFld-ContribAuthor ">Xianming  Deng</span>, <span class="hlFld-ContribAuthor ">Sara J.  Buhrlage</span>, <span class="hlFld-ContribAuthor ">Taebo  Sim</span>, <span class="hlFld-ContribAuthor ">Philip  Cohen</span>, <span class="hlFld-ContribAuthor ">Gopal  Sapkota</span>, <span class="hlFld-ContribAuthor ">Kenneth D.  Westover</span>, and <span class="hlFld-ContribAuthor ">Nathanael S.  Gray</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Type II Inhibitors of TGFβ-Activated Kinase 1 (TAK1) and Mitogen-Activated Protein Kinase Kinase Kinase Kinase 2 (MAP4K2). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (1)
                                     , 183-196. <a href="https://doi.org/10.1021/jm500480k" title="DOI URL">https://doi.org/10.1021/jm500480k</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm500480k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm500480k%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BType%252BII%252BInhibitors%252Bof%252BTGF%2525CE%2525B2-Activated%252BKinase%252B1%252B%252528TAK1%252529%252Band%252BMitogen-Activated%252BProtein%252BKinase%252BKinase%252BKinase%252BKinase%252B2%252B%252528MAP4K2%252529%26aulast%3DTan%26aufirst%3DLi%26date%3D2015%26date%3D2014%26date%3D2014%26date%3D26032014%26date%3D30072014%26date%3D08012015%26date%3D17072014%26volume%3D58%26issue%3D1%26spage%3D183%26epage%3D196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Oscar P. J.  van Linden</span>, <span class="hlFld-ContribAuthor ">Albert J.  Kooistra</span>, <span class="hlFld-ContribAuthor ">Rob  Leurs</span>, <span class="hlFld-ContribAuthor ">Iwan J. P.  de Esch</span>, and <span class="hlFld-ContribAuthor ">Chris  de Graaf</span>  . </span><span class="cited-content_cbyCitation_article-title">KLIFS: A Knowledge-Based Structural Database To Navigate Kinase–Ligand Interaction Space. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>57 </em>
                                    (2)
                                     , 249-277. <a href="https://doi.org/10.1021/jm400378w" title="DOI URL">https://doi.org/10.1021/jm400378w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm400378w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm400378w%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DKLIFS%25253A%252BA%252BKnowledge-Based%252BStructural%252BDatabase%252BTo%252BNavigate%252BKinase%2525E2%252580%252593Ligand%252BInteraction%252BSpace%26aulast%3Dvan%2BLinden%26aufirst%3DOscar%2BP.%2BJ.%26date%3D2014%26date%3D2013%26date%3D2013%26date%3D14032013%26date%3D20092013%26date%3D23012014%26date%3D13082013%26volume%3D57%26issue%3D2%26spage%3D249%26epage%3D277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Martin W.  Rowbottom</span>, <span class="hlFld-ContribAuthor ">Raffaella  Faraoni</span>, <span class="hlFld-ContribAuthor ">Qi  Chao</span>, <span class="hlFld-ContribAuthor ">Brian T.  Campbell</span>, <span class="hlFld-ContribAuthor ">Andiliy G.  Lai</span>, <span class="hlFld-ContribAuthor ">Eduardo  Setti</span>, <span class="hlFld-ContribAuthor ">Maiko  Ezawa</span>, <span class="hlFld-ContribAuthor ">Kelly G.  Sprankle</span>, <span class="hlFld-ContribAuthor ">Sunny  Abraham</span>, <span class="hlFld-ContribAuthor ">Lan  Tran</span>, <span class="hlFld-ContribAuthor ">Brian  Struss</span>, <span class="hlFld-ContribAuthor ">Michael  Gibney</span>, <span class="hlFld-ContribAuthor ">Robert C.  Armstrong</span>, <span class="hlFld-ContribAuthor ">Ruwanthi N.  Gunawardane</span>, <span class="hlFld-ContribAuthor ">Ronald R.  Nepomuceno</span>, <span class="hlFld-ContribAuthor ">Ianina  Valenta</span>, <span class="hlFld-ContribAuthor ">Helen  Hua</span>, <span class="hlFld-ContribAuthor ">Michael F.  Gardner</span>, <span class="hlFld-ContribAuthor ">Merryl D.  Cramer</span>, <span class="hlFld-ContribAuthor ">Dana  Gitnick</span>, <span class="hlFld-ContribAuthor ">Darren E.  Insko</span>, <span class="hlFld-ContribAuthor ">Julius L.  Apuy</span>, <span class="hlFld-ContribAuthor ">Susan  Jones-Bolin</span>, <span class="hlFld-ContribAuthor ">Arup K.  Ghose</span>, <span class="hlFld-ContribAuthor ">Torsten  Herbertz</span>, <span class="hlFld-ContribAuthor ">Mark A.  Ator</span>, <span class="hlFld-ContribAuthor ">Bruce D.  Dorsey</span>, <span class="hlFld-ContribAuthor ">Bruce  Ruggeri</span>, <span class="hlFld-ContribAuthor ">Michael  Williams</span>, <span class="hlFld-ContribAuthor ">Shripad  Bhagwat</span>, <span class="hlFld-ContribAuthor ">Joyce  James</span>, and <span class="hlFld-ContribAuthor ">Mark W.  Holladay</span>  . </span><span class="cited-content_cbyCitation_article-title">Identification of 1-(3-(6,7-Dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea Hydrochloride (CEP-32496), a Highly Potent and Orally Efficacious Inhibitor of V-RAF Murine Sarcoma Viral Oncogene Homologue B1 (BRAF) V600E. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2012,</strong> <em>55 </em>
                                    (3)
                                     , 1082-1105. <a href="https://doi.org/10.1021/jm2009925" title="DOI URL">https://doi.org/10.1021/jm2009925</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm2009925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm2009925%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252B1-%2525283-%2525286%25252C7-Dimethoxyquinazolin-4-yloxy%252529phenyl%252529-3-%2525285-%2525281%25252C1%25252C1-trifluoro-2-methylpropan-2-yl%252529isoxazol-3-yl%252529urea%252BHydrochloride%252B%252528CEP-32496%252529%25252C%252Ba%252BHighly%252BPotent%252Band%252BOrally%252BEfficacious%252BInhibitor%252Bof%252BV-RAF%252BMurine%252BSarcoma%252BViral%252BOncogene%252BHomologue%252BB1%252B%252528BRAF%252529%252BV600E%26aulast%3DRowbottom%26aufirst%3DMartin%2BW.%26date%3D2012%26date%3D2012%26date%3D2011%26date%3D25072011%26date%3D23012012%26date%3D09022012%26date%3D14122011%26volume%3D55%26issue%3D3%26spage%3D1082%26epage%3D1105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rahim  Ullah</span>, <span class="hlFld-ContribAuthor ">Qing  Yin</span>, <span class="hlFld-ContribAuthor ">Aidan H.  Snell</span>, <span class="hlFld-ContribAuthor ">Lixin  Wan</span>. </span><span class="cited-content_cbyCitation_article-title">RAF-MEK-ERK pathway in cancer evolution and treatment. </span><span class="cited-content_cbyCitation_journal-name">Seminars in Cancer Biology</span><span> <strong>2021,</strong> <em>84 </em><a href="https://doi.org/10.1016/j.semcancer.2021.05.010" title="DOI URL">https://doi.org/10.1016/j.semcancer.2021.05.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.semcancer.2021.05.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.semcancer.2021.05.010%26sid%3Dliteratum%253Aachs%26jtitle%3DSeminars%2520in%2520Cancer%2520Biology%26atitle%3DRAF-MEK-ERK%252Bpathway%252Bin%252Bcancer%252Bevolution%252Band%252Btreatment%26aulast%3DUllah%26aufirst%3DRahim%26date%3D2021%26volume%3D84" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jaydeepsinh  Chavda</span>, <span class="hlFld-ContribAuthor ">Hardik  Bhatt</span>. </span><span class="cited-content_cbyCitation_article-title">Systemic review on B-RafV600E mutation as potential therapeutic target for the treatment of cancer. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>206 </em>, 112675. <a href="https://doi.org/10.1016/j.ejmech.2020.112675" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112675</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112675%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSystemic%252Breview%252Bon%252BB-RafV600E%252Bmutation%252Bas%252Bpotential%252Btherapeutic%252Btarget%252Bfor%252Bthe%252Btreatment%252Bof%252Bcancer%26aulast%3DChavda%26aufirst%3DJaydeepsinh%26date%3D2020%26volume%3D206%26spage%3D112675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lu  Wang</span>, <span class="hlFld-ContribAuthor ">Yanmin  Zhang</span>, <span class="hlFld-ContribAuthor ">Qing  Zhang</span>, <span class="hlFld-ContribAuthor ">Gaoyuan  Zhu</span>, <span class="hlFld-ContribAuthor ">Zhimin  Zhang</span>, <span class="hlFld-ContribAuthor ">Chunqi  Duan</span>, <span class="hlFld-ContribAuthor ">Tao  Lu</span>, <span class="hlFld-ContribAuthor ">Weifang  Tang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of potent Pan-Raf inhibitors with increased solubility to overcome drug resistance. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>163 </em>, 243-255. <a href="https://doi.org/10.1016/j.ejmech.2018.11.033" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.11.033</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.11.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.11.033%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bpotent%252BPan-Raf%252Binhibitors%252Bwith%252Bincreased%252Bsolubility%252Bto%252Bovercome%252Bdrug%252Bresistance%26aulast%3DWang%26aufirst%3DLu%26date%3D2019%26volume%3D163%26spage%3D243%26epage%3D255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nulgumnalli Manjunathaiah  Raghavendra</span>, <span class="hlFld-ContribAuthor ">Divya  Pingili</span>, <span class="hlFld-ContribAuthor ">Sundeep  Kadasi</span>, <span class="hlFld-ContribAuthor ">Akhila  Mettu</span>, <span class="hlFld-ContribAuthor ">S.V.U.M.  Prasad</span>. </span><span class="cited-content_cbyCitation_article-title">Dual or multi-targeting inhibitors: The next generation anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>143 </em>, 1277-1300. <a href="https://doi.org/10.1016/j.ejmech.2017.10.021" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.10.021</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.10.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.10.021%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDual%252Bor%252Bmulti-targeting%252Binhibitors%25253A%252BThe%252Bnext%252Bgeneration%252Banticancer%252Bagents%26aulast%3DRaghavendra%26aufirst%3DNulgumnalli%2BManjunathaiah%26date%3D2018%26volume%3D143%26spage%3D1277%26epage%3D1300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lu  Wang</span>, <span class="hlFld-ContribAuthor ">Qing  Zhang</span>, <span class="hlFld-ContribAuthor ">Gaoyuan  Zhu</span>, <span class="hlFld-ContribAuthor ">Zhimin  Zhang</span>, <span class="hlFld-ContribAuthor ">Yanle  Zhi</span>, <span class="hlFld-ContribAuthor ">Li  Zhang</span>, <span class="hlFld-ContribAuthor ">Tianxiao  Mao</span>, <span class="hlFld-ContribAuthor ">Xiang  Zhou</span>, <span class="hlFld-ContribAuthor ">Yadong  Chen</span>, <span class="hlFld-ContribAuthor ">Tao  Lu</span>, <span class="hlFld-ContribAuthor ">Weifang  Tang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and evaluation of derivatives based on pyrimidine scaffold as potent Pan-Raf inhibitors to overcome resistance. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>130 </em>, 86-106. <a href="https://doi.org/10.1016/j.ejmech.2017.02.041" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.02.041</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.02.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.02.041%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bevaluation%252Bof%252Bderivatives%252Bbased%252Bon%252Bpyrimidine%252Bscaffold%252Bas%252Bpotent%252BPan-Raf%252Binhibitors%252Bto%252Bovercome%252Bresistance%26aulast%3DWang%26aufirst%3DLu%26date%3D2017%26volume%3D130%26spage%3D86%26epage%3D106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">D.D.  Stuart</span>. </span><span class="cited-content_cbyCitation_article-title">Next-Generation Strategies to Target RAF. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 175-191. <a href="https://doi.org/10.1016/B978-0-12-803505-4.00010-2" title="DOI URL">https://doi.org/10.1016/B978-0-12-803505-4.00010-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-803505-4.00010-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-803505-4.00010-2%26sid%3Dliteratum%253Aachs%26atitle%3DNext-Generation%252BStrategies%252Bto%252BTarget%252BRAF%26aulast%3DStuart%26aufirst%3DD.D.%26date%3D2017%26spage%3D175%26epage%3D191%26pub%3DElsevier%26atitle%3DConquering%252BRAS%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lu  Wang</span>, <span class="hlFld-ContribAuthor ">Gaoyuan  Zhu</span>, <span class="hlFld-ContribAuthor ">Qing  Zhang</span>, <span class="hlFld-ContribAuthor ">Chunqi  Duan</span>, <span class="hlFld-ContribAuthor ">Yanmin  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhimin  Zhang</span>, <span class="hlFld-ContribAuthor ">Yujun  Zhou</span>, <span class="hlFld-ContribAuthor ">Tao  Lu</span>, <span class="hlFld-ContribAuthor ">Weifang  Tang</span>. </span><span class="cited-content_cbyCitation_article-title">Rational design, synthesis, and biological evaluation of Pan-Raf inhibitors to overcome resistance. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2017,</strong> <em>15 </em>
                                    (16)
                                     , 3455-3465. <a href="https://doi.org/10.1039/C7OB00518K" title="DOI URL">https://doi.org/10.1039/C7OB00518K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7OB00518K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7OB00518K%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DRational%252Bdesign%25252C%252Bsynthesis%25252C%252Band%252Bbiological%252Bevaluation%252Bof%252BPan-Raf%252Binhibitors%252Bto%252Bovercome%252Bresistance%26aulast%3DWang%26aufirst%3DLu%26date%3D2017%26date%3D2017%26volume%3D15%26issue%3D16%26spage%3D3455%26epage%3D3465" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">José F.  Cívicos</span>, <span class="hlFld-ContribAuthor ">Carlos M.R.  Ribeiro</span>, <span class="hlFld-ContribAuthor ">Paulo R.R.  Costa</span>, <span class="hlFld-ContribAuthor ">Carmen  Nájera</span>. </span><span class="cited-content_cbyCitation_article-title">Copper- versus palladium-catalyzed aromatization of 2-(methoxycarbonyl) tetralones: synthesis of methyl 1-hydroxy-2-naphthoates. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2016,</strong> <em>72 </em>
                                    (16)
                                     , 1897-1902. <a href="https://doi.org/10.1016/j.tet.2016.01.057" title="DOI URL">https://doi.org/10.1016/j.tet.2016.01.057</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2016.01.057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2016.01.057%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DCopper-%252Bversus%252Bpalladium-catalyzed%252Baromatization%252Bof%252B2-%252528methoxycarbonyl%252529%252Btetralones%25253A%252Bsynthesis%252Bof%252Bmethyl%252B1-hydroxy-2-naphthoates%26aulast%3DC%25C3%25ADvicos%26aufirst%3DJos%25C3%25A9%2BF.%26date%3D2016%26volume%3D72%26issue%3D16%26spage%3D1897%26epage%3D1902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhan  Yao</span>, <span class="hlFld-ContribAuthor ">Neilawattie M.  Torres</span>, <span class="hlFld-ContribAuthor ">Anthony  Tao</span>, <span class="hlFld-ContribAuthor ">Yijun  Gao</span>, <span class="hlFld-ContribAuthor ">Lusong  Luo</span>, <span class="hlFld-ContribAuthor ">Qi  Li</span>, <span class="hlFld-ContribAuthor ">Elisa  de Stanchina</span>, <span class="hlFld-ContribAuthor ">Omar  Abdel-Wahab</span>, <span class="hlFld-ContribAuthor ">David B.  Solit</span>, <span class="hlFld-ContribAuthor ">Poulikos I.  Poulikakos</span>, <span class="hlFld-ContribAuthor ">Neal  Rosen</span>. </span><span class="cited-content_cbyCitation_article-title">BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition. </span><span class="cited-content_cbyCitation_journal-name">Cancer Cell</span><span> <strong>2015,</strong> <em>28 </em>
                                    (3)
                                     , 370-383. <a href="https://doi.org/10.1016/j.ccell.2015.08.001" title="DOI URL">https://doi.org/10.1016/j.ccell.2015.08.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ccell.2015.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ccell.2015.08.001%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Cell%26atitle%3DBRAF%252BMutants%252BEvade%252BERK-Dependent%252BFeedback%252Bby%252BDifferent%252BMechanisms%252Bthat%252BDetermine%252BTheir%252BSensitivity%252Bto%252BPharmacologic%252BInhibition%26aulast%3DYao%26aufirst%3DZhan%26date%3D2015%26volume%3D28%26issue%3D3%26spage%3D370%26epage%3D383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">A A  Mian</span>, <span class="hlFld-ContribAuthor ">A  Rafiei</span>, <span class="hlFld-ContribAuthor ">I  Haberbosch</span>, <span class="hlFld-ContribAuthor ">A  Zeifman</span>, <span class="hlFld-ContribAuthor ">I  Titov</span>, <span class="hlFld-ContribAuthor ">V  Stroylov</span>, <span class="hlFld-ContribAuthor ">A  Metodieva</span>, <span class="hlFld-ContribAuthor ">O  Stroganov</span>, <span class="hlFld-ContribAuthor ">F  Novikov</span>, <span class="hlFld-ContribAuthor ">B  Brill</span>, <span class="hlFld-ContribAuthor ">G  Chilov</span>, <span class="hlFld-ContribAuthor ">D  Hoelzer</span>, <span class="hlFld-ContribAuthor ">O G  Ottmann</span>, <span class="hlFld-ContribAuthor ">M  Ruthardt</span>. </span><span class="cited-content_cbyCitation_article-title">PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation. </span><span class="cited-content_cbyCitation_journal-name">Leukemia</span><span> <strong>2015,</strong> <em>29 </em>
                                    (5)
                                     , 1104-1114. <a href="https://doi.org/10.1038/leu.2014.326" title="DOI URL">https://doi.org/10.1038/leu.2014.326</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/leu.2014.326&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fleu.2014.326%26sid%3Dliteratum%253Aachs%26jtitle%3DLeukemia%26atitle%3DPF-114%25252C%252Ba%252Bpotent%252Band%252Bselective%252Binhibitor%252Bof%252Bnative%252Band%252Bmutated%252BBCR%25252FABL%252Bis%252Bactive%252Bagainst%252BPhiladelphia%252Bchromosome-positive%252B%252528Ph%25252B%252529%252Bleukemias%252Bharboring%252Bthe%252BT315I%252Bmutation%26aulast%3DMian%26aufirst%3DA%2BA%26date%3D2015%26date%3D2014%26volume%3D29%26issue%3D5%26spage%3D1104%26epage%3D1114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Venky  Soundararajan</span>, <span class="hlFld-ContribAuthor ">Murali  Aravamudan</span>. </span><span class="cited-content_cbyCitation_article-title">Global connectivity of hub residues in Oncoprotein structures encodes genetic factors dictating personalized drug response to targeted Cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2015,</strong> <em>4 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/srep07294" title="DOI URL">https://doi.org/10.1038/srep07294</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/srep07294&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fsrep07294%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DGlobal%252Bconnectivity%252Bof%252Bhub%252Bresidues%252Bin%252BOncoprotein%252Bstructures%252Bencodes%252Bgenetic%252Bfactors%252Bdictating%252Bpersonalized%252Bdrug%252Bresponse%252Bto%252Btargeted%252BCancer%252Btherapy%26aulast%3DSoundararajan%26aufirst%3DVenky%26date%3D2015%26date%3D2014%26volume%3D4%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qing-Shan  Li</span>, <span class="hlFld-ContribAuthor ">Xian-Hai  Lü</span>, <span class="hlFld-ContribAuthor ">Yang  Yang</span>, <span class="hlFld-ContribAuthor ">Ban-Feng  Ruan</span>, <span class="hlFld-ContribAuthor ">Ri-Sheng  Yao</span>, <span class="hlFld-ContribAuthor ">Chen-Zhong  Liao</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and Pharmacophore Studies of Novel Pyrazole-Based Anti-Melanoma Agents. </span><span class="cited-content_cbyCitation_journal-name">Chemistry & Biodiversity</span><span> <strong>2015,</strong> <em>12 </em>
                                    (1)
                                     , 116-132. <a href="https://doi.org/10.1002/cbdv.201400143" title="DOI URL">https://doi.org/10.1002/cbdv.201400143</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cbdv.201400143&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcbdv.201400143%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520%2526%2520Biodiversity%26atitle%3DDiscovery%252Band%252BPharmacophore%252BStudies%252Bof%252BNovel%252BPyrazole-Based%252BAnti-Melanoma%252BAgents%26aulast%3DLi%26aufirst%3DQing-Shan%26date%3D2015%26date%3D2015%26volume%3D12%26issue%3D1%26spage%3D116%26epage%3D132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gregory A  Ryslik</span>, <span class="hlFld-ContribAuthor ">Yuwei  Cheng</span>, <span class="hlFld-ContribAuthor ">Kei-Hoi  Cheung</span>, <span class="hlFld-ContribAuthor ">Robert D  Bjornson</span>, <span class="hlFld-ContribAuthor ">Daniel  Zelterman</span>, <span class="hlFld-ContribAuthor ">Yorgo  Modis</span>, <span class="hlFld-ContribAuthor ">Hongyu  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">A spatial simulation approach to account for protein structure when identifying non-random somatic mutations. </span><span class="cited-content_cbyCitation_journal-name">BMC Bioinformatics</span><span> <strong>2014,</strong> <em>15 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/1471-2105-15-231" title="DOI URL">https://doi.org/10.1186/1471-2105-15-231</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/1471-2105-15-231&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2F1471-2105-15-231%26sid%3Dliteratum%253Aachs%26jtitle%3DBMC%2520Bioinformatics%26atitle%3DA%252Bspatial%252Bsimulation%252Bapproach%252Bto%252Baccount%252Bfor%252Bprotein%252Bstructure%252Bwhen%252Bidentifying%252Bnon-random%252Bsomatic%252Bmutations%26aulast%3DRyslik%26aufirst%3DGregory%2BA%26date%3D2014%26date%3D2014%26volume%3D15%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jarrad M.  Altimari</span>, <span class="hlFld-ContribAuthor ">Birunthi  Niranjan</span>, <span class="hlFld-ContribAuthor ">Gail P.  Risbridger</span>, <span class="hlFld-ContribAuthor ">Stephanie S.  Schweiker</span>, <span class="hlFld-ContribAuthor ">Anna E.  Lohning</span>, <span class="hlFld-ContribAuthor ">Luke C.  Henderson</span>. </span><span class="cited-content_cbyCitation_article-title">Preliminary investigations into triazole derived androgen receptor antagonists. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2014,</strong> <em>22 </em>
                                    (9)
                                     , 2692-2706. <a href="https://doi.org/10.1016/j.bmc.2014.03.018" title="DOI URL">https://doi.org/10.1016/j.bmc.2014.03.018</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2014.03.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2014.03.018%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DPreliminary%252Binvestigations%252Binto%252Btriazole%252Bderived%252Bandrogen%252Breceptor%252Bantagonists%26aulast%3DAltimari%26aufirst%3DJarrad%2BM.%26date%3D2014%26volume%3D22%26issue%3D9%26spage%3D2692%26epage%3D2706" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Süleyman  Yılmaz</span>, <span class="hlFld-ContribAuthor ">Süleyman  Göksu</span>. </span><span class="cited-content_cbyCitation_article-title">First Synthesis of Dopamine and Rotigotin Analogue 2-Amino-6,8-dimethoxy-1,2,3,4-tetrahydronaphthalene. </span><span class="cited-content_cbyCitation_journal-name">Synthetic Communications</span><span> <strong>2014,</strong> <em>44 </em>
                                    (8)
                                     , 1058-1065. <a href="https://doi.org/10.1080/00397911.2013.841939" title="DOI URL">https://doi.org/10.1080/00397911.2013.841939</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/00397911.2013.841939&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F00397911.2013.841939%26sid%3Dliteratum%253Aachs%26jtitle%3DSynthetic%2520Communications%26atitle%3DFirst%252BSynthesis%252Bof%252BDopamine%252Band%252BRotigotin%252BAnalogue%252B2-Amino-6%25252C8-dimethoxy-1%25252C2%25252C3%25252C4-tetrahydronaphthalene%26aulast%3DY%25C4%25B1lmaz%26aufirst%3DS%25C3%25BCleyman%26date%3D2014%26date%3D2014%26volume%3D44%26issue%3D8%26spage%3D1058%26epage%3D1065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hala Bakr  El-Nassan</span>. </span><span class="cited-content_cbyCitation_article-title">Recent progress in the identification of BRAF inhibitors as anti-cancer agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>72 </em>, 170-205. <a href="https://doi.org/10.1016/j.ejmech.2013.11.018" title="DOI URL">https://doi.org/10.1016/j.ejmech.2013.11.018</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2013.11.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2013.11.018%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Bprogress%252Bin%252Bthe%252Bidentification%252Bof%252BBRAF%252Binhibitors%252Bas%252Banti-cancer%252Bagents%26aulast%3DEl-Nassan%26aufirst%3DHala%2BBakr%26date%3D2014%26volume%3D72%26spage%3D170%26epage%3D205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaolun  Wang</span>, <span class="hlFld-ContribAuthor ">Kristin  Schleicher</span>. </span><span class="cited-content_cbyCitation_article-title">Conformation-Specific Inhibitors of Raf Kinases. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2013,</strong>,, 41-66. <a href="https://doi.org/10.1016/B978-0-12-420146-0.00003-2" title="DOI URL">https://doi.org/10.1016/B978-0-12-420146-0.00003-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-420146-0.00003-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-420146-0.00003-2%26sid%3Dliteratum%253Aachs%26atitle%3DConformation-Specific%252BInhibitors%252Bof%252BRaf%252BKinases%26aulast%3DWang%26aufirst%3DXiaolun%26date%3D2013%26spage%3D41%26epage%3D66%26pub%3DElsevier%26atitle%3DInhibitors%252Bof%252Bthe%252BRas%252Bsuperfamily%252BG-proteins%25252C%252BPart%252BB%26date%3D2013%26volume%3D34" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qing-Shan  Li</span>, <span class="hlFld-ContribAuthor ">Cui-Yun  Li</span>, <span class="hlFld-ContribAuthor ">Xiang  Lu</span>, <span class="hlFld-ContribAuthor ">Hui  Zhang</span>, <span class="hlFld-ContribAuthor ">Hai-Liang  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of novel (E)-α-benzylsulfonyl chalcone derivatives as potential BRAF inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2012,</strong> <em>50 </em>, 288-295. <a href="https://doi.org/10.1016/j.ejmech.2012.02.007" title="DOI URL">https://doi.org/10.1016/j.ejmech.2012.02.007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2012.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2012.02.007%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252B%252528E%252529-%2525CE%2525B1-benzylsulfonyl%252Bchalcone%252Bderivatives%252Bas%252Bpotential%252BBRAF%252Binhibitors%26aulast%3DLi%26aufirst%3DQing-Shan%26date%3D2012%26volume%3D50%26spage%3D288%26epage%3D295" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hwangseo  Park</span>, <span class="hlFld-ContribAuthor ">Yujeong  Jeong</span>, <span class="hlFld-ContribAuthor ">Sungwoo  Hong</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-based de novo design and biochemical evaluation of novel BRAF kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2012,</strong> <em>22 </em>
                                    (2)
                                     , 1027-1030. <a href="https://doi.org/10.1016/j.bmcl.2011.11.124" title="DOI URL">https://doi.org/10.1016/j.bmcl.2011.11.124</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2011.11.124&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2011.11.124%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DStructure-based%252Bde%252Bnovo%252Bdesign%252Band%252Bbiochemical%252Bevaluation%252Bof%252Bnovel%252BBRAF%252Bkinase%252Binhibitors%26aulast%3DPark%26aufirst%3DHwangseo%26date%3D2012%26volume%3D22%26issue%3D2%26spage%3D1027%26epage%3D1030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hwangseo  Park</span>, <span class="hlFld-ContribAuthor ">Hwanho  Choi</span>, <span class="hlFld-ContribAuthor ">Seunghee  Hong</span>, <span class="hlFld-ContribAuthor ">Sungwoo  Hong</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of novel BRAF kinase inhibitors with structure-based virtual screening. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2011,</strong> <em>21 </em>
                                    (19)
                                     , 5753-5756. <a href="https://doi.org/10.1016/j.bmcl.2011.08.010" title="DOI URL">https://doi.org/10.1016/j.bmcl.2011.08.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2011.08.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2011.08.010%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DIdentification%252Bof%252Bnovel%252BBRAF%252Bkinase%252Binhibitors%252Bwith%252Bstructure-based%252Bvirtual%252Bscreening%26aulast%3DPark%26aufirst%3DHwangseo%26date%3D2011%26volume%3D21%26issue%3D19%26spage%3D5753%26epage%3D5756" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-6/jm101479y/production/images/medium/jm-2010-01479y_0001.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-6/jm101479y/production/images/large/jm-2010-01479y_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm101479y&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-6/jm101479y/production/images/medium/jm-2010-01479y_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-6/jm101479y/production/images/large/jm-2010-01479y_0005.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Amide-Based Raf Inhibitors<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-6/jm101479y/production/images/large/jm-2010-01479y_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm101479y&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 4-Chloro-<i>N</i>-methylpicolinamide, KOtBu, DMPU, DMF, 100 °C. (b) (±)-<b>15</b> or (<i>S</i>)-<b>15</b>, Cs<sub>2</sub>CO<sub>3</sub>, DMF, heat and then amide coupling. (c) Compound <b>17</b>, Cs<sub>2</sub>CO<sub>3</sub>, DMF, heat and then amide coupling.</p></p></figure><figure data-id="sch2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-6/jm101479y/production/images/medium/jm-2010-01479y_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-6/jm101479y/production/images/large/jm-2010-01479y_0006.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of 4-Fluoropyridine Lactam<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-6/jm101479y/production/images/large/jm-2010-01479y_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm101479y&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <i>t</i>-Butyl carbamate, Pd(OAc)<sub>2</sub>, Xantphos, NaOH, H<sub>2</sub>O, dioxane, 80%. (b) <i>n</i>-BuLi, TMEDA, THF, −78 °C and then I<sub>2</sub>, 86%. (c) Pd catalyst <b>29</b>, 3,3-diethoxy-1-propene, DIPEA, H<sub>2</sub>O, DMF, 140 °C, 47%.</p></p></figure><figure data-id="sch3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-6/jm101479y/production/images/medium/jm-2010-01479y_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-6/jm101479y/production/images/large/jm-2010-01479y_0007.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of <i>S</i>-Tetrahydronaphthalene Carboxylic Acid<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-6/jm101479y/production/images/large/jm-2010-01479y_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm101479y&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) THF, −78 °C, 89%. (b) NaHMDS, THF −78 °C and then <i>t</i>-butyl bromoacetate, 79%. (c) CF<sub>3</sub>SO<sub>3</sub>H, PhH, 80 °C, o/n. (d) H<sub>2</sub>O<sub>2</sub>, NaOH, THF 0 °C, 70% for two steps. (e) Pd/C, H<sub>2</sub>, H<sub>2</sub>SO<sub>4</sub>, AcOH, 80 °C, 20 psi, 65%. (f) BBr<sub>3</sub>, DCM, −78 to 0 °C, 74%.</p></p></figure><figure data-id="sch4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-6/jm101479y/production/images/medium/jm-2010-01479y_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-6/jm101479y/production/images/large/jm-2010-01479y_0008.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Amino Tetrahydronaphthalene<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-6/jm101479y/production/images/large/jm-2010-01479y_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm101479y&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) BnNH<sub>2</sub>, NaBH(OAc)<sub>3</sub>, AcOH, DCM, 100%. (b) Pd(OH)<sub>2</sub>, H<sub>2</sub>, EtOH, AcOH, 92%. (c) NaOH, EtOAc, 92% and then <i>S</i>-(+)-mandelic acid, iPrOH, MeOH, H<sub>2</sub>O, PhMe, 60%. (d) HBr, H<sub>2</sub>O, reflux, 99%.</p></p></figure><figure data-id="fig1" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-6/jm101479y/production/images/medium/jm-2010-01479y_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-6/jm101479y/production/images/large/jm-2010-01479y_0003.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Inhibition of subcutaneous A375 M xenografts in immunocompromised mice by <b>26</b> and <b>27</b>. The doses shown are the maximum daily dose tolerated without body weight loss. Each compound was administered po/qd for 21 days.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-6/jm101479y/production/images/large/jm-2010-01479y_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm101479y&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-6/jm101479y/production/images/medium/jm-2010-01479y_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-6/jm101479y/production/images/large/jm-2010-01479y_0004.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Crystal structure of <b>24</b> solved in complex with B-Raf (3.1 Å resolution).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-6/jm101479y/production/images/large/jm-2010-01479y_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm101479y&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i37">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83716" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83716" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 22 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Robinson, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cobb, M. H.</span><span> </span><span class="NLM_article-title">Mitogen-activated Protein Kinase Pathways</span> <span class="citation_source-journal">Curr. Opin. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">180</span><span class="NLM_x">–</span> <span class="NLM_lpage">186</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm101479y&amp;key=10.1016%2FS0955-0674%2897%2980061-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm101479y&amp;key=9069255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm101479y&amp;key=1%3ACAS%3A528%3ADyaK2sXisVWntLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1997&pages=180-186&author=M.+J.+Robinsonauthor=M.+H.+Cobb&title=Mitogen-activated+Protein+Kinase+Pathways"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Mitogen-activated protein kinase pathways</span></div><div class="casAuthors">Robinson, Megan J.; Cobb, Melanie H.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Cell Biology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">180-186</span>CODEN:
                <span class="NLM_cas:coden">COCBE3</span>;
        ISSN:<span class="NLM_cas:issn">0955-0674</span>.
    
            (<span class="NLM_cas:orgname">Current Biology</span>)
        </div><div class="casAbstract">A review with 87 refs.  Nearly all cell surface receptors utilize one or more of the mitogen-activated protein kinase cascades in their repertoire of signal transduction mechanisms.  Recent advances in the study of such cascades include the cloning of genes encoding novel members of the cascades, further definition of the roles of the cascades in responses to extracellular signals, and examn. of cross-talk between different cascades.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHUil3pmYpQbVg90H21EOLACvtfcHk0lhiDC30bRlgqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXisVWntLk%253D&md5=c51543227d52f723ba92072d72c3006a</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS0955-0674%2897%2980061-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0955-0674%252897%252980061-0%26sid%3Dliteratum%253Aachs%26aulast%3DRobinson%26aufirst%3DM.%2BJ.%26aulast%3DCobb%26aufirst%3DM.%2BH.%26atitle%3DMitogen-activated%2520Protein%2520Kinase%2520Pathways%26jtitle%3DCurr.%2520Opin.%2520Cell%2520Biol.%26date%3D1997%26volume%3D9%26spage%3D180%26epage%3D186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Roberts, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Der, C. J.</span><span> </span><span class="NLM_article-title">Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">3291</span><span class="NLM_x">–</span> <span class="NLM_lpage">3310</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm101479y&amp;key=10.1038%2Fsj.onc.1210422" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm101479y&amp;key=17496923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm101479y&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlt1Wktb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=3291-3310&author=P.+J.+Robertsauthor=C.+J.+Der&title=Targeting+the+Raf-MEK-ERK+mitogen-activated+protein+kinase+cascade+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer</span></div><div class="casAuthors">Roberts, P. J.; Der, C. J.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">3291-3310</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Mitogen-activated protein kinase (MAPK) cascades are key signaling pathways involved in the regulation of normal cell proliferation, survival and differentiation.  Aberrant regulation of MAPK cascades contribute to cancer and other human diseases.  In particular, the extracellular signal-regulated kinase (ERK) MAPK pathway has been the subject of intense research scrutiny leading to the development of pharmacol. inhibitors for the treatment of cancer.  ERK is a downstream component of an evolutionarily conserved signaling module that is activated by the Raf serine/threonine kinases.  Raf activates the MAPK/ERK kinase (MEK)1/2 dual-specificity protein kinases, which then activate ERK1/2.  The mutational activation of Raf in human cancers supports the important role of this pathway in human oncogenesis.  Addnl., the Raf-MEK-ERK pathway is a key downstream effector of the Ras small GTPase, the most frequently mutated oncogene in human cancers.  Finally, Ras is a key downstream effector of the epidermal growth factor receptor (EGFR), which is mutationally activated and/or overexpressed in a wide variety of human cancers.  ERK activation also promotes upregulated expression of EGFR ligands, promoting an autocrine growth loop crit. for tumor growth.  Thus, the EGFR-Ras-Raf-MEK-ERK signaling network has been the subject of intense research and pharmaceutical scrutiny to identify novel target-based approaches for cancer treatment.  In this review, we summarize the current status of the different approaches and targets that are under evaluation and development for the therapeutic intervention of this key signaling pathway in human disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7hdVDVyRBHrVg90H21EOLACvtfcHk0lhiDC30bRlgqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlt1Wktb4%253D&md5=bf56109e3b4defc12004471da30178c0</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1210422&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1210422%26sid%3Dliteratum%253Aachs%26aulast%3DRoberts%26aufirst%3DP.%2BJ.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26atitle%3DTargeting%2520the%2520Raf-MEK-ERK%2520mitogen-activated%2520protein%2520kinase%2520cascade%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D3291%26epage%3D3310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Davies, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bignell, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephens, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edkins, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clegg, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teague, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woffendin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garnett, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bottomley, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dicks, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ewing, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawes, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosmidou, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menzies, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mould, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hooper, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayatilake, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Busterson, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shipley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hargrave, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard-Jones, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maitland, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chenevix-Trench, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riggins, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bigner, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmieri, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cossu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flanagan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, J. W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuen, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seigler, H. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darrow, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paterson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marais, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wooster, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stratton, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Futreal, P. A.</span><span> </span><span class="NLM_article-title">Mutations of the BRAF Gene in Human Cancer</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">417</span><span class="NLM_x">, </span> <span class="NLM_fpage">949</span><span class="NLM_x">–</span> <span class="NLM_lpage">954</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm101479y&amp;key=10.1038%2Fnature00766" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm101479y&amp;key=12068308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm101479y&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvVagsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=417&publication_year=2002&pages=949-954&author=H.+Daviesauthor=G.+R.+Bignellauthor=C.+Coxauthor=P.+Stephensauthor=S.+Edkinsauthor=S.+Cleggauthor=J.+Teagueauthor=H.+Woffendinauthor=M.+J.+Garnettauthor=W.+Bottomleyauthor=N.+Davisauthor=E.+Dicksauthor=R.+Ewingauthor=Y.+Floydauthor=K.+Grayauthor=S.+Hallauthor=R.+Hawesauthor=J.+Hughesauthor=V.+Kosmidouauthor=A.+Menziesauthor=C.+Mouldauthor=A.+Parkerauthor=C.+Stevensauthor=S.+Wattauthor=S.+Hooperauthor=R.+Wilsonauthor=H.+Jayatilakeauthor=B.+A.+Bustersonauthor=C.+Cooperauthor=J.+Shipleyauthor=D.+Hargraveauthor=K.+Pritchard-Jonesauthor=N.+Maitlandauthor=G.+Chenevix-Trenchauthor=G.+J.+Rigginsauthor=D.+D.+Bignerauthor=G.+Palmieriauthor=A.+Cossuauthor=A.+Flanaganauthor=A.+Nicholsonauthor=J.+W.+C.+Hoauthor=S.+Y.+Leungauthor=S.+T.+Yuenauthor=B.+L.+Weberauthor=H.+F.+Seiglerauthor=T.+L.+Darrowauthor=H.+Patersonauthor=R.+Maraisauthor=C.+J.+Marshallauthor=R.+Woosterauthor=M.+R.+Strattonauthor=P.+A.+Futreal&title=Mutations+of+the+BRAF+Gene+in+Human+Cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations of the BRAF gene in human cancer</span></div><div class="casAuthors">Davies, Helen; Bignell, Graham R.; Cox, Charles; Stephens, Philip; Edkins, Sarah; Clegg, Sheila; Teague, Jon; Woffendin, Hayley; Garnett, Mathew J.; Bottomley, William; Davis, Neil; Dicks, Ed; Ewing, Rebecca; Floyd, Yvonne; Gray, Kristian; Hall, Sarah; Hawes, Rachel; Hughes, Jaime; Kosmidou, Vivian; Menzies, Andrew; Mould, Catherine; Parker, Adrian; Stevens, Claire; Watt, Stephen; Hooper, Steven; Wilson, Rebecca; Jayatilake, Hiran; Gusterson, Barry A.; Cooper, Colin; Shipley, Janet; Hargrave, Darren; Pritchard-Jones, Katherine; Maitland, Norman; Chenevix-Trench, Georgia; Riggins, Gregory J.; Bigner, Darell D.; Palmieri, Giuseppe; Cossu, Antonio; Flanagan, Adrienne; Nicholson, Andrew; Ho, Judy W. C.; Leung, Suet Y.; Yuen, Siu T.; Weber, Barbara L.; Seigler, Hilliard F.; Darrow, Timothy L.; Paterson, Hugh; Marais, Richard; Marshall, Christopher J.; Wooster, Richard; Stratton, Michael R.; Futreal, P. Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">417</span>
        (<span class="NLM_cas:issue">6892</span>),
    <span class="NLM_cas:pages">949-954</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cancers arise owing to the accumulation of mutations in crit. genes that alter normal programs of cell proliferation, differentiation and death.  As the first stage of a systematic genome-wide screen for these genes, we have prioritized for anal. signalling pathways in which at least one gene is mutated in human cancer.  The RAS-RAF-MEK-ERK-MAP kinase pathway mediates cellular responses to growth signals.  RAS is mutated to an oncogenic form in about 15% of human cancer.  The three RAF genes code for cytoplasmic serine/threonine kinases that are regulated by binding RAS.  Here we report BRAF somatic missense mutations in 66% of malignant melanomas and at lower frequency in a wide range of human cancers.  All mutations are within the kinase domain, with a single substitution (V599E) accounting for 80%.  Mutated BRAF proteins have elevated kinase activity and are transforming in NIH3T3 cells.  Furthermore, RAS function is not required for the growth of cancer cell lines with the V599E mutation.  As BRAF is a serine/threonine kinase that is commonly activated by somatic point mutation in human cancer, it may provide new therapeutic opportunities in malignant melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPBmhJC0GAjrVg90H21EOLACvtfcHk0lhiDC30bRlgqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvVagsLo%253D&md5=4625be53ad9a382d51b6ee753d0c17e8</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnature00766&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature00766%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DH.%26aulast%3DBignell%26aufirst%3DG.%2BR.%26aulast%3DCox%26aufirst%3DC.%26aulast%3DStephens%26aufirst%3DP.%26aulast%3DEdkins%26aufirst%3DS.%26aulast%3DClegg%26aufirst%3DS.%26aulast%3DTeague%26aufirst%3DJ.%26aulast%3DWoffendin%26aufirst%3DH.%26aulast%3DGarnett%26aufirst%3DM.%2BJ.%26aulast%3DBottomley%26aufirst%3DW.%26aulast%3DDavis%26aufirst%3DN.%26aulast%3DDicks%26aufirst%3DE.%26aulast%3DEwing%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DY.%26aulast%3DGray%26aufirst%3DK.%26aulast%3DHall%26aufirst%3DS.%26aulast%3DHawes%26aufirst%3DR.%26aulast%3DHughes%26aufirst%3DJ.%26aulast%3DKosmidou%26aufirst%3DV.%26aulast%3DMenzies%26aufirst%3DA.%26aulast%3DMould%26aufirst%3DC.%26aulast%3DParker%26aufirst%3DA.%26aulast%3DStevens%26aufirst%3DC.%26aulast%3DWatt%26aufirst%3DS.%26aulast%3DHooper%26aufirst%3DS.%26aulast%3DWilson%26aufirst%3DR.%26aulast%3DJayatilake%26aufirst%3DH.%26aulast%3DBusterson%26aufirst%3DB.%2BA.%26aulast%3DCooper%26aufirst%3DC.%26aulast%3DShipley%26aufirst%3DJ.%26aulast%3DHargrave%26aufirst%3DD.%26aulast%3DPritchard-Jones%26aufirst%3DK.%26aulast%3DMaitland%26aufirst%3DN.%26aulast%3DChenevix-Trench%26aufirst%3DG.%26aulast%3DRiggins%26aufirst%3DG.%2BJ.%26aulast%3DBigner%26aufirst%3DD.%2BD.%26aulast%3DPalmieri%26aufirst%3DG.%26aulast%3DCossu%26aufirst%3DA.%26aulast%3DFlanagan%26aufirst%3DA.%26aulast%3DNicholson%26aufirst%3DA.%26aulast%3DHo%26aufirst%3DJ.%2BW.%2BC.%26aulast%3DLeung%26aufirst%3DS.%2BY.%26aulast%3DYuen%26aufirst%3DS.%2BT.%26aulast%3DWeber%26aufirst%3DB.%2BL.%26aulast%3DSeigler%26aufirst%3DH.%2BF.%26aulast%3DDarrow%26aufirst%3DT.%2BL.%26aulast%3DPaterson%26aufirst%3DH.%26aulast%3DMarais%26aufirst%3DR.%26aulast%3DMarshall%26aufirst%3DC.%2BJ.%26aulast%3DWooster%26aufirst%3DR.%26aulast%3DStratton%26aufirst%3DM.%2BR.%26aulast%3DFutreal%26aufirst%3DP.%2BA.%26atitle%3DMutations%2520of%2520the%2520BRAF%2520Gene%2520in%2520Human%2520Cancer%26jtitle%3DNature%26date%3D2002%26volume%3D417%26spage%3D949%26epage%3D954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Lee, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, E.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y.-S.</span><span> </span><span class="NLM_article-title">Clinicopathologic Significance of BRAF V600E Mutations in Papillary Carcinomas of the Thyroid</span> <span class="citation_source-journal">Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">38</span><span class="NLM_x">–</span> <span class="NLM_lpage">46</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2007&pages=38-46&author=J.+H.+Leeauthor=E.-S.+Leeauthor=Y.-S.+Kim&title=Clinicopathologic+Significance+of+BRAF+V600E+Mutations+in+Papillary+Carcinomas+of+the+Thyroid"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DLee%26aufirst%3DE.-S.%26aulast%3DKim%26aufirst%3DY.-S.%26atitle%3DClinicopathologic%2520Significance%2520of%2520BRAF%2520V600E%2520Mutations%2520in%2520Papillary%2520Carcinomas%2520of%2520the%2520Thyroid%26jtitle%3DCancer%26date%3D2007%26volume%3D110%26spage%3D38%26epage%3D46" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Gray-Schopfer, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wellbrock, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marais, R.</span><span> </span><span class="NLM_article-title">Melanoma biology and new targeted therapy</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">445</span><span class="NLM_x">, </span> <span class="NLM_fpage">851</span><span class="NLM_x">–</span> <span class="NLM_lpage">857</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm101479y&amp;key=10.1038%2Fnature05661" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm101479y&amp;key=17314971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm101479y&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvFGiu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=445&publication_year=2007&pages=851-857&author=V.+Gray-Schopferauthor=C.+Wellbrockauthor=R.+Marais&title=Melanoma+biology+and+new+targeted+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Melanoma biology and new targeted therapy</span></div><div class="casAuthors">Gray-Schopfer, Vanessa; Wellbrock, Claudia; Marais, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">445</span>
        (<span class="NLM_cas:issue">7130</span>),
    <span class="NLM_cas:pages">851-857</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Melanoma is a cancer that arises from melanocytes, specialized pigmented cells that are found predominantly in the skin.  The incidence of melanoma is rising steadily in western populations - the no. of cases worldwide has doubled in the past 20 years.  In its early stages malignant melanoma can be cured by surgical resection, but once it has progressed to the metastatic stage it is extremely difficult to treat and does not respond to current therapies.  Recent discoveries in cell signalling have provided greater understanding of the biol. that underlies melanoma, and these advances are being exploited to provide targeted drugs and new therapeutic approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXWnhlx-AzCbVg90H21EOLACvtfcHk0lgGHA7QGRqnrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvFGiu7g%253D&md5=a898105964c68ba64eca76489a703e8d</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnature05661&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature05661%26sid%3Dliteratum%253Aachs%26aulast%3DGray-Schopfer%26aufirst%3DV.%26aulast%3DWellbrock%26aufirst%3DC.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DMelanoma%2520biology%2520and%2520new%2520targeted%2520therapy%26jtitle%3DNature%26date%3D2007%26volume%3D445%26spage%3D851%26epage%3D857" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6a"><span><span class="NLM_contrib-group">King, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patrick, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batorsky, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Do, H. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusnak, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takle, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hugger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wnag, L</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karreth, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lougheed, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chau, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stout, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">May, E. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rominger, Ch. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaber, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lou., L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lakdawala, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Contractor, R. G</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smalley, K. S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herlyn, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrissey, M M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuveson, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, P. S.</span><span> </span><span class="NLM_article-title">Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">11100</span><span class="NLM_x">–</span> <span class="NLM_lpage">11105</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=11100-11105&author=A.+J.+Kingauthor=D.+R.+Patrickauthor=R.+S.+Batorskyauthor=M.+L.+Hoauthor=H.+T.+Doauthor=S.+Y.+Zhangauthor=R.+Kumarauthor=D.+W.+Rusnakauthor=A.+K.+Takleauthor=D.+M.+Wilsonauthor=E.+Huggerauthor=L+Wnagauthor=F.+Karrethauthor=J.+C.+Lougheedauthor=J.+Leeauthor=D.+Chauauthor=T.+J.+Stoutauthor=E.+W.+Mayauthor=Ch.+M.+Romingerauthor=M.+D.+Schaberauthor=L.+Lou.author=A.+S.+Lakdawalaauthor=J.+L.+Adamsauthor=R.+G+Contractorauthor=K.+S.+M.+Smalleyauthor=M.+Herlynauthor=M+M.+Morrisseyauthor=D.+A.+Tuvesonauthor=P.+S.+Huang&title=Demonstration+of+a+genetic+therapeutic+index+for+tumors+expressing+oncogenic+BRAF+by+the+kinase+inhibitor+SB-590885"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKing%26aufirst%3DA.%2BJ.%26aulast%3DPatrick%26aufirst%3DD.%2BR.%26aulast%3DBatorsky%26aufirst%3DR.%2BS.%26aulast%3DHo%26aufirst%3DM.%2BL.%26aulast%3DDo%26aufirst%3DH.%2BT.%26aulast%3DZhang%26aufirst%3DS.%2BY.%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DTakle%26aufirst%3DA.%2BK.%26aulast%3DWilson%26aufirst%3DD.%2BM.%26aulast%3DHugger%26aufirst%3DE.%26aulast%3DWnag%26aufirst%3DL%26aulast%3DKarreth%26aufirst%3DF.%26aulast%3DLougheed%26aufirst%3DJ.%2BC.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DChau%26aufirst%3DD.%26aulast%3DStout%26aufirst%3DT.%2BJ.%26aulast%3DMay%26aufirst%3DE.%2BW.%26aulast%3DRominger%26aufirst%3DCh.%2BM.%26aulast%3DSchaber%26aufirst%3DM.%2BD.%26aulast%3DLou.%26aufirst%3DL.%26aulast%3DLakdawala%26aufirst%3DA.%2BS.%26aulast%3DAdams%26aufirst%3DJ.%2BL.%26aulast%3DContractor%26aufirst%3DR.%2BG%26aulast%3DSmalley%26aufirst%3DK.%2BS.%2BM.%26aulast%3DHerlyn%26aufirst%3DM.%26aulast%3DMorrissey%26aufirst%3DM%2BM.%26aulast%3DTuveson%26aufirst%3DD.%2BA.%26aulast%3DHuang%26aufirst%3DP.%2BS.%26atitle%3DDemonstration%2520of%2520a%2520genetic%2520therapeutic%2520index%2520for%2520tumors%2520expressing%2520oncogenic%2520BRAF%2520by%2520the%2520kinase%2520inhibitor%2520SB-590885%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D11100%26epage%3D11105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6b"><span><span class="NLM_contrib-group">Tsai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mamo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bremer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillette, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haass, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sproesser, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smalley, K. S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fong, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Y.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marimuthu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settachatgul, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shellooe, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantwell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlessinger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, K. Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habets, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ibrahim, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirth, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Artis, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herlyn, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bollag, G.</span><span> </span><span class="NLM_article-title">Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">3041</span><span class="NLM_x">–</span> <span class="NLM_lpage">3046</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Fjm101479y&amp;key=10.1073%2Fpnas.0711741105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=8&amp;doi=10.1021%2Fjm101479y&amp;key=18287029" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=32&amp;doi=10.1021%2Fjm101479y&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjtVSitrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=3041-3046&author=J.+Tsaiauthor=J.+T.+Leeauthor=W.+Wangauthor=J.+Zhangauthor=H.+Choauthor=S.+Mamoauthor=R.+Bremerauthor=S.+Gilletteauthor=J.+Kongauthor=N.+K.+Haassauthor=K.+Sproesserauthor=L.+Liauthor=K.+S.+M.+Smalleyauthor=D.+Fongauthor=Y.-L.+Zhuauthor=A.+Marimuthuauthor=H.+Nguyenauthor=B.+Lamauthor=J.+Liuauthor=I.+Cheungauthor=J.+Riceauthor=Y.+Suzukiauthor=C.+Luuauthor=C.+Settachatgulauthor=R.+Shellooeauthor=J.+Cantwellauthor=S.-H.+Kimauthor=J.+Schlessingerauthor=K.+Y.+J.+Zhangauthor=B.+L.+Westauthor=B.+Powellauthor=G.+Habetsauthor=C.+Zhangauthor=P.+N.+Ibrahimauthor=P.+Hirthauthor=D.+R.+Artisauthor=M.+Herlynauthor=G.+Bollag&title=Discovery+of+a+selective+inhibitor+of+oncogenic+B-Raf+kinase+with+potent+antimelanoma+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6bR"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity</span></div><div class="casAuthors">Tsai, James; Lee, John T.; Wang, Weiru; Zhang, Jiazhong; Cho, Hanna; Mamo, Shumeye; Bremer, Ryan; Gillette, Sam; Kong, Jun; Haass, Nikolas K.; Sproesser, Katrin; Li, Ling; Smalley, Keiran S. M.; Fong, Daniel; Zhu, Yong-Liang; Marimuthu, Adhirai; Nguyen, Hoa; Lam, Billy; Liu, Jennifer; Cheung, Ivana; Rice, Julie; Suzuki, Yoshihisa; Luu, Catherine; Settachatgul, Calvin; Shellooe, Rafe; Cantwell, John; Kim, Sung-Hou; Schlessinger, Joseph; Zhang, Kam Y. J.; West, Brian L.; Powell, Ben; Habets, Gaston; Zhang, Chao; Ibrahim, Prabha N.; Hirth, Peter; Artis, Dean R.; Herlyn, Meenhard; Bollag, Gideon</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3041-3046</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">BRAFV600E is the most frequent oncogenic protein kinase mutation known.  Furthermore, inhibitors targeting "active" protein kinases have demonstrated significant utility in the therapeutic repertoire against cancer.  Therefore, the authors pursued the development of specific kinase inhibitors targeting B-Raf, and the V600E allele in particular.  By using a structure-guided discovery approach, a potent and selective inhibitor of active B-Raf has been discovered.  PLX4720, a 7-azaindole deriv. that inhibits B-RafV600E with an IC50 of 13 nM, defines a class of kinase inhibitor with marked selectivity in both biochem. and cellular assays.  PLX4720 preferentially inhibits the active B-RafV600E kinase compared with a broad spectrum of other kinases, and potent cytotoxic effects are also exclusive to cells bearing the V600E allele.  Consistent with the high degree of selectivity, ERK phosphorylation is potently inhibited by PLX4720 in B-RafV600E-bearing tumor cell lines but not in cells lacking oncogenic B-Raf.  In melanoma models, PLX4720 induces cell cycle arrest and apoptosis exclusively in B-RafV600E-pos. cells.  In B-RafV600E-dependent tumor xenograft models, orally dosed PLX4720 causes significant tumor growth delays, including tumor regressions, without evidence of toxicity.  The work described here represents the entire discovery process, from initial identification through structural and biol. studies in animal models to a promising therapeutic for testing in cancer patients bearing B-RafV600E-driven tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPX53IQCbDJ7Vg90H21EOLACvtfcHk0lgPQ9e9l9-RYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjtVSitrk%253D&md5=273b94202f99984e6eb24723d0c6141f</span></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0711741105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0711741105%26sid%3Dliteratum%253Aachs%26aulast%3DTsai%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DJ.%2BT.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DCho%26aufirst%3DH.%26aulast%3DMamo%26aufirst%3DS.%26aulast%3DBremer%26aufirst%3DR.%26aulast%3DGillette%26aufirst%3DS.%26aulast%3DKong%26aufirst%3DJ.%26aulast%3DHaass%26aufirst%3DN.%2BK.%26aulast%3DSproesser%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DSmalley%26aufirst%3DK.%2BS.%2BM.%26aulast%3DFong%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DY.-L.%26aulast%3DMarimuthu%26aufirst%3DA.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DLam%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DCheung%26aufirst%3DI.%26aulast%3DRice%26aufirst%3DJ.%26aulast%3DSuzuki%26aufirst%3DY.%26aulast%3DLuu%26aufirst%3DC.%26aulast%3DSettachatgul%26aufirst%3DC.%26aulast%3DShellooe%26aufirst%3DR.%26aulast%3DCantwell%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DS.-H.%26aulast%3DSchlessinger%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DK.%2BY.%2BJ.%26aulast%3DWest%26aufirst%3DB.%2BL.%26aulast%3DPowell%26aufirst%3DB.%26aulast%3DHabets%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DIbrahim%26aufirst%3DP.%2BN.%26aulast%3DHirth%26aufirst%3DP.%26aulast%3DArtis%26aufirst%3DD.%2BR.%26aulast%3DHerlyn%26aufirst%3DM.%26aulast%3DBollag%26aufirst%3DG.%26atitle%3DDiscovery%2520of%2520a%2520selective%2520inhibitor%2520of%2520oncogenic%2520B-Raf%2520kinase%2520with%2520potent%2520antimelanoma%2520activity%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2008%26volume%3D105%26spage%3D3041%26epage%3D3046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6c"><span><span class="NLM_contrib-group">Yang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higgins, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolinsky, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Packman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Go, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iyer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grippo, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schostack, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simcox, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heimbrook, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bollag, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, F.</span><span> </span><span class="NLM_article-title">RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">5518</span><span class="NLM_x">–</span> <span class="NLM_lpage">5527</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=5518-5527&author=H.+Yangauthor=B.+Higginsauthor=K.+Kolinskyauthor=K.+Packmanauthor=Z.+Goauthor=R.+Iyerauthor=S.+Kolisauthor=S.+Zhaoauthor=R.+Leeauthor=J.+F.+Grippoauthor=K.+Schostackauthor=M.+E.+Simcoxauthor=D.+Heimbrookauthor=G.+Bollagauthor=F.+Su&title=RG7204+%28PLX4032%29%2C+a+Selective+BRAFV600E+Inhibitor%2C+Displays+Potent+Antitumor+Activity+in+Preclinical+Melanoma+Models"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DH.%26aulast%3DHiggins%26aufirst%3DB.%26aulast%3DKolinsky%26aufirst%3DK.%26aulast%3DPackman%26aufirst%3DK.%26aulast%3DGo%26aufirst%3DZ.%26aulast%3DIyer%26aufirst%3DR.%26aulast%3DKolis%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DR.%26aulast%3DGrippo%26aufirst%3DJ.%2BF.%26aulast%3DSchostack%26aufirst%3DK.%26aulast%3DSimcox%26aufirst%3DM.%2BE.%26aulast%3DHeimbrook%26aufirst%3DD.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DSu%26aufirst%3DF.%26atitle%3DRG7204%2520%2528PLX4032%2529%252C%2520a%2520Selective%2520BRAFV600E%2520Inhibitor%252C%2520Displays%2520Potent%2520Antitumor%2520Activity%2520in%2520Preclinical%2520Melanoma%2520Models%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D5518%26epage%3D5527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6d"><span><span class="NLM_contrib-group">Joseph, E. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pratilas, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poulikakos, P. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tadi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halilovic, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Persaud, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xing, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viale, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bollag, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solit, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, N.</span><span> </span><span class="NLM_article-title">The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner</span> <span class="citation_source-journal">Proc. Natl Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">14903</span><span class="NLM_x">–</span> <span class="NLM_lpage">14908</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6d&amp;dbid=16&amp;doi=10.1021%2Fjm101479y&amp;key=10.1073%2Fpnas.1008990107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6d&amp;dbid=8&amp;doi=10.1021%2Fjm101479y&amp;key=20668238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6d&amp;dbid=32&amp;doi=10.1021%2Fjm101479y&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVOjsLrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=14903-14908&author=E.+W.+Josephauthor=C.+A.+Pratilasauthor=P.+I.+Poulikakosauthor=M.+Tadiauthor=W.+Wangauthor=B.+S.+Taylorauthor=E.+Halilovicauthor=Y.+Persaudauthor=F.+Xingauthor=A.+Vialeauthor=J.+Tsaiauthor=P.+B.+Chapmanauthor=G.+Bollagauthor=D.+B.+Solitauthor=N.+Rosen&title=The+RAF+inhibitor+PLX4032+inhibits+ERK+signaling+and+tumor+cell+proliferation+in+a+V600E+BRAF-selective+manner"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6dR"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner</span></div><div class="casAuthors">Joseph, Eric W.; Pratilas, Christine A.; Poulikakos, Poulikos I.; Tadi, Madhavi; Wang, Weiqing; Taylor, Barry S.; Halilovic, Ensar; Persaud, Yogindra; Xing, Feng; Viale, Agnes; Tsai, James; Chapman, Paul B.; Bollag, Gideon; Solit, David B.; Rosen, Neal</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">14903-14908, S14903/1-S14903/8</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Tumors with mutant BRAF and some with mutant RAS are dependent upon ERK signaling for proliferation, and their growth is suppressed by MAPK/ERK kinase (MEK) inhibitors.  In contrast, tumor cells with human EGF receptor (HER) kinase activation proliferate in a MEK-independent manner.  These findings have led to the development of RAF and MEK inhibitors as anticancer agents.  Like MEK inhibitors, the RAF inhibitor PLX4032 inhibits the proliferation of BRAFV600E tumor cells but not that of HER kinase-dependent tumors.  However, tumors with RAS mutation that are sensitive to MEK inhibition are insensitive to PLX4032.  MEK inhibitors inhibit ERK phosphorylation in all normal and tumor cells, whereas PLX4032 inhibits ERK signaling only in tumor cells expressing BRAFV600E.  In contrast, the drug activates MEK and ERK phosphorylation in cells with wild-type BRAF.  In BRAFV600E tumor cells, MEK and RAF inhibitors affect the expression of a common set of genes.  PLX4032 inhibits ERK signaling output in mutant BRAF cells, whereas it transiently activates the expression of these genes in tumor cells with wild-type RAF.  Thus, PLX4032 inhibits ERK signaling output in a mutant BRAF-selective manner.  These data explain why the drug selectively inhibits the growth of mutant BRAF tumors and suggest that it will not cause toxicity resulting from the inhibition of ERK signaling in normal cells.  This selectivity may lead to a broader therapeutic index and help explain the greater antitumor activity obsd. with this drug than with MEK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_6Gff4DQiprVg90H21EOLACvtfcHk0lgPQ9e9l9-RYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVOjsLrP&md5=c5c99b7faca898bd8e4b1d4ae82a5f84</span></div><a href="/servlet/linkout?suffix=cit6d&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1008990107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1008990107%26sid%3Dliteratum%253Aachs%26aulast%3DJoseph%26aufirst%3DE.%2BW.%26aulast%3DPratilas%26aufirst%3DC.%2BA.%26aulast%3DPoulikakos%26aufirst%3DP.%2BI.%26aulast%3DTadi%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DTaylor%26aufirst%3DB.%2BS.%26aulast%3DHalilovic%26aufirst%3DE.%26aulast%3DPersaud%26aufirst%3DY.%26aulast%3DXing%26aufirst%3DF.%26aulast%3DViale%26aufirst%3DA.%26aulast%3DTsai%26aufirst%3DJ.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DSolit%26aufirst%3DD.%2BB.%26aulast%3DRosen%26aufirst%3DN.%26atitle%3DThe%2520RAF%2520inhibitor%2520PLX4032%2520inhibits%2520ERK%2520signaling%2520and%2520tumor%2520cell%2520proliferation%2520in%2520a%2520V600E%2520BRAF-selective%2520manner%26jtitle%3DProc.%2520Natl%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2010%26volume%3D107%26spage%3D14903%26epage%3D14908" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7a"><span><span class="NLM_contrib-group">Solit, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garraway, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pratilas, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Getz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basso, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lobo, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">She, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osman, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golub, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sebolt-Leopold, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellers, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, N.</span><span> </span><span class="NLM_article-title">BRAF mutation predicts sensitivity to MEK inhibition</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">439</span><span class="NLM_x">, </span> <span class="NLM_fpage">358</span><span class="NLM_x">–</span> <span class="NLM_lpage">362</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Fjm101479y&amp;key=10.1038%2Fnature04304" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=8&amp;doi=10.1021%2Fjm101479y&amp;key=16273091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=32&amp;doi=10.1021%2Fjm101479y&amp;key=1%3ACAS%3A528%3ADC%252BD28XkvF2mtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=439&publication_year=2006&pages=358-362&author=D.+B.+Solitauthor=L.+A.+Garrawayauthor=C.+A.+Pratilasauthor=A.+Sawaiauthor=G.+Getzauthor=A.+Bassoauthor=Q.+Yeauthor=J.+M.+Loboauthor=Y.+Sheauthor=I.+Osmanauthor=T.+R.+Golubauthor=J.+Sebolt-Leopoldauthor=W.+R.+Sellersauthor=N.+Rosen&title=BRAF+mutation+predicts+sensitivity+to+MEK+inhibition"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7aR"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">BRAF mutation predicts sensitivity to MEK inhibition</span></div><div class="casAuthors">Solit, David B.; Garraway, Levi A.; Pratilas, Christine A.; Sawai, Ayana; Getz, Gad; Basso, Andrea; Ye, Qing; Lobo, Jose M.; She, Yuhong; Osman, Iman; Golub, Todd R.; Sebolt-Leopold, Judith; Sellers, William R.; Rosen, Neal</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">439</span>
        (<span class="NLM_cas:issue">7074</span>),
    <span class="NLM_cas:pages">358-362</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The kinase pathway comprising RAS, RAF, mitogen-activated protein kinase kinase (MEK) and extracellular signal regulated kinase (ERK) is activated in most human tumors, often through gain-of-function mutations of RAS and RAF family members.  Using small-mol. inhibitors of MEK and an integrated genetic and pharmacol. anal., we find that mutation of BRAF is assocd. with enhanced and selective sensitivity to MEK inhibition when compared to either 'wild-type' cells or cells harboring a RAS mutation.  This MEK dependency was obsd. in BRAF mutant cells regardless of tissue lineage, and correlated with both downregulation of cyclin D1 protein expression and the induction of G1 arrest.  Pharmacol. MEK inhibition completely abrogated tumor growth in BRAF mutant xenografts, whereas RAS mutant tumors were only partially inhibited.  These data suggest an exquisite dependency on MEK activity in BRAF mutant tumors, and offer a rational therapeutic strategy for this genetically defined tumor subtype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpBpONOvd0vbVg90H21EOLACvtfcHk0lhIPYcf8JfuRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XkvF2mtw%253D%253D&md5=37c8976aa5bb371ef5580aab2a91f89e</span></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1038%2Fnature04304&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature04304%26sid%3Dliteratum%253Aachs%26aulast%3DSolit%26aufirst%3DD.%2BB.%26aulast%3DGarraway%26aufirst%3DL.%2BA.%26aulast%3DPratilas%26aufirst%3DC.%2BA.%26aulast%3DSawai%26aufirst%3DA.%26aulast%3DGetz%26aufirst%3DG.%26aulast%3DBasso%26aufirst%3DA.%26aulast%3DYe%26aufirst%3DQ.%26aulast%3DLobo%26aufirst%3DJ.%2BM.%26aulast%3DShe%26aufirst%3DY.%26aulast%3DOsman%26aufirst%3DI.%26aulast%3DGolub%26aufirst%3DT.%2BR.%26aulast%3DSebolt-Leopold%26aufirst%3DJ.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DRosen%26aufirst%3DN.%26atitle%3DBRAF%2520mutation%2520predicts%2520sensitivity%2520to%2520MEK%2520inhibition%26jtitle%3DNature%26date%3D2006%26volume%3D439%26spage%3D358%26epage%3D362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7b"><span><span class="NLM_contrib-group">Davies, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Logie, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKay, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stelle, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cockerill, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cartlidge, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P. D.</span><span> </span><span class="NLM_article-title">AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">2209</span><span class="NLM_x">–</span> <span class="NLM_lpage">2219</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Fjm101479y&amp;key=10.1158%2F1535-7163.MCT-07-0231" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Fjm101479y&amp;key=17699718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Fjm101479y&amp;key=1%3ACAS%3A528%3ADC%252BD2sXptVGltb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=2209-2219&issue=8&author=B.+R.+Daviesauthor=A.+Logieauthor=J.+S.+McKayauthor=P.+Martinauthor=S.+Stelleauthor=R.+Jenkinsauthor=M.+Cockerillauthor=S.+Cartlidgeauthor=P.+D.+Smith&title=AZD6244+%28ARRY-142886%29%2C+a+potent+inhibitor+of+mitogen-activated+protein+kinase%2Fextracellular+signal-regulated+kinase+kinase+1%2F2+kinases%3A+mechanism+of+action+in+vivo%2C+pharmacokinetic%2Fpharmacodynamic+relationship%2C+and+potential+for+combination+in+preclinical+models"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models</span></div><div class="casAuthors">Davies, Barry R.; Logie, Armelle; McKay, Jennifer S.; Martin, Paul; Steele, Samantha; Jenkins, Richard; Cockerill, Mark; Cartlidge, Sue; Smith, Paul D.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2209-2219</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Constitutive activation of the extracellular signal-regulated kinase 1/2 (ERK1/2) mitogen-activated protein kinase (MAPK) signaling pathway in human cancers is often assocd. with mutational activation of BRAF or RAS.  MAPK/ERK kinase 1/2 kinases lie downstream of RAS and BRAF and are the only acknowledged activators of ERK1/2, making them attractive targets for therapeutic intervention.  AZD6244 (ARRY-142886) is a potent, selective, and ATP-uncompetitive inhibitor of MAPK/ERK kinase 1/2.  In vitro cell viability inhibition screening of a tumor cell line panel found that lines harboring BRAF or RAS mutations were more likely to be sensitive to AZD6244.  The in vivo mechanisms by which AZD6244 inhibits tumor growth were investigated.  Chronic dosing with 25 mg/kg AZD6244 bd resulted in suppression of growth of Colo-205, Calu-6, and SW-620 xenografts, whereas an acute dose resulted in significant inhibition of ERK1/2 phosphorylation.  Increased cleaved caspase-3, a marker of apoptosis, was detected in Colo-205 and Calu-6 but not in SW-620 tumors where a significant decrease in cell proliferation was detected.  Chronic dosing of AZD6244 induced a morphol. change in SW-620 tumors to a more differentiated phenotype.  The potential of AZD6244 in combination with cytotoxic drugs was evaluated in mice bearing SW-620 xenografts.  Treatment with tolerated doses of AZD6244 and either irinotecan or docetaxel resulted in significantly enhanced antitumor efficacy relative to that of either agent alone.  These results indicate that AZD6244 has potential to inhibit proliferation and induce apoptosis and differentiation, but the response varies between different xenografts.  Moreover, enhanced antitumor efficacy can be obtained by combining AZD6244 with the cytotoxic drugs irinotecan or docetaxel.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2EFINn6kko7Vg90H21EOLACvtfcHk0lhIPYcf8JfuRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXptVGltb8%253D&md5=0720c73c534ebc08a40dbb309e98ffa4</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-0231&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-0231%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DB.%2BR.%26aulast%3DLogie%26aufirst%3DA.%26aulast%3DMcKay%26aufirst%3DJ.%2BS.%26aulast%3DMartin%26aufirst%3DP.%26aulast%3DStelle%26aufirst%3DS.%26aulast%3DJenkins%26aufirst%3DR.%26aulast%3DCockerill%26aufirst%3DM.%26aulast%3DCartlidge%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DP.%2BD.%26atitle%3DAZD6244%2520%2528ARRY-142886%2529%252C%2520a%2520potent%2520inhibitor%2520of%2520mitogen-activated%2520protein%2520kinase%252Fextracellular%2520signal-regulated%2520kinase%2520kinase%25201%252F2%2520kinases%253A%2520mechanism%2520of%2520action%2520in%2520vivo%252C%2520pharmacokinetic%252Fpharmacodynamic%2520relationship%252C%2520and%2520potential%2520for%2520combination%2520in%2520preclinical%2520models%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26issue%3D8%26spage%3D2209%26epage%3D2219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8a"><span><span class="NLM_contrib-group">Bollag, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirth, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ibrahim, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spevak, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habets, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burton, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shellooe, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marimuthu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, K. Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Artis, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlessinger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higgins, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iyer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D'Andrea, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koehler, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stumm, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grippo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puzanov, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nathanson, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolop, K.</span><span> </span><span class="NLM_article-title">Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">467</span><span class="NLM_x">, </span> <span class="NLM_fpage">596</span><span class="NLM_x">–</span> <span class="NLM_lpage">599</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=16&amp;doi=10.1021%2Fjm101479y&amp;key=10.1038%2Fnature09454" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=8&amp;doi=10.1021%2Fjm101479y&amp;key=20823850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=32&amp;doi=10.1021%2Fjm101479y&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1ajtbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=467&publication_year=2010&pages=596-599&author=G.+Bollagauthor=P.+Hirthauthor=J.+Tsaiauthor=J.+Zhangauthor=P.+N.+Ibrahimauthor=H.+Choauthor=W.+Spevakauthor=C.+Zhangauthor=Y.+Zhangauthor=G.+Habetsauthor=E.+A.+Burtonauthor=B.+Wongauthor=G.+Tsangauthor=B.+L.+Westauthor=B.+Powellauthor=R.+Shellooeauthor=A.+Marimuthuauthor=H.+Nguyenauthor=K.+Y.+J.+Zhangauthor=D.+R.+Artisauthor=J.+Schlessingerauthor=F.+Suauthor=B.+Higginsauthor=R.+Iyerauthor=K.+D%27Andreaauthor=A.+Koehlerauthor=M.+Stummauthor=P.+S.+Linauthor=R.+J.+Leeauthor=J.+Grippoauthor=I.+Puzanovauthor=K.+B.+Kimauthor=A.+Ribasauthor=G.+A.+McArthurauthor=J.+A.+Sosmanauthor=P.+B.+Chapmanauthor=K.+T.+Flahertyauthor=X.+Xuauthor=K.+L.+Nathansonauthor=K.+Nolop&title=Clinical+efficacy+of+a+RAF+inhibitor+needs+broad+target+blockade+in+BRAF-mutant+melanoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8aR"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma</span></div><div class="casAuthors">Bollag, Gideon; Hirth, Peter; Tsai, James; Zhang, Jiazhong; Ibrahim, Prabha N.; Cho, Hanna; Spevak, Wayne; Zhang, Chao; Zhang, Ying; Habets, Gaston; Burton, Elizabeth A.; Wong, Bernice; Tsang, Garson; West, Brian L.; Powell, Ben; Shellooe, Rafe; Marimuthu, Adhirai; Nguyen, Hoa; Zhang, Kam Y. J.; Artis, Dean R.; Schlessinger, Joseph; Su, Fei; Higgins, Brian; Iyer, Raman; D'Andrea, Kurt; Koehler, Astrid; Stumm, Michael; Lin, Paul S.; Lee, Richard J.; Grippo, Joseph; Puzanov, Igor; Kim, Kevin B.; Ribas, Antoni; McArthur, Grant A.; Sosman, Jeffrey A.; Chapman, Paul B.; Flaherty, Keith T.; Xu, Xiaowei; Nathanson, Katherine L.; Nolop, Keith</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">467</span>
        (<span class="NLM_cas:issue">7315</span>),
    <span class="NLM_cas:pages">596-599</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">B-RAF is the most frequently mutated protein kinase in human cancers.  The finding that oncogenic mutations in BRAF are common in melanoma, followed by the demonstration that these tumors are dependent on the RAF/MEK/ERK pathway, offered hope that inhibition of B-RAF kinase activity could benefit melanoma patients.  Herein, we describe the structure-guided discovery of PLX4032 (RG7204), a potent inhibitor of oncogenic B-RAF kinase activity.  Preclin. expts. demonstrated that PLX4032 selectively blocked the RAF/MEK/ERK pathway in BRAF mutant cells and caused regression of BRAF mutant xenografts.  Toxicol. studies confirmed a wide safety margin consistent with the high degree of selectivity, enabling Phase 1 clin. trials using a cryst. formulation of PLX4032 (ref. 5).  In a subset of melanoma patients, pathway inhibition was monitored in paired biopsy specimens collected before treatment initiation and following 2 wk of treatment.  This anal. revealed substantial inhibition of ERK phosphorylation, yet clin. evaluation did not show tumor regressions.  At higher drug exposures afforded by a new amorphous drug formulation, greater than 80% inhibition of ERK phosphorylation in the tumors of patients correlated with clin. response.  Indeed, the Phase 1 clin. data revealed a remarkably high 81% response rate in metastatic melanoma patients treated at an oral dose of 960 mg twice daily.  These data demonstrate that BRAF-mutant melanomas are highly dependent on B-RAF kinase activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpYwlns1EfcLVg90H21EOLACvtfcHk0lhIPYcf8JfuRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1ajtbfK&md5=8a26d0ab41970f39a109ddafff2f17b4</span></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=10.1038%2Fnature09454&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09454%26sid%3Dliteratum%253Aachs%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DHirth%26aufirst%3DP.%26aulast%3DTsai%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DIbrahim%26aufirst%3DP.%2BN.%26aulast%3DCho%26aufirst%3DH.%26aulast%3DSpevak%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHabets%26aufirst%3DG.%26aulast%3DBurton%26aufirst%3DE.%2BA.%26aulast%3DWong%26aufirst%3DB.%26aulast%3DTsang%26aufirst%3DG.%26aulast%3DWest%26aufirst%3DB.%2BL.%26aulast%3DPowell%26aufirst%3DB.%26aulast%3DShellooe%26aufirst%3DR.%26aulast%3DMarimuthu%26aufirst%3DA.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DK.%2BY.%2BJ.%26aulast%3DArtis%26aufirst%3DD.%2BR.%26aulast%3DSchlessinger%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DF.%26aulast%3DHiggins%26aufirst%3DB.%26aulast%3DIyer%26aufirst%3DR.%26aulast%3DD%2527Andrea%26aufirst%3DK.%26aulast%3DKoehler%26aufirst%3DA.%26aulast%3DStumm%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DP.%2BS.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DGrippo%26aufirst%3DJ.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DNathanson%26aufirst%3DK.%2BL.%26aulast%3DNolop%26aufirst%3DK.%26atitle%3DClinical%2520efficacy%2520of%2520a%2520RAF%2520inhibitor%2520needs%2520broad%2520target%2520blockade%2520in%2520BRAF-mutant%2520melanoma%26jtitle%3DNature%26date%3D2010%26volume%3D467%26spage%3D596%26epage%3D599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit8b"><span><span class="NLM_contrib-group">Flaherty, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puzanov, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grippo, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolop, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, P.</span><span> </span><span class="NLM_article-title">Phase I study of PLX4032: Proof of concept for V600EBRAF mutation as a therapeutic target in human cancer</span> <span class="citation_source-journal">J. Clin. Oncol. (Meeting Abstr.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">9000</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=9000&author=K.+Flahertyauthor=I.+Puzanovauthor=J.+Sosmanauthor=K.+Kimauthor=A.+Ribasauthor=G.+McArthurauthor=R.+J.+Leeauthor=J.+F.+Grippoauthor=K.+Nolopauthor=P.+Chapman&title=Phase+I+study+of+PLX4032%3A+Proof+of+concept+for+V600EBRAF+mutation+as+a+therapeutic+target+in+human+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFlaherty%26aufirst%3DK.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DSosman%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DK.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DMcArthur%26aufirst%3DG.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DGrippo%26aufirst%3DJ.%2BF.%26aulast%3DNolop%26aufirst%3DK.%26aulast%3DChapman%26aufirst%3DP.%26atitle%3DPhase%2520I%2520study%2520of%2520PLX4032%253A%2520Proof%2520of%2520concept%2520for%2520V600EBRAF%2520mutation%2520as%2520a%2520therapeutic%2520target%2520in%2520human%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%2520%2528Meeting%2520Abstr.%2529%26date%3D2009%26volume%3D27%26spage%3D9000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit8c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Wellbrock, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurlstone, A.</span><span> </span><span class="NLM_article-title">BRAF as therapeutic target in melanoma</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">80</span><span class="NLM_x">, </span> <span class="NLM_fpage">561</span><span class="NLM_x">–</span> <span class="NLM_lpage">567</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2010&pages=561-567&author=C.+Wellbrockauthor=A.+Hurlstone&title=BRAF+as+therapeutic+target+in+melanoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWellbrock%26aufirst%3DC.%26aulast%3DHurlstone%26aufirst%3DA.%26atitle%3DBRAF%2520as%2520therapeutic%2520target%2520in%2520melanoma%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2010%26volume%3D80%26spage%3D561%26epage%3D567" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="note"><p class="first last">Sorafenib (<b>1</b>) is a multikinase inhibitor with modest inhibitory activity against Raf. This compound has shown efficacy in the clinic and is now marketed as Nexavar. </p></div><div class="NLM_citation" id="rightTab-cit9a"><span><span class="NLM_contrib-group">Wilhelm, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNabola, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHugh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shujath, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gawlak, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eveleigh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowley, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adnane, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Auclair, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gedrich, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voznesensky, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riedl, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Post, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bollag, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trail, P. A.</span><span> </span><span class="NLM_article-title">BAY43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">7099</span><span class="NLM_x">–</span> <span class="NLM_lpage">7109</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=7099-7109&author=S.+M.+Wilhelmauthor=C.+Carterauthor=L.+Tangauthor=D.+Wilkieauthor=A.+McNabolaauthor=H.+Rongauthor=C.+Chenauthor=X.+Zhangauthor=P.+Vincentauthor=M.+McHughauthor=Y.+Caoauthor=J.+Shujathauthor=S.+Gawlakauthor=D.+Eveleighauthor=B.+Rowleyauthor=L.+Liuauthor=L.+Adnaneauthor=M.+Lynchauthor=D.+Auclairauthor=I.+Taylorauthor=R.+Gedrichauthor=A.+Voznesenskyauthor=B.+Riedlauthor=L.+E.+Postauthor=G.+Bollagauthor=P.+A.+Trail&title=BAY43-9006+exhibits+broad+spectrum+oral+antitumor+activity+and+targets+the+RAF%2FMEK%2FERK+pathway+and+receptor+tyrosine+kinases+involved+in+tumor+progression+and+angiogenesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWilhelm%26aufirst%3DS.%2BM.%26aulast%3DCarter%26aufirst%3DC.%26aulast%3DTang%26aufirst%3DL.%26aulast%3DWilkie%26aufirst%3DD.%26aulast%3DMcNabola%26aufirst%3DA.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DVincent%26aufirst%3DP.%26aulast%3DMcHugh%26aufirst%3DM.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DShujath%26aufirst%3DJ.%26aulast%3DGawlak%26aufirst%3DS.%26aulast%3DEveleigh%26aufirst%3DD.%26aulast%3DRowley%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DAdnane%26aufirst%3DL.%26aulast%3DLynch%26aufirst%3DM.%26aulast%3DAuclair%26aufirst%3DD.%26aulast%3DTaylor%26aufirst%3DI.%26aulast%3DGedrich%26aufirst%3DR.%26aulast%3DVoznesensky%26aufirst%3DA.%26aulast%3DRiedl%26aufirst%3DB.%26aulast%3DPost%26aufirst%3DL.%2BE.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DTrail%26aufirst%3DP.%2BA.%26atitle%3DBAY43-9006%2520exhibits%2520broad%2520spectrum%2520oral%2520antitumor%2520activity%2520and%2520targets%2520the%2520RAF%252FMEK%252FERK%2520pathway%2520and%2520receptor%2520tyrosine%2520kinases%2520involved%2520in%2520tumor%2520progression%2520and%2520angiogenesis%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D7099%26epage%3D7109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9b"><span><span class="NLM_contrib-group">Adnane, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trail, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilhelm, S. M.</span><span> </span><span class="NLM_article-title">Sorafenib (BAY43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinasese VEGFR/PDGFR in tumor vasculature</span> <span class="citation_source-journal">Methods Enzymol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">407</span><span class="NLM_x">, </span> <span class="NLM_fpage">597</span><span class="NLM_x">–</span> <span class="NLM_lpage">612</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=407&publication_year=2006&pages=597-612&author=L.+Adnaneauthor=P.+A.+Trailauthor=I.+Taylorauthor=S.+M.+Wilhelm&title=Sorafenib+%28BAY43-9006%2C+Nexavar%29%2C+a+dual-action+inhibitor+that+targets+RAF%2FMEK%2FERK+pathway+in+tumor+cells+and+tyrosine+kinasese+VEGFR%2FPDGFR+in+tumor+vasculature"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAdnane%26aufirst%3DL.%26aulast%3DTrail%26aufirst%3DP.%2BA.%26aulast%3DTaylor%26aufirst%3DI.%26aulast%3DWilhelm%26aufirst%3DS.%2BM.%26atitle%3DSorafenib%2520%2528BAY43-9006%252C%2520Nexavar%2529%252C%2520a%2520dual-action%2520inhibitor%2520that%2520targets%2520RAF%252FMEK%252FERK%2520pathway%2520in%2520tumor%2520cells%2520and%2520tyrosine%2520kinasese%2520VEGFR%252FPDGFR%2520in%2520tumor%2520vasculature%26jtitle%3DMethods%2520Enzymol.%26date%3D2006%26volume%3D407%26spage%3D597%26epage%3D612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10a"><span><span class="NLM_contrib-group">Bankston, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dumas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Natero, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riedl, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monahan, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sibley, R.</span><span> </span><span class="NLM_article-title">A Scaleable Synthesis of BAY43-9006: A Potent Raf Kinase Inhibitor for the Treatment of Cancer</span> <span class="citation_source-journal">Org. Process Res. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">777</span><span class="NLM_x">–</span> <span class="NLM_lpage">781</span></span><div class="citationLinks">[<a href="/doi/10.1021/op020205n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2002&pages=777-781&author=D.+Bankstonauthor=J.+Dumasauthor=R.+Nateroauthor=B.+Riedlauthor=M.+K.+Monahanauthor=R.+Sibley&title=A+Scaleable+Synthesis+of+BAY43-9006%3A+A+Potent+Raf+Kinase+Inhibitor+for+the+Treatment+of+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1021%2Fop020205n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop020205n%26sid%3Dliteratum%253Aachs%26aulast%3DBankston%26aufirst%3DD.%26aulast%3DDumas%26aufirst%3DJ.%26aulast%3DNatero%26aufirst%3DR.%26aulast%3DRiedl%26aufirst%3DB.%26aulast%3DMonahan%26aufirst%3DM.%2BK.%26aulast%3DSibley%26aufirst%3DR.%26atitle%3DA%2520Scaleable%2520Synthesis%2520of%2520BAY43-9006%253A%2520A%2520Potent%2520Raf%2520Kinase%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Cancer%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2002%26volume%3D6%26spage%3D777%26epage%3D781" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10b"><span><span class="NLM_contrib-group">Riedl, B.; Dumas, J.; Khire, U.; Lowinger, T. B.; Scott, W. J.; Smith, R. A.; Wood, J. E.; Monahan, M.-K.; Natero, R.; Renick, J.; Sibley, R. N.</span> U.S. Patent 7 235 576 B1,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Riedl%2C+B.%3B+Dumas%2C+J.%3B+Khire%2C+U.%3B+Lowinger%2C+T.+B.%3B+Scott%2C+W.+J.%3B+Smith%2C+R.+A.%3B+Wood%2C+J.+E.%3B+Monahan%2C+M.-K.%3B+Natero%2C+R.%3B+Renick%2C+J.%3B+Sibley%2C+R.+N.+U.S.+Patent+7+235+576+B1%2C+2007."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRiedl%26aufirst%3DB.%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Calderwood, E. F.; Duffey, M.; Gould, A. E.; Greenspan, P. D.; Kulkarni, B.; Lamarche, M. J.; Rowland, R. S.; Tregay, M.; Vos, T. J.</span> PCT Int. Appl. WO 2007067444 A1 20070614,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Calderwood%2C+E.+F.%3B+Duffey%2C+M.%3B+Gould%2C+A.+E.%3B+Greenspan%2C+P.+D.%3B+Kulkarni%2C+B.%3B+Lamarche%2C+M.+J.%3B+Rowland%2C+R.+S.%3B+Tregay%2C+M.%3B+Vos%2C+T.+J.+PCT+Int.+Appl.+WO+2007067444+A1+20070614%2C+2007."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCalderwood%26aufirst%3DE.%2BF.%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Xi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hale, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norman, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stec, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumgartner, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fotsch, C.</span><span> </span><span class="NLM_article-title">Synthesis of novel melanocortin 4 recpetor agonists and antagonists containing a succinamide core</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">377</span><span class="NLM_x">–</span> <span class="NLM_lpage">381</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=377-381&author=N.+Xiauthor=C.+Haleauthor=M.+G.+Kellyauthor=M.+H.+Normanauthor=M.+Stecauthor=S.+Xuauthor=J.+W.+Baumgartnerauthor=C.+Fotsch&title=Synthesis+of+novel+melanocortin+4+recpetor+agonists+and+antagonists+containing+a+succinamide+core"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DXi%26aufirst%3DN.%26aulast%3DHale%26aufirst%3DC.%26aulast%3DKelly%26aufirst%3DM.%2BG.%26aulast%3DNorman%26aufirst%3DM.%2BH.%26aulast%3DStec%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DBaumgartner%26aufirst%3DJ.%2BW.%26aulast%3DFotsch%26aufirst%3DC.%26atitle%3DSynthesis%2520of%2520novel%2520melanocortin%25204%2520recpetor%2520agonists%2520and%2520antagonists%2520containing%2520a%2520succinamide%2520core%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D377%26epage%3D381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Van Heerden, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bezuidenhoudt, B. C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferreira, D.</span><span> </span><span class="NLM_article-title">Efficient Asymmetric Synthesis of the Four Diastereomers of Diphenacoum and Brodifacoum</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x"> (</span><span class="NLM_issue">17</span><span class="NLM_x">) </span> <span class="NLM_fpage">6045</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1997&pages=6045&issue=17&author=P.+S.+Van+Heerdenauthor=B.+C.+B.+Bezuidenhoudtauthor=D.+Ferreira&title=Efficient+Asymmetric+Synthesis+of+the+Four+Diastereomers+of+Diphenacoum+and+Brodifacoum"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BHeerden%26aufirst%3DP.%2BS.%26aulast%3DBezuidenhoudt%26aufirst%3DB.%2BC.%2BB.%26aulast%3DFerreira%26aufirst%3DD.%26atitle%3DEfficient%2520Asymmetric%2520Synthesis%2520of%2520the%2520Four%2520Diastereomers%2520of%2520Diphenacoum%2520and%2520Brodifacoum%26jtitle%3DTetrahedron%26date%3D1997%26volume%3D53%26issue%3D17%26spage%3D6045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="note"><p class="first last">The opposite enantiomer can be prepared by employing the opposite enantiomer of the Evans' auxiliary.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Boigegrain, R.; Cecchi, R.; Boveri, S.</span> U.S. Patent 5 159 103,<span class="NLM_x"> </span><span class="NLM_year">1992</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Boigegrain%2C+R.%3B+Cecchi%2C+R.%3B+Boveri%2C+S.+U.S.+Patent+5+159+103%2C+1992."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBoigegrain%26aufirst%3DR.%26date%3D1992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Hirayama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikuaka, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsumoto, J.</span><span> </span><span class="NLM_article-title">An Expeditious Scalable Synthesis of (S)-2-Amino-5-methoxytetralin via Resolution</span> <span class="citation_source-journal">Org. Process Res. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">30</span><span class="NLM_x">–</span> <span class="NLM_lpage">38</span></span><div class="citationLinks">[<a href="/doi/10.1021/op0498363" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2005&pages=30-38&author=Y.+Hirayamaauthor=M.+Ikuakaauthor=J.+Matsumoto&title=An+Expeditious+Scalable+Synthesis+of+%28S%29-2-Amino-5-methoxytetralin+via+Resolution"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fop0498363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop0498363%26sid%3Dliteratum%253Aachs%26aulast%3DHirayama%26aufirst%3DY.%26aulast%3DIkuaka%26aufirst%3DM.%26aulast%3DMatsumoto%26aufirst%3DJ.%26atitle%3DAn%2520Expeditious%2520Scalable%2520Synthesis%2520of%2520%2528S%2529-2-Amino-5-methoxytetralin%2520via%2520Resolution%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2005%26volume%3D9%26spage%3D30%26epage%3D38" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Wan, P. T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garnett, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roe, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niculescu-Duvaz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Good, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springer, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barford, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marais, R.</span><span> </span><span class="NLM_article-title">Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">855</span><span class="NLM_x">–</span> <span class="NLM_lpage">867</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm101479y&amp;key=10.1016%2FS0092-8674%2804%2900215-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm101479y&amp;key=15035987" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm101479y&amp;key=1%3ACAS%3A528%3ADC%252BD2cXivVyksLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2004&pages=855-867&author=P.+T.+C.+Wanauthor=M.+J.+Garnettauthor=M.+S.+Roeauthor=S.+Leeauthor=D.+Niculescu-Duvazauthor=V.+M.+Goodauthor=M.+J.+Jonesauthor=C.+J.+Marshallauthor=C.+J.+Springerauthor=D.+Barfordauthor=R.+Marais&title=Mechanism+of+Activation+of+the+RAF-ERK+Signaling+Pathway+by+Oncogenic+Mutations+of+B-RAF"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF</span></div><div class="casAuthors">Wan, Paul T. C.; Garnett, Mathew J.; Roe, S. Mark; Lee, Sharlene; Niculescu-Duvaz, Dan; Good, Valerie M.; Project, Cancer Genome; Jones, C. Michael; Marshall, Christopher J.; Springer, Caroline J.; Barford, David; Marais, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">855-867</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Over 30 mutations of the B-RAF gene assocd. with human cancers have been identified, the majority of which are located within the kinase domain.  Here the authors show that of 22 B-RAF mutants analyzed, 18 have elevated kinase activity and signal to ERK in vivo.  Surprisingly, three mutants have reduced kinase activity towards MEK in vitro but, by activating C-RAF in vivo, signal to ERK in cells.  The structures of wild type and oncogenic V599EB-RAF kinase domains in complex with the RAF inhibitor BAY43-9006 show that the activation segment is held in an inactive conformation by assocn. with the P loop.  The clustering of most mutations to these two regions suggests that disruption of this interaction converts B-RAF into its active conformation.  The high activity mutants signal to ERK by directly phosphorylating MEK, whereas the impaired activity mutants stimulate MEK by activating endogenous C-RAF, possibly via an allosteric or transphosphorylation mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYiQicwc1xVLVg90H21EOLACvtfcHk0lhel7GtHUJyBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXivVyksLw%253D&md5=4cc020056c64e514286c000666da1972</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2804%2900215-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252804%252900215-6%26sid%3Dliteratum%253Aachs%26aulast%3DWan%26aufirst%3DP.%2BT.%2BC.%26aulast%3DGarnett%26aufirst%3DM.%2BJ.%26aulast%3DRoe%26aufirst%3DM.%2BS.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DNiculescu-Duvaz%26aufirst%3DD.%26aulast%3DGood%26aufirst%3DV.%2BM.%26aulast%3DJones%26aufirst%3DM.%2BJ.%26aulast%3DMarshall%26aufirst%3DC.%2BJ.%26aulast%3DSpringer%26aufirst%3DC.%2BJ.%26aulast%3DBarford%26aufirst%3DD.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DMechanism%2520of%2520Activation%2520of%2520the%2520RAF-ERK%2520Signaling%2520Pathway%2520by%2520Oncogenic%2520Mutations%2520of%2520B-RAF%26jtitle%3DCell%26date%3D2004%26volume%3D116%26spage%3D855%26epage%3D867" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Gould, A. E.; Harrison, S. J.; Mizutani, H.; Shen, M.; Smyser, T. E.; Stroud, S. G.</span> U.S. Patent Appl. US 20100197924 A1 20100805,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Gould%2C+A.+E.%3B+Harrison%2C+S.+J.%3B+Mizutani%2C+H.%3B+Shen%2C+M.%3B+Smyser%2C+T.+E.%3B+Stroud%2C+S.+G.+U.S.+Patent+Appl.+US+20100197924+A1+20100805%2C+2010."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGould%26aufirst%3DA.%2BE.%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="note"><p class="first last">Additional kinase binding data for <b>26</b> and <b>27</b> can be found in the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>, Table 1.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="note"><p class="first last">Crystallization work was done with wt B-Raf protein (residues 445−726). The crystallization conditions were as follows: 14.025% PEG 8000, 0.8 M NP Lithium Cl, 0.06 M Tris base, and 0.04 M Tris Cl. A 50 mM stock concentration of compound was made in 100% DMSO. The compound (50 mM) was mixed with B-raf (2.64 mg/mL) to a final concentration of 1 mM compound at room temperature. The precipitate was removed by centrifugation. The crystals appeared after 7 days. Crystals were frozen by flash freezing in liquid nitrogen using 25% ethylene glycol in mother liquor. The crystals diffracted to 3.1 Å, and clear omit electron density for the compound was observed. The data collection summary and refinement statistics have been deposited in the RCSB Protein Data Bank (RCSB ID code rcsb063351 and PDB ID code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3Q96">3Q96</a>).</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Corma, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leyva, A.</span><span> </span><span class="NLM_article-title">Comparison between polyethylenglycol and imidazolium ionic liquids as solvents for developing a homogeneous and reusable palladium catalytic system for the Suzuki and Sonogashira coupling</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">9848</span><span class="NLM_x">–</span> <span class="NLM_lpage">9854</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2005&pages=9848-9854&author=A.+Cormaauthor=H.+Garciaauthor=A.+Leyva&title=Comparison+between+polyethylenglycol+and+imidazolium+ionic+liquids+as+solvents+for+developing+a+homogeneous+and+reusable+palladium+catalytic+system+for+the+Suzuki+and+Sonogashira+coupling"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCorma%26aufirst%3DA.%26aulast%3DGarcia%26aufirst%3DH.%26aulast%3DLeyva%26aufirst%3DA.%26atitle%3DComparison%2520between%2520polyethylenglycol%2520and%2520imidazolium%2520ionic%2520liquids%2520as%2520solvents%2520for%2520developing%2520a%2520homogeneous%2520and%2520reusable%2520palladium%2520catalytic%2520system%2520for%2520the%2520Suzuki%2520and%2520Sonogashira%2520coupling%26jtitle%3DTetrahedron%26date%3D2005%26volume%3D61%26spage%3D9848%26epage%3D9854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Li, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bucana, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidler, I. J.</span><span> </span><span class="NLM_article-title">Correlation of growth capacity of human tumor cells in hard agarose with their in vivo proliferative capacity at specific metastatic sites</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">81</span><span class="NLM_x">, </span> <span class="NLM_fpage">1406</span><span class="NLM_x">–</span> <span class="NLM_lpage">1412</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm101479y&amp;key=10.1093%2Fjnci%2F81.18.1406" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm101479y&amp;key=2778827" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm101479y&amp;key=1%3ACAS%3A280%3ADyaL1Mzot1Kktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=1989&pages=1406-1412&author=L.+Liauthor=J.+E.+Priceauthor=D.+Fanauthor=R.+D.+Zhangauthor=C.+D.+Bucanaauthor=I.+J.+Fidler&title=Correlation+of+growth+capacity+of+human+tumor+cells+in+hard+agarose+with+their+in+vivo+proliferative+capacity+at+specific+metastatic+sites"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Correlation of growth capacity of human tumor cells in hard agarose with their in vivo proliferative capacity at specific metastatic sites</span></div><div class="casAuthors">Li L; Price J E; Fan D; Zhang R D; Bucana C D; Fidler I J</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1406-12</span>
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    </div><div class="casAbstract">The purpose of this study was to determine whether the degree of anchorage-independent growth of human tumor cells in increasing concentrations of agarose correlated with the capacity of the cells to produce experimental metastases in nude mice.  Human melanoma, breast carcinoma, and colon carcinoma cells from parental lines and variants selected in vivo for metastasis and in vitro cloned lines were plated into medium containing 0.3%, 0.6%, 0.9%, or 1.2% of agarose.  These cells were also injected into nude mice: intravenously for melanoma, into the mammary fat pad for breast carcinoma, and into the spleen for colon carcinoma.  Production of tumor cell colonies in dense agarose (greater than 0.6%) correlated with production of experimental metastases in the lung (melanoma, breast carcinoma) or liver (colon carcinoma).  We conclude that the degree of anchorage-independent growth of tumor cells can predict their biological behavior and metastatic potential in vivo.  Thus, this technique may be useful for the isolation of metastatic cells from heterogeneous human neoplasms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSbQIPR-IkehmGmni0r9GoKfW6udTcc2eZ79IWdLFIwq7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL1Mzot1Kktg%253D%253D&md5=9846886e6d86091aa7aae686b2c95823</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2F81.18.1406&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252F81.18.1406%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DL.%26aulast%3DPrice%26aufirst%3DJ.%2BE.%26aulast%3DFan%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DR.%2BD.%26aulast%3DBucana%26aufirst%3DC.%2BD.%26aulast%3DFidler%26aufirst%3DI.%2BJ.%26atitle%3DCorrelation%2520of%2520growth%2520capacity%2520of%2520human%2520tumor%2520cells%2520in%2520hard%2520agarose%2520with%2520their%2520in%2520vivo%2520proliferative%2520capacity%2520at%2520specific%2520metastatic%2520sites%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D1989%26volume%3D81%26spage%3D1406%26epage%3D1412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3Q96" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3Q96','PDB','3Q96'); return false;">PDB: 3Q96</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i34"><a href="/doi/suppl/10.1021/jm101479y">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_62484"></div></div></div></div></div><hr /></hr><p class="last">Synthetic details and characterization data for 7-(2-acetamidopyridin-4-yloxy)-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid, <i>N</i>-(4-{[(7<i>R</i>)-7-amino-5,6,7,8-tetrahydronaphthalen-2-yl]oxy}pyridin-2-yl)cyclopropanecarboxamide, <i>N</i>-(4-nitropyridin-2-yl)-acetamide, <i>N</i>-(4-nitropyridin-2-yl)-cyclopropane-carboxamide, <i>tert</i>-butyl [3-amino-5-(trifluoromethyl)benzyl]isopropylcarbamate, 3-[(dimethylamino)methyl]-5-(trifluoromethyl)benzoic acid·Li salt, 3-{1-[(<i>tert</i>-butoxycarbonyl)amino]-1-methylethyl}-5-(trifluoromethyl)benzoic acid, and compounds <b>6</b>, (±)-<b>15</b>, (<i>S</i>)-<b>15</b>, <b>17</b>, and <b>19</b>−<b>25</b>; and kinase binding data for <b>26</b> and <b>27</b>. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm101479y/suppl_file/jm101479y_si_001.pdf">jm101479y_si_001.pdf (240.42 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm101479y&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2011.54.issue-6%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Fjm101479y" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm101479y" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677aea3038673d0c","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
